Treatment of cancer using chimeric antigen receptor
Engineering immune effector cells with CARs that bind to multiple tumor antigens addresses the limitations of current therapies by enhancing specificity and efficacy in treating a range of cancers.
Patent Information
- Application Number
- JP2024115421
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-12-29
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2035-03-13
AI Technical Summary
Current adoptive cell transfer therapies using autologous T cells transduced with chimeric antigen receptors (CARs) show promise but have limitations in effectively targeting a wide range of tumor antigens, necessitating the development of diverse and specific CARs for various cancer types.
Engineering immune effector cells, such as T cells and NK cells, to express CARs that bind to a variety of tumor antigens, including CD19, CD123, CD22, and others, with specific antigen-binding domains, transmembrane domains, and intracellular signaling domains to enhance targeting and activation.
The engineered CAR-expressing immune cells demonstrate enhanced specificity and efficacy in recognizing and targeting diverse tumor antigens, potentially improving treatment outcomes for various cancers, including hematological and solid tumors.
Smart Images

Figure 2024164002000053 
Figure 2024164002000054 
Figure 2024164002000055
Abstract
Description
[Technical Field]
[0001] Related Applications This application claims priority to U.S. Application No. 61 / 953,783, filed March 15, 2014, U.S. Application No. 61 / 976,375, filed April 7, 2014, U.S. Application No. 62 / 027,154, filed July 21, 2014, U.S. Application No. 62 / 076,146, filed November 6, 2014, and U.S. Application No. 62 / 097,286, filed December 29, 2014, the contents of which are incorporated herein by reference in their entireties.
[0002] FIELD OF THE INVENTION The present invention relates generally to the use of immune effector cells (e.g., T cells, NK cells) engineered to express chimeric antigen receptors (CARs) to treat diseases associated with tumor antigen expression. [Background technology]
[0003] Background of the Invention Adoptive cell transfer (ACT) therapy using autologous T cells, particularly those transduced with chimeric antigen receptors (CARs), has shown promise in clinical trials for hematological cancers. Summary of the Invention
[0004] Summary of the Invention The present invention relates, at least in part, to the use of immune effector cells (e.g., T cells, NK cells) engineered to express a CAR that binds to a tumor antigen described herein in the treatment of cancers associated with expression of the tumor antigen.
[0005] CAR-encoding nucleic acid Accordingly, in one aspect, the present invention pertains to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain (e.g., an antibody or antibody fragment, a TCR or TCR fragment) that binds to a tumor antigen described herein, a transmembrane domain (e.g., a transmembrane domain described herein), and an intracellular signaling domain (e.g., an intracellular signaling domain described herein) (e.g., an intracellular signaling domain comprising a costimulatory domain (e.g., a costimulatory domain described herein) and / or a primary signaling domain (e.g., a primary signaling domain described herein). In some embodiments, the tumor antigen includes CD19; CD123; CD22; CD30; CD171; CS-1 (also known as CD2 subset 1, CRACC, SLAMF7, CD319, and 19A24); C-type lectin-like molecule-1 (CLL-1 or CLECL1); CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); TNF receptor family member B-cell maturation antigen (BCMA); Tn antigen ((Tn Ag) or (GalNAcα-Ser / Thr)); prostate-specific membrane antigen (PSMA); receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-like tyrosine kinase 3 (FLT3); tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; carcinoembryonic antigen (CEA); epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2 or CD213A2); mesothelial interleukin-11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); protease serine 21 (testisin or PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Lewis (Y) antigen; CD24; platelet-derived growth factor receptor beta (PDGFR-beta); stage-specific embryonic antigen-4 (SSEA-4); CD20; folate receptor alpha; receptor tyrosine-protein kinase ERBB2 (Her2 / neu); mucin 1, cell surface associated (MUC1);epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); prostase; prostatic acid phosphatase (PAP); elongation factor 2 mutated (ELF2M); ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor); carbonic anhydrase IX (CAIX); proteasome (prosome, macropain) subunit, beta, 9 (LMP2); glycoprotein 100 (gp100); BCR (Bone Cranial Cytoplasmic Receptor) region; and Abelson murine leukemia viral oncogene homolog 1 (Abl) oncogene fusion protein (bcr-abl); tyrosinase; ephrin type A receptor 2 (EphA2); fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); transglutaminase 5 (TGS5); high molecular weight melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); folate receptor beta; tumor endothelial marker 1 (TEM1 / CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (C LDN6); thyroid-stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); hexasaccharide moiety of globoH glycoceramide (GloboH); mammary differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); hepatitis A virus cellular receptor 1 (HAVCR1); adrenergic receptor beta 3 (ADRB3); pannexin Panx3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K9 (LY6K); olfactory receptor 51E2 (OR51E2); TCR gamma alternative reading frame protein (TARP); Wilms tumor protein (WT1); cancer / testis antigen 1 (NY-ESO-1); cancer / testis antigen 2 (LAGE-1a); melanoma-associated antigen 1 (MAGE-A1); ETS translocation variant gene 6 located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family, member 1A (XAGE1);angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutant; prostein; survivin; telomerase; prostate cancer tumor antigen-1 (PCTA-1 or galectin 8), melanoma antigen recognized by T cells 1 (Melan-A or MART1); rat sarcoma (Ras) mutant; human telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; apoptosis melanoma inhibitory protein (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-acetylglucosaminyltransferase V (NA17); paired box protein Pax-3 (PAX3); androgen receptor; cyclin B1; v-myc avian myelocytoma viral oncogene neuroblastoma-derived homolog (MYCN); Ras homolog family member C (RhoC); tyrosinase-related protein 2 (TRP-2); cytochrome P450 1B1 (CYP1B1); CCCTC-binding factor (zinc finger protein)-like (BORIS or Brother of the Regulator of Imprinted Sites), squamous cell carcinoma antigen recognized by T cells 3 (SART3); paired box protein Pax-5 (PAX5); proacrosin-binding protein p32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A-kinase anchor protein 4 (AKAP-4); synovial sarcoma, X-breakpoint 2 (SSX2); receptor for advanced glycation end products (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papillomavirus E6 (HPV E6); human papillomavirus E7 (HPV E7); intestinal carboxylesterase; heat shock protein 70-2 mutant (mut hsp70-2); CD79a; CD79b; CD72; leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR or CD89); leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member (CD300LF);One or more selected from C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1);
[0006] In some embodiments, the tumor antigen bound by the encoded CAR molecule is TSHR, CD171, CS-1, CLL-1, GD3, Tn Ag, FLT3, CD38, CD44v6, B7H3, KIT, IL-13Ra2, IL-11Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-beta, SSEA-4, MUC1, EGFR, NCAM, CAIX, LMP2, EphA2, fucosyl-GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53 mutant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1.
[0007] In some embodiments, the tumor antigen bound by the encoded CAR molecule is selected from one or more of TSHR, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, and OR51E2.
[0008] In some embodiments, the antigen binding domain of the encoded CAR molecule comprises an antibody, antibody fragment, scFv, Fv, Fab, (Fab')2, single domain antibody (SDAB), VH or VL domain, or camelid VHH domain.
[0009] In some embodiments, the transmembrane domain of the encoded CAR molecule is selected from the group consisting of the alpha, beta, or zeta chain of the T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R alpha, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d , ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB 7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD16 0 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKp44, NKp30, NKp46, NKG2D and / or NKG2C.
[0010] In one embodiment, the encoded transmembrane domain comprises the amino acid sequence of a CD8 transmembrane domain having at least one, two, or three modifications but not more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO: 12, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 12. In one embodiment, the encoded transmembrane domain comprises the sequence of SEQ ID NO: 12.
[0011] In other embodiments, the nucleic acid molecule comprises a nucleotide sequence of the CD8 transmembrane domain, including, for example, the sequence of SEQ ID NO: 13, or a sequence having 95-99% identity thereto.
[0012] In some embodiments, the encoded antigen-binding domain is connected to the transmembrane domain by a hinge region. In some embodiments, the encoded hinge region comprises the amino acid sequence of a CD8 hinge, e.g., SEQ ID NO: 2; or the amino acid sequence of an IgG4 hinge, e.g., SEQ ID NO: 6, or a sequence with 95-99% identity to SEQ ID NO: 2 or 6. In other embodiments, the nucleic acid sequence encoding the hinge region comprises the sequence of SEQ ID NO: 3 or SEQ ID NO: 7, corresponding to a CD8 hinge or an IgG4 hinge, respectively, or a sequence with 95-99% identity to SEQ ID NO: 3 or 7.
[0013] In other embodiments, the nucleic acid molecule encodes an intracellular signaling domain comprising a sequence encoding a primary signaling domain and / or a sequence encoding a costimulatory signaling domain. In some embodiments, the intracellular signaling domain comprises a sequence encoding a primary signaling domain. In some embodiments, the intracellular signaling domain comprises a sequence encoding a costimulatory signaling domain. In some embodiments, the intracellular signaling domain comprises a sequence encoding a primary signaling domain and a sequence encoding a costimulatory signaling domain.
[0014] In some embodiments, the encoded primary signaling domain comprises a functional signaling domain of a protein selected from the group consisting of CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCER1G), FcR beta (Fc epsilon R1b), CD79a, CD79b, Fc gamma RIIa, DAP10, and DAP12.
[0015] In some embodiments, the encoded primary signaling domain comprises a functional signaling domain of CD3 zeta. The encoded CD3 zeta primary signaling domain can comprise an amino acid sequence having at least one, two, or three modifications, but not more than 20, 10, or 5 modifications, of the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 20, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 20. In some embodiments, the encoded primary signaling domain comprises the sequence of SEQ ID NO: 18 or SEQ ID NO: 20. In other embodiments, the nucleic acid sequence encoding the primary signaling domain comprises the sequence of SEQ ID NO: 19 or SEQ ID NO: 21, or a sequence with 95-99% identity thereto.
[0016] In some embodiments, the encoded intracellular signaling domain comprises a sequence encoding a costimulatory signaling domain. For example, the intracellular signaling domain can comprise a sequence encoding a primary signaling domain and a sequence encoding a costimulatory signaling domain. In some embodiments, the encoded costimulatory signaling domain is selected from the group consisting of CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, CD4, CD8 alpha, CD8 beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITG The present invention includes a functional signaling domain of one or more proteins selected from AM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, NKp44, NKp30, NKp46, and NKG2D.
[0017] In some embodiments, the encoded costimulatory signaling domain comprises an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 16, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 16. In some embodiments, the encoded costimulatory signaling domain comprises the sequence of SEQ ID NO: 14 or SEQ ID NO: 16. In other embodiments, the nucleic acid sequence encoding the costimulatory signaling domain comprises the sequence of SEQ ID NO: 15 or SEQ ID NO: 17, or a sequence with 95-99% identity thereto.
[0018] In other embodiments, the encoded intracellular domain comprises the sequence of SEQ ID NO:14 or SEQ ID NO:16 and the sequence of SEQ ID NO:18 or SEQ ID NO:20, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.
[0019] In some embodiments, the nucleic acid sequence encoding the intracellular signaling domain comprises the sequence of SEQ ID NO: 15 or SEQ ID NO: 17, or a sequence having 95-99% identity thereto, and the sequence of SEQ ID NO: 19 or SEQ ID NO: 21, or a sequence having 95-99% identity thereto.
[0020] In some embodiments, the nucleic acid molecule further comprises a leader sequence. In some embodiments, the leader sequence comprises the sequence of SEQ ID NO:2.
[0021] In one embodiment, the encoded antigen binding domain comprises 10 -4 M~10 -8 Binding affinity K of M D It has.
[0022] In one embodiment, the encoded antigen binding domain is an antigen binding domain described herein, e.g., an antigen binding domain described herein against a target provided above.
[0023] In some embodiments, the encoded CAR molecule binds to the target antigen in a 10 -4 M~10-8 M, e.g., 10 -5 M~10 -7 M, e.g., 10 -6 M or 10 -7 Binding affinity K of M D In some embodiments, the antigen-binding domain has a binding affinity that is at least 5-fold, 10-fold, 20-fold, 30-fold, 50-fold, 100-fold, or 1,000-fold lower than a reference antibody, e.g., an antibody described herein. In some embodiments, the encoded antigen-binding domain has a binding affinity that is at least 5-fold lower than a reference antibody (e.g., the antibody from which the antigen-binding domain is derived).
[0024] In one aspect, the present invention pertains to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain (e.g., an antibody or antibody fragment, TCR or TCR fragment) that binds to a tumor-supporting antigen (e.g., a tumor-supporting antigen described herein), a transmembrane domain (e.g., a transmembrane domain described herein), and an intracellular signaling domain (e.g., an intracellular signaling domain described herein) (e.g., an intracellular signaling domain comprising a costimulatory domain (e.g., a costimulatory domain described herein) and / or a primary signaling domain (e.g., a primary signaling domain described herein). In one embodiment, the tumor-supporting antigen is an antigen present on a stromal cell or a myeloid-derived suppressor cell (MDSC).
[0025] vector In another aspect, the present invention pertains to a vector comprising a nucleic acid sequence encoding a CAR described herein. In some embodiments, the vector is selected from a DNA vector, an RNA vector, a plasmid, a lentiviral vector, an adenoviral vector, or a retroviral vector. In some embodiments, the vector is a lentiviral vector.
[0026] In some embodiments, the vector comprises a nucleic acid sequence encoding a CAR, e.g., a CAR described herein, and a nucleic acid sequence encoding an inhibitory molecule comprising an inhKIR cytoplasmic domain; a transmembrane domain, e.g., a KIR transmembrane domain; and an inhibitor cytoplasmic domain, e.g., an ITIM domain, e.g., an inhKIR ITIM domain. In some embodiments, the inhibitory molecule is a naturally occurring inhKIR or a sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, or 99% homology to, or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 residues from, a naturally occurring inhKIR.
[0027] In some embodiments, the nucleic acid sequence encoding the inhibitory molecule comprises a SLAM family cytoplasmic domain; a transmembrane domain, such as a SLAM family transmembrane domain; and an inhibitor cytoplasmic domain, such as a SLAM family domain, such as a SLAM family ITIM domain. In some embodiments, the inhibitory molecule is a naturally occurring SLAM family member or a sequence that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95% or 99% homology with a naturally occurring SLAM family member, or does not differ by more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 residues.
[0028] In some embodiments, the vector further comprises a promoter. In some embodiments, the promoter is selected from the group consisting of an EF-1 promoter, a CMV IE gene promoter, an EF-1α promoter, a ubiquitin C promoter, and a phosphoglycerate kinase (PGK) promoter. In some embodiments, the promoter is an EF-1 promoter. In some embodiments, the EF-1 promoter comprises the sequence of SEQ ID NO: 1.
[0029] In some embodiments, the vector is an in vitro transcription vector, e.g., a vector that transcribes RNA of a nucleic acid molecule described herein. In some embodiments, the nucleic acid sequence in the vector further comprises a poly(A) tail, e.g., a poly(A) tail comprising approximately 150 adenosine bases (SEQ ID NO: 33), e.g., a poly(A) tail described herein. In some embodiments, the nucleic acid sequence in the vector further comprises a 3' UTR, e.g., a 3' UTR comprising at least one repeat of the 3' UTR from human beta-globulin, e.g., a 3' UTR described herein. In some embodiments, the nucleic acid sequence in the vector further comprises a promoter, e.g., a T2 promoter.
[0030] CAR polypeptide In another aspect, the invention pertains to an isolated CAR polypeptide molecule comprising an antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the antigen binding domain is selected from the group consisting of CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1 (CLECL1), CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, mesothelin, IL-11Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-beta, SSEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1, EGFR, NCAM, prostase, PAP, ELF2M, ephrin B2, FAP, IGF-I receptor, CAIX, LMP2, gp100, bcr-ab l, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, TSHR, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin and telomerase, PCTA-1 / galectin 8, MelanA / MART1, Ras mutant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, legumain, HPV E6Binds to one or more tumor antigens selected from E7, intestinal carboxylesterase, mutated hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1.
[0031] In some embodiments, the antigen binding domain of the CAR polypeptide molecule is selected from the group consisting of TSHR, CD171, CS-1, CLL-1, GD3, Tn Ag, FLT3, CD38, CD44v6, B7H3, KIT, IL-13Ra2, IL-11Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-beta, SSEA-4, MUC1, EGFR, NCAM, CAIX, LMP2, EphA2, fucosyl-GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53 mutant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1.
[0032] In some embodiments, the antigen binding domain of the CAR polypeptide molecule binds to one or more tumor antigens selected from TSHR, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, and OR51E2.
[0033] In some embodiments, the antigen binding domain of the CAR polypeptide molecule comprises an antibody, antibody fragment, scFv, Fv, Fab, (Fab')2, single domain antibody (SDAB), VH or VL domain, or camelid VHH domain.
[0034] In some embodiments, the antigen binding domain of the CAR polypeptide molecule comprises the alpha, beta, or zeta chain of the T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD1 1a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R alpha, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD 11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, I TGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD 160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKp44, NKp30, NKp46, NKG2D and / or NKG2C.
[0035] In other embodiments, the transmembrane domain of the CAR polypeptide molecule comprises a CD8 transmembrane domain, e.g., an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications of SEQ ID NO: 12, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 12. In one embodiment, the transmembrane domain comprises the sequence of SEQ ID NO: 12.
[0036] In other embodiments, the antigen binding domain of the CAR polypeptide molecule is connected to the transmembrane domain by a hinge region. In some embodiments, the encoded hinge region comprises a CD8 hinge, e.g., the amino acid sequence of SEQ ID NO: 2, or an IgG4 hinge, e.g., the amino acid sequence of SEQ ID NO: 6, or a sequence having 95-99% identity thereof.
[0037] In other embodiments, the intracellular signaling domain of the CAR polypeptide molecule comprises a primary signaling domain and / or a costimulatory signaling domain. In other embodiments, the intracellular signaling domain of the CAR polypeptide molecule comprises a primary signaling domain. In other embodiments, the intracellular signaling domain of the CAR polypeptide molecule comprises a costimulatory signaling domain. In yet other embodiments, the intracellular signaling domain of the CAR polypeptide molecule comprises a primary signaling domain and a costimulatory signaling domain.
[0038] In other embodiments, the primary signaling domain of the CAR polypeptide molecule comprises a functional signaling domain of a protein selected from the group consisting of CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCER1G), FcR beta (Fc epsilon R1b), CD79a, CD79b, Fc gamma RIIa, DAP10, and DAP12. In some embodiments, the primary signaling domain comprises a functional signaling domain of CD3 zeta. The CD3 zeta primary signaling domain can comprise an amino acid sequence having at least one, two, or three modifications, but not more than 20, 10, or 5 modifications, of the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 20, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 20. In some embodiments, the primary signaling domain of the CAR polypeptide molecule comprises the sequence of SEQ ID NO: 18 or SEQ ID NO: 20.
[0039] In some embodiments, the intracellular signaling domain of the CAR polypeptide molecule comprises a sequence encoding a costimulatory signaling domain. For example, the intracellular signaling domain can comprise a sequence encoding a primary signaling domain and a sequence encoding a costimulatory signaling domain. In some embodiments, the encoded costimulatory signaling domain is selected from the group consisting of CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds with CD83, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, CD4, CD8 alpha, CD8 beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITG The present invention includes a functional signaling domain of one or more proteins selected from AM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, NKp44, NKp30, NKp46, and NKG2D.
[0040] In some embodiments, the costimulatory signaling domain of the CAR polypeptide molecule comprises an amino acid sequence having at least one, two, or three modifications but not more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 16, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 16. In some embodiments, the encoded costimulatory signaling domain comprises the sequence of SEQ ID NO: 14 or SEQ ID NO: 16. In other embodiments, the intracellular domain of the CAR polypeptide molecule comprises the sequence of SEQ ID NO: 14 or SEQ ID NO: 16 and the sequence of SEQ ID NO: 18 or SEQ ID NO: 20, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.
[0041] In some embodiments, the CAR polypeptide molecule further comprises a leader sequence. In some embodiments, the leader sequence comprises the sequence of SEQ ID NO:2.
[0042] In one embodiment, the antigen binding domain of the CAR polypeptide molecule comprises 10 -4 M~10 -8 Binding affinity K of M D In some embodiments, the antigen binding domain is an antigen binding domain described herein, e.g., an antigen binding domain described herein for a target provided above. In some embodiments, the CAR molecule has a 10 -4 M~10 -8 M, e.g., 10 -5 M~10 -7 M, e.g., 10 -6 M or 10 -7 Binding affinity K of M D In some embodiments, the antigen-binding domain has a binding affinity that is at least 5-fold, 10-fold, 20-fold, 30-fold, 50-fold, 100-fold, or 1,000-fold less than a reference antibody, e.g., an antibody described herein. In some embodiments, the encoded antigen-binding domain has a binding affinity that is at least 5-fold less than a reference antibody (e.g., the antibody from which the antigen-binding domain is derived).
[0043] In another aspect, the invention pertains to an isolated CAR polypeptide molecule comprising an antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the antigen binding domain binds to a tumor-supporting antigen (e.g., a tumor-supporting antigen described herein). In some embodiments, the tumor-supporting antigen is an antigen present on stromal cells or myeloid-derived suppressor cells (MDSCs).
[0044] CAR-expressing cells In another aspect, the invention pertains to a cell, e.g., an immune effector cell (e.g., a population of cells, e.g., an immune effector cell population), comprising a nucleic acid molecule, a CAR polypeptide molecule, or a vector described herein.
[0045] In one embodiment, the cell is a human T cell. In one embodiment, the cell is a cell described herein, e.g., a human T cell, e.g., a human T cell described herein; or a human NK cell, e.g., a human NK cell described herein. In one embodiment, the human T cell is a CD8+ T cell. In one embodiment, the cell is a T cell, and the T cell is diacylglycerol kinase (DGK) deficient. In one embodiment, the cell is a T cell, and the T cell is Ikaros deficient. In one embodiment, the cell is a T cell, and the T cell is both DGK and Ikaros deficient.
[0046] In other embodiments, the CAR-expressing immune effector cells described herein can further express other agents, e.g., agents that enhance the activity of the CAR-expressing cells. For example, in some embodiments, the agent can be an agent that inhibits an inhibitory molecule. Examples of inhibitory molecules include PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3, and / or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and TGFR beta, e.g., as described herein. In some embodiments, the agent that inhibits an inhibitory molecule comprises a first polypeptide, e.g., an inhibitory molecule, linked to a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide, e.g., of an inhibitory molecule such as PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and / or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR beta, or a fragment of any of these, and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27 or CD28, e.g., as described herein) and / or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD-1 or a fragment thereof, and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28, CD27, OX40 or 4-IBB signaling domain described herein and / or a CD3 zeta signaling domain described herein).
[0047] In some embodiments, the CAR-expressing immune effector cells described herein can further comprise a second CAR, e.g., a second CAR comprising a different antigen binding domain, e.g., directed against the same target (e.g., a target described above) or a different target. In some embodiments, the second CAR comprises an antigen binding domain directed against a target expressed on the same cancer cell type as the target of the first CAR. In some embodiments, the CAR-expressing immune effector cells comprise a first CAR that targets a first antigen and comprises an intracellular signaling domain with a costimulatory signaling domain but without a primary signaling domain, and a second CAR that targets a second, different antigen and comprises an intracellular signaling domain with a primary signaling domain but without a costimulatory signaling domain.
[0048] While not wishing to be bound by theory, the placement of a costimulatory signaling domain, e.g., 4-1BB, CD28, CD27, or OX-40, on a first CAR and a primary signaling domain, e.g., CD3 zeta, on a second CAR can limit CAR activity to cells where both targets are expressed. In some embodiments, CAR-expressing immune effector cells comprise a first CAR that includes, for example, an antigen-binding domain that targets the target, a transmembrane domain, and a costimulatory domain, and a second CAR that targets an antigen different from the antigen targeted by the first CAR (e.g., an antigen expressed on the same cancer cell type as the first target) and includes an antigen-binding domain, a transmembrane domain, and a primary signaling domain. In other embodiments, CAR-expressing immune effector cells comprise, for example, a first CAR that includes, for example, an antigen-binding domain that targets the target, a transmembrane domain, and a primary signaling domain, and a second CAR that targets an antigen different from the antigen targeted by the first CAR (e.g., an antigen expressed on the same cancer cell type as the first target) and includes an antigen-binding domain that binds to the antigen, a transmembrane domain, and a costimulatory signaling domain.
[0049] In some embodiments, the CAR-expressing immune effector cells include a CAR described herein, e.g., a CAR directed against the target described above, and an inhibitory CAR. In some embodiments, the inhibitory CAR includes an antigen-binding domain that binds to an antigen found on normal cells but not on cancer cells, e.g., a normal cell that also expresses the target. In some embodiments, the inhibitory CAR includes an antigen-binding domain, a transmembrane domain, and an intracellular domain of an inhibitory molecule. For example, the intracellular domain of the inhibitory CAR can be the intracellular domain of PD1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3, and / or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, or TGFR beta.
[0050] In some embodiments, the immune effector cell (e.g., T cell, NK cell) comprises a first CAR comprising an antigen binding domain that binds to a tumor antigen described herein and a second CAR comprising the PD1 extracellular domain or a fragment thereof.
[0051] In some embodiments, the cell further comprises an inhibitory molecule comprising an inhKIR cytoplasmic domain; a transmembrane domain, e.g., a KIR transmembrane domain; and an inhibitor cytoplasmic domain, e.g., an ITIM domain, e.g., an inhKIR ITIM domain. In some embodiments, the inhibitory molecule is a naturally occurring inhKIR or a sequence having at least 50%, 60%, 70%, 80%, 85%, 90%, 95%, or 99% homology to, or differing by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 residues from, a naturally occurring inhKIR.
[0052] In some embodiments, the cell further comprises an inhibitory molecule comprising a SLAM family cytoplasmic domain; a transmembrane domain, e.g., a SLAM family transmembrane domain; and an inhibitor cytoplasmic domain, e.g., a SLAM family domain, e.g., a SLAM family ITIM domain. In some embodiments, the inhibitory molecule is a naturally occurring SLAM family member or a sequence that has at least 50%, 60%, 70%, 80%, 85%, 90%, 95% or 99% homology with a naturally occurring SLAM family member, or does not differ by more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 or 20 residues.
[0053] In some embodiments, the second CAR in the cell is an inhibitory CAR, wherein the inhibitory CAR comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain of an inhibitory molecule. The inhibitory molecule can be selected from one or more of PD1, PD-L1, CTLA-4, TIM-3, LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, TGFR beta, CEACAM-1, CEACAM-3, and CEACAM-5. In some embodiments, the second CAR molecule comprises the extracellular domain of PD1 or a fragment thereof.
[0054] In some embodiments, the second CAR molecule in the cell further comprises an intracellular signaling domain comprising a primary signaling domain and / or a costimulatory signaling domain.
[0055] In other embodiments, the intracellular signaling domain in the cell comprises a primary signaling domain comprising a functional domain of CD3 zeta and a costimulatory signaling domain comprising a functional domain of 4-1BB.
[0056] In some embodiments, the second CAR molecule in the cell comprises the amino acid sequence of SEQ ID NO:26.
[0057] In some embodiments, the antigen binding domain of the first CAR molecule comprises an scFv and the antigen binding domain of the second CAR molecule does not comprise an scFv, e.g., the antigen binding domain of the first CAR molecule comprises an scFv and the antigen binding domain of the second CAR molecule comprises a camelid VHH domain.
[0058] Treatment / Combination Therapy In another aspect, the invention provides methods comprising administering a CAR molecule, e.g., a CAR molecule described herein, or a cell comprising a nucleic acid encoding a CAR molecule, e.g., a CAR molecule described herein. In some embodiments, the subject has a disorder described herein, e.g., the subject has cancer, e.g., the subject has a cancer that expresses a target antigen described herein. In some embodiments, the subject is human.
[0059] In another aspect, the invention features a method of treating a subject having a disease associated with expression of a cancer-associated antigen described herein, comprising administering to the subject an effective amount of cells comprising a CAR molecule, e.g., a CAR molecule described herein.
[0060] In yet another aspect, the invention features a method of treating a subject having a disease associated with expression of a tumor antigen, comprising administering to the subject an effective amount of a cell, e.g., an immune effector cell (e.g., a population of immune effector cells), comprising a CAR molecule, wherein the CAR molecule comprises an antigen binding domain, a transmembrane domain, and an intracellular domain, wherein the intracellular domain comprises a costimulatory domain and / or a primary signaling domain, and wherein the antigen binding domain binds to a tumor antigen associated with the disease, e.g., a tumor antigen described herein.
[0061] In a related aspect, the invention relates to a method of treating a subject having a disease associated with expression of a tumor antigen, the method comprising administering to the subject an effective amount of cells, e.g., immune effector cells (e.g., a population of immune effector cells), comprising a CAR molecule, in combination with an agent that enhances the effectiveness of the immune cells, wherein: (i) the CAR molecule comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain comprising a costimulatory domain and / or a primary signaling domain, wherein the antigen-binding domain binds to a tumor antigen associated with the disease, e.g., a tumor antigen disclosed herein; and (ii) Agents that enhance the effectiveness of immune cells include: (i) protein phosphatase inhibitors; (ii) kinase inhibitors; (iii) cytokines; (iv) an inhibitor of an immune inhibitory molecule; or (v)T REG Drugs that decrease the level or activity of cells One or more of the following is selected.
[0062] In a related aspect, the invention features a method of treating a subject having a disease associated with expression of a tumor antigen, comprising administering to the subject an effective amount of a cell, e.g., an immune effector cell (e.g., a population of immune effector cells), comprising a CAR molecule, wherein: (i) the CAR molecule comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain comprising a costimulatory domain and / or a primary signaling domain, wherein the antigen-binding domain binds to a tumor antigen associated with the disease, e.g., a tumor antigen disclosed herein; and (ii) the antigen-binding domain of the CAR molecule has a binding affinity that is at least 5-fold lower than the antibody from which the antigen-binding domain is derived;
[0063] In another aspect, the invention pertains to a composition comprising an immune effector cell (e.g., a population of immune effector cells) comprising a CAR molecule (e.g., a CAR molecule described herein) for use in treating a subject having a disease associated with expression of a tumor antigen, e.g., a disorder described herein.
[0064] In certain embodiments of any of the above methods or uses, the disease associated with a tumor antigen, e.g., a tumor antigen described herein, is selected from a proliferative disease, such as a cancer or malignancy, or a precancerous condition, such as myelodysplasia, myelodysplastic syndrome, or preleukemia, or is a non-cancer-related indication associated with expression of a tumor antigen described herein. In some embodiments, the disease is a cancer described herein, e.g., a cancer described herein as being associated with a target described herein. In some embodiments, the disease is a hematological cancer. In some embodiments, the hematological cancer is leukemia. In some embodiments, the cancer is one or more acute leukemias, including but not limited to B-cell acute lymphoblastic leukemia ("BALL"), T-cell acute lymphoblastic leukemia ("TALL"), acute lymphoblastic leukemia (ALL); one or more chronic leukemias, including but not limited to chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL); B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and additional blood cancers or hematological conditions including, but not limited to, myelodysplastic syndromes, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's hypergammaglobulinemia, and "preleukemia," a diverse collection of hematological conditions united by the inadequate production (or dysplasia) of myeloid blood cells; diseases associated with expression of a tumor antigen described herein include, but are not limited to, atypical and / or non-classical cancers, malignancies, precancerous conditions, or proliferative disorders that express a tumor antigen described herein; and any combination thereof. In other embodiments, the disease associated with a tumor antigen described herein is a solid tumor.
[0065]
[0013] In certain embodiments of any of the above methods or uses, the tumor antigen associated with the disease is CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1 (CLECL1), CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, mesothelin, IL-11Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-beta, SSEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1, EGFR, NCAM, prostase, PAP, ELF2M, ephrin B2, FAP, IGF-I receptor, CAIX, LMP2, gp100, bcr-ab l, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, TSHR, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin and telomerase, PCTA-1 / galectin 8, MelanA / MART1, Ras mutant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, legumain, HPV E6, E7, intestinal carboxylesterase, mut One or more of hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5 and IGLL1 are selected.
[0066] In other embodiments of any of the above methods or uses, the tumor antigen associated with the disease is TSHR, TSHR, CD171, CS-1, CLL-1, GD3, Tn Ag, FLT3, CD38, CD44v6, B7H3, KIT, IL-13Ra2, IL-11Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-beta, SSEA-4, MUC1, EGFR, NCAM, CAIX, LMP2, EphA2, fucosyl-GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53 mutant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1.
[0067] In other embodiments of any of the above methods or uses, the tumor antigen associated with the disease is selected from one or more of TSHR, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, and OR51E2.
[0068] In some embodiments, the method or use is performed in combination with an agent that increases the effectiveness of immune effector cells, e.g., an agent described herein.
[0069] In any of the above methods or uses, the disease associated with tumor antigen expression is selected from the group consisting of proliferative diseases, pre-cancerous conditions, cancer and non-cancer related indications associated with tumor antigen expression.
[0070] The cancer can be a hematological cancer, for example, one or more cancers selected from chronic lymphocytic leukemia (CLL), acute leukemia, acute lymphocytic leukemia (ALL), B-cell acute lymphocytic leukemia (B-ALL), T-cell acute lymphocytic leukemia (T-ALL), chronic myeloid leukemia (CML), B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndromes, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's hypergammaglobulinemia, or preleukemic conditions.
[0071] Cancers include colon cancer, rectal cancer, renal cell carcinoma, liver cancer, non-small cell lung cancer, small intestine cancer, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, non-Hodgkin's lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer The cancer may also be selected from adenocarcinoma, adrenal gland carcinoma, sarcoma of soft tissue, urethral carcinoma, penile carcinoma, solid tumors of childhood, bladder carcinoma, kidney or ureter carcinoma, renal pelvis carcinoma, central nervous system (CNS) neoplasm, primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancer, combinations of said cancers, and metastatic lesions of said cancers.
[0072] In certain embodiments of the methods or uses described herein, the CAR molecule is administered in combination with an agent that enhances the effectiveness of immune effector cells, such as one or more of a protein phosphatase inhibitor, a kinase inhibitor, a cytokine, an inhibitor of an immune inhibitory molecule; or a T REG It is administered in combination with an agent that reduces the level or activity of the cells.
[0073] In certain embodiments of the methods or uses described herein, the protein phosphatase inhibitor is an SHP-1 inhibitor and / or an SHP-2 inhibitor.
[0074] In other embodiments of the methods or uses described herein, the kinase inhibitor is selected from one or more of a CDK4 inhibitor, a CDK4 / 6 inhibitor (e.g., palbociclib), a BTK inhibitor (e.g., ibrutinib or RN-486), an mTOR inhibitor (e.g., rapamycin or everolimus (RAD001)), an MNK inhibitor, or a dual P13K / mTOR inhibitor. In some embodiments, the BTK inhibitor does not reduce or inhibit the kinase activity of interleukin-2-inducible kinase (ITK).
[0075] In other embodiments of the methods or uses described herein, the agent that inhibits an immune inhibitory molecule comprises an antibody or antibody fragment that inhibits expression of an inhibitory molecule, an inhibitory nucleic acid, a clustered regularly interspaced short palindromic repeats (CRISPR), a transcription activator-like effector nuclease (TALEN), or a zinc finger endonuclease (ZFN).
[0076] In other embodiments of the methods or uses described herein, T REG The agent that reduces the level or activity of the cells is selected from cyclophosphamide, anti-GITR antibodies, CD25 depletion, or a combination thereof.
[0077] In certain embodiments of the methods or uses described herein, the immune inhibitory molecule is selected from the group consisting of PD1, PD-L1, CTLA-4, TIM-3, LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, TGFR beta, CEACAM-1, CEACAM-3, and CEACAM-5.
[0078] In other embodiments, the agent that inhibits an inhibitory molecule comprises a first polypeptide comprising the inhibitory molecule or a fragment thereof and a second polypeptide that provides a positive signal to a cell, wherein the first and second polypeptides are expressed on a CAR-containing immune cell, and wherein (i) the first polypeptide comprises PD1, PD-L1, CTLA-4, TIM-3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, TGFR beta, CEACAM-1, CEACAM-3, and CEACAM-5, or fragments thereof; and / or (ii) the second polypeptide comprises an intracellular signaling domain comprising a primary signaling domain and / or a costimulatory signaling domain. In certain embodiments, the primary signaling domain comprises a functional domain of CD3 zeta; and / or the costimulatory signaling domain comprises a functional domain of a protein selected from 41BB, CD27, and CD28.
[0079] In other embodiments, the cytokine is selected from IL-7, IL-15, or IL-21, or both.
[0080] In other embodiments, the immune effector cells comprising a CAR molecule and a second, e.g., any of the combination therapies disclosed herein (e.g., an agent that increases the efficacy of the immune effector cells), are administered substantially simultaneously or sequentially.
[0081] In other embodiments, immune cells containing a CAR molecule are administered in combination with a molecule that targets GITR and / or modulates GITR function. In some embodiments, the molecule that targets GITR and / or modulates GITR function is administered before the CAR-expressing cells or cell population or before apheresis.
[0082] In some embodiments, lymphocyte infusion, e.g., allogeneic lymphocyte infusion, is used to treat cancer, wherein the lymphocyte infusion comprises at least one CAR-expressing cell of the present invention. In some embodiments, autologous lymphocyte infusion is used to treat cancer, wherein the autologous lymphocyte infusion comprises at least one CAR-expressing cell described herein.
[0083] In some embodiments, the cell is a T cell, and the T cell is diacylglycerol kinase (DGK) deficient. In some embodiments, the cell is a T cell, and the T cell is Ikaros deficient. In some embodiments, the cell is a T cell, and the T cell is both DGK and Ikaros deficient.
[0084] In some embodiments, the method comprises administering a cell expressing a CAR molecule described herein in combination with an agent that enhances the activity of the CAR-expressing cell, wherein the agent is a cytokine, e.g., IL-7, IL-15, IL-21, or a combination thereof. The cytokine can be delivered in combination with, e.g., simultaneously with, or shortly after, administration of the CAR-expressing cell. Alternatively, the cytokine can be delivered an extended period of time after administration of the CAR-expressing cell, e.g., after evaluation of the subject's response to the CAR-expressing cell. In some embodiments, the cytokine is administered to the subject simultaneously (e.g., administered on the same day) or shortly after (e.g., administered 1, 2, 3, 4, 5, 6, or 7 days after administration) with the cells or cell population. In other embodiments, the cytokine is administered to the subject an extended period of time (e.g., at least 2, 3, 4, 6, 8, 10, or more weeks) after administration of the cells or cell population, or after evaluation of the subject's response to the cells.
[0085] In other embodiments, the cells expressing a CAR molecule are administered in combination with an agent that alleviates one or more side effects associated with the administration of the cells expressing a CAR molecule. The side effects associated with the administration of the CAR-expressing cells can be selected from cytokine release syndrome (CRS) or hemophagocytic lymphohistiocytosis (HLH).
[0086] In embodiments of any of the foregoing methods or uses, the cells expressing a CAR molecule are administered in combination with an agent that treats a disease associated with expression of a tumor antigen, such as any of the second or third therapies disclosed herein. Further exemplary combinations include one or more of the following:
[0087] In other embodiments, cells expressing a CAR molecule, e.g., as described herein, can be administered in combination with other agents, e.g., kinase inhibitors and / or checkpoint inhibitors described herein. In some embodiments, cells expressing a CAR molecule can further express other agents, e.g., agents that enhance the activity of the CAR-expressing cells.
[0088] For example, in some embodiments, an agent that enhances the activity of a CAR-expressing cell can be an agent that inhibits an inhibitory molecule (e.g., an immune inhibitor molecule). Examples of inhibitory molecules include PD1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3, and / or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and TGFR beta.
[0089] In some embodiments, the agent that inhibits inhibitory molecule is an inhibitory nucleic acid that is dsRNA, siRNA or shRNA.In some embodiments, inhibitory nucleic acid is linked with the nucleic acid that encodes the element of CAR molecule.For example, inhibitory molecule can be expressed on CAR-expressing cell.
[0090] In other embodiments, the agent that inhibits an inhibitory molecule is, e.g., a molecule described herein, e.g., an agent that includes a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide of an inhibitory molecule such as, e.g., PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and / or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR beta, or a fragment of any of these (e.g., at least a portion of the extracellular domain of any of these), and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., as described herein, e.g., 41BB, CD27 or CD28) and / or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD1 or a fragment thereof (e.g., at least a portion of the extracellular domain of PD1), and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28 signaling domain described herein and / or a CD3 zeta signaling domain described herein).
[0091] In one embodiment, the CAR-expressing immune effector cells of the invention, e.g., T cells or NK cells, are administered to a subject who has previously undergone a stem cell transplant, e.g., an autologous stem cell transplant.
[0092] In some embodiments, the CAR-expressing immune effector cells of the invention, e.g., T cells or NK cells, are administered to a subject who has previously received melphalan.
[0093] In one embodiment, the cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered in combination with an agent that increases the efficacy of the cells expressing the CAR molecule, e.g., an agent described herein.
[0094] In some embodiments, cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered in combination with a low, immune-enhancing dose of an mTOR inhibitor. Without being bound by theory, it is believed that treatment with a low, immune-enhancing dose (e.g., a dose insufficient to completely suppress the immune system but sufficient to improve immune function) is accompanied by a decrease in PD-1-positive T cells or an increase in PD-1-negative cells. PD-1-positive T cells, but not PD-1-negative T cells, may be exhausted by binding to cells expressing a PD-1 ligand, e.g., PD-L1 or PD-L2.
[0095] In some embodiments, this method can be used to optimize the performance of CAR cells described herein in a subject. Without being bound by theory, it is believed that in some embodiments, the performance of endogenous, unmodified immune effector cells, e.g., T cells or NK cells, is improved. Without being bound by theory, it is believed that in some embodiments, the performance of target antigen CAR-expressing cells is improved. In other embodiments, cells, e.g., T cells or NK cells, that have been or will be engineered to express a CAR can be treated ex vivo by contacting them with an amount of an mTOR inhibitor that increases the number of PD1-negative immune effector cells, e.g., T cells, or increases the ratio of PD1-negative immune effector cells, e.g., T cells / PD1-positive immune effector cells, e.g., T cells.
[0096] In some embodiments, administration of an mTOR inhibitor, e.g., an allosteric inhibitor, e.g., RAD001 or a catalytic inhibitor, is initiated before administration of a CAR-expressing cell described herein, e.g., T cells or NK cells. In some embodiments, the CAR cells are administered after a sufficient time, or sufficient administration, of the mTOR inhibitor, such that the level of PD1-negative immune effector cells, e.g., T cells or NK cells, or the ratio of PD1-negative immune effector cells, e.g., T cells / PD1-positive immune effector cells, e.g., T cells, is increased, at least transiently.
[0097] In some embodiments, the cells, e.g., T cells or NK cells, engineered to express a CAR are harvested after a sufficient time, or sufficient administration of a low, immune enhancing dose of an mTOR inhibitor, such that the level of PD1 negative immune effector cells, e.g., T cells, or the ratio of PD1 negative immune effector cells, e.g., T cells / PD1 positive immune effector cells, e.g., T cells, in the subject or harvested from the subject has been increased, at least transiently.
[0098] In one embodiment, the cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered in combination with an agent that mitigates one or more side effects associated with administration of cells expressing a CAR molecule, e.g., an agent described herein.
[0099] In one embodiment, the cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered in combination with an agent that treats a disease associated with a cancer-associated antigen described herein, e.g., an agent described herein.
[0100] In some embodiments, cells expressing two or more CAR molecules, e.g., as described herein, are administered to a subject in need thereof to treat cancer. In some embodiments, a cell population comprising CAR-expressing cells, e.g., as described herein, is administered to a subject in need thereof to treat cancer.
[0101] In some embodiments, cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered at a dose and / or administration schedule described herein.
[0102] In some embodiments, the CAR molecule is introduced into immune effector cells (e.g., T cells, NK cells), e.g., using in vitro transcription, and the subject (e.g., human) receives an initial administration of cells comprising the CAR molecule and one or more subsequent administrations of cells comprising the CAR molecule, where the subsequent administration or administrations occur within 15 days, e.g., 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2 days, after the previous administration. In some embodiments, more than one administration of cells comprising the CAR molecule is administered to the subject (e.g., human) per week, e.g., two, three, or four administrations of cells comprising the CAR molecule per week. In some embodiments, a subject (e.g., a human subject) receives more than one administration of cells comprising a CAR molecule per week (e.g., two, three, or four administrations per week) (also referred to herein as a cycle), followed by one week without administration of cells comprising a CAR molecule, and then more than one additional administration of cells comprising a CAR molecule (e.g., more than one administration of cells comprising a CAR molecule per week). In other embodiments, a subject (e.g., a human subject) receives more than one cycle of cells comprising a CAR molecule, and the time between each cycle is less than 10, 9, 8, 7, 6, 5, 4, or 3 days. In some embodiments, cells comprising a CAR molecule are administered three times a week, every other day. In some embodiments, cells comprising a CAR molecule are administered for at least 2, 3, 4, 5, 6, 7, 8, or more weeks.
[0103] In one embodiment, the cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered as a first line treatment for a disease, e.g., cancer, e.g., a cancer described herein. In other embodiments, the cells expressing a CAR molecule, e.g., a CAR molecule described herein, are administered as a second, third, or fourth line treatment for a disease, e.g., cancer, e.g., a cancer described herein.
[0104] In one embodiment, a population of cells described herein is administered.
[0105] In other aspects, the invention pertains to isolated nucleic acid molecules encoding a CAR of the invention, isolated polypeptide molecules of a CAR of the invention, vectors comprising a CAR of the invention, and cells comprising a CAR of the invention, for use as a medicament.
[0106] In other aspects, the invention pertains to isolated nucleic acid molecules encoding a CAR of the invention, isolated polypeptide molecules of a CAR of the invention, vectors comprising a CAR of the invention, and cells comprising a CAR of the invention, for use in treating a disease expressing a cancer associated antigen as described herein.
[0107] In another aspect, the invention pertains to a cell expressing a CAR molecule described herein for use as a medicament in combination with a cytokine, e.g., IL-7, IL-15, and / or IL-21, described herein. In another aspect, the invention pertains to a cytokine described herein for use as a medicament in combination with a cell expressing a CAR molecule described herein.
[0108] In another aspect, the invention pertains to a cell expressing a CAR molecule described herein, for use as a pharmaceutical in combination with a kinase inhibitor and / or checkpoint inhibitor described herein. In another aspect, the invention pertains to a kinase inhibitor and / or checkpoint inhibitor described herein, for use as a pharmaceutical in combination with a cell expressing a CAR molecule described herein.
[0109] In another aspect, the invention pertains to a cell expressing a CAR molecule described herein for use in combination with a cytokine, e.g., IL-7, IL-15, and / or IL-21, described herein, in the treatment of a disease expressing a tumor antigen targeted by the CAR. In another aspect, the invention pertains to a cytokine described herein for use in combination with a cell expressing a CAR molecule described herein, in the treatment of a disease expressing a tumor antigen targeted by the CAR.
[0110] In another aspect, the invention pertains to a cell expressing a CAR molecule described herein for use in combination with a kinase inhibitor and / or a checkpoint inhibitor described herein in the treatment of a disease expressing a tumor antigen targeted by the CAR. In another aspect, the invention pertains to a kinase inhibitor and / or a checkpoint inhibitor described herein for use in combination with a cell expressing a CAR molecule described herein in the treatment of a disease expressing a tumor antigen targeted by the CAR.
[0111] In another aspect, the invention provides methods comprising administering a CAR molecule, e.g., a CAR molecule described herein, or a cell comprising a nucleic acid encoding a CAR molecule, e.g., a CAR molecule described herein. In some embodiments, the subject has a disorder described herein, e.g., the subject has cancer, e.g., the subject has cancer and has tumor-supporting cells that express a tumor-supporting antigen described herein. In some embodiments, the subject is human.
[0112] In another aspect, the invention features a method of treating a subject having a disease associated with expression of a tumor-supporting antigen described herein, comprising administering to the subject an effective amount of cells comprising a CAR molecule, e.g., a CAR molecule described herein.
[0113] In yet another aspect, the invention features a method of treating a subject having a disease associated with expression of a tumor-supporting antigen, comprising administering to the subject an effective amount of a cell, e.g., an immune effector cell (e.g., a population of immune effector cells), comprising a CAR molecule, wherein the CAR molecule comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain, wherein the intracellular domain comprises a costimulatory domain and / or a primary signaling domain, and wherein the antigen-binding domain binds to a tumor-supporting antigen associated with the disease, e.g., a tumor-supporting antigen described herein.
[0114] In a related aspect, the invention relates to a method of treating a subject having a disease associated with expression of a tumor-supporting antigen, the method comprising administering to the subject an effective amount of cells, e.g., immune effector cells (e.g., a population of immune effector cells), comprising a CAR molecule, in combination with an agent that enhances the effectiveness of the immune cells, wherein: (i) the CAR molecule comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain comprising a costimulatory domain and / or a primary signaling domain, wherein the antigen-binding domain binds to a tumor-supporting antigen associated with the disease, e.g., a tumor-supporting antigen described herein; and (ii) Agents that enhance the effectiveness of immune cells include: (i) protein phosphatase inhibitors; (ii) kinase inhibitors; (iii) cytokines; (iv) an inhibitor of an immune inhibitory molecule; or (v)T REG Drugs that decrease the level or activity of cells One or more of the following is selected.
[0115] In a related aspect, the invention features a method of treating a subject having a disease associated with expression of a tumor-supporting antigen, comprising administering to the subject an effective amount of a cell, e.g., an immune effector cell (e.g., a population of immune effector cells), comprising a CAR molecule, wherein: (i) the CAR molecule comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain comprising a costimulatory domain and / or a primary signaling domain, wherein the antigen-binding domain binds to a tumor-supporting antigen associated with the disease, e.g., a tumor-supporting antigen described herein; and (ii) the antigen-binding domain of the CAR molecule has a binding affinity that is at least 5-fold lower than the antibody from which the antigen-binding domain is derived;
[0116] In another aspect, the invention pertains to a composition comprising an immune effector cell (e.g., a population of immune effector cells) comprising a CAR molecule (e.g., a CAR molecule described herein) for use in treating a subject having a disease associated with expression of a tumor-supporting antigen, e.g., a disorder described herein.
[0117] In any of the above methods or uses, the disease associated with expression of a tumor-supporting antigen is selected from the group consisting of a proliferative disease, a precancerous condition, a cancer, and a non-cancer-related indication associated with expression of a tumor-supporting antigen. In some embodiments, the disease associated with a tumor-supporting antigen described herein is a solid tumor.
[0118] In some embodiments of the methods or uses described herein, the CAR molecule is administered in combination with other drugs. In some embodiments, the drug can be a kinase inhibitor, such as a CDK4 / 6 inhibitor, a BTK inhibitor, an mTOR inhibitor, an MNK inhibitor, or a dual PI3K / mTOR inhibitor, and combinations thereof. In some embodiments, the kinase inhibitor is a CDK4 inhibitor, such as a CDK4 inhibitor described herein, for example, a CD4 / 6 inhibitor, such as 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, hydrochloride (also known as palbociclib or PD0332991). In some embodiments, the kinase inhibitor is a BTK inhibitor, such as a BTK inhibitor described herein, for example, ibrutinib. In some embodiments, the kinase inhibitor is an mTOR inhibitor, such as rapamycin, a rapamycin analog, or an mTOR inhibitor described herein, such as OSI-027. The mTOR inhibitor can be, for example, an mTORC1 inhibitor and / or an mTORC2 inhibitor, for example, an mTORC1 inhibitor and / or an mTORC2 inhibitor described herein. In some embodiments, the kinase inhibitor is an MNK inhibitor, for example, an MNK inhibitor described herein, such as 4-amino-5-(4-fluoroanilino)-pyrazolo[3,4-d]pyrimidine. The MNK inhibitor can be, for example, an MNK1a, MNK1b, MNK2a, and / or MNK2b inhibitor. The dual PI3K / mTOR inhibitor can be, for example, PF-04695102.
[0119] In certain embodiments of the methods or uses described herein, the kinase inhibitor is aloisine A; flavopiridol or HMR-1275, 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methyl-4-piperidinyl]-4-chromenone; crizotinib (PF-02341066); 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methyl-3-pyrrolidine dinaciclib (SCH727965); N-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-1H-benzimidazol-2-amine (RAF265); indisulam (E7070); roscovitine (CYC202); palbociclib (PD0332991); dinaciclib (SCH727965); N- [5-[[(5-tert-butyloxazol-2-yl)methyl]thio]thiazol-2-yl]piperidine-4-carboxamide (BMS387032); 4-[[9-chloro-7-(2,6-difluorophenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-benzoic acid (MLN8054); 5-[3-(4,6-difluoro-1H-benzimidazol-2-yl)-1H-indazol-5-yl]-N-ethyl-4 4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid N-(piperidin-4-yl)amide (AT7519); 4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]-2-pyrimidinamine (AZD5438); and XL281 (BMS908662).
[0120] In some embodiments of the methods or uses described herein, the kinase inhibitor is a CDK4 inhibitor, e.g., palbociclib (PD0332991), and the palbociclib is administered at a dose of about 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 90 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg (e.g., 75 mg, 100 mg, or 125 mg) daily for a period of time, e.g., daily for 14 to 21 days of a 28-day cycle or daily for 7 to 12 days of a 21-day cycle. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of palbociclib are administered.
[0121] In certain embodiments of the methods or uses described herein, the kinase inhibitor is a BTK inhibitor selected from ibrutinib (PCI-32765); GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13. In certain embodiments, the BTK inhibitor does not reduce or inhibit the kinase activity of interleukin-2-inducible kinase (ITK) and is selected from GDC-0834; RN-486; CGI-560; CGI-1764; HM-71224; CC-292; ONO-4059; CNX-774; and LFM-A13.
[0122] In some embodiments of the methods or uses described herein, the kinase inhibitor is a BTK inhibitor, e.g., ibrutinib (PCI-32765), and ibrutinib is administered at a dose of about 250 mg, 300 mg, 350 mg, 400 mg, 420 mg, 440 mg, 460 mg, 480 mg, 500 mg, 520 mg, 540 mg, 560 mg, 580 mg, 600 mg (e.g., 250 mg, 420 mg, or 560 mg) daily for a period of time, e.g., daily in a 21-day cycle or daily in a 28-day cycle. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of ibrutinib are administered.
[0123] In some embodiments of the methods or uses described herein, the kinase inhibitor is a BTK inhibitor that does not inhibit the kinase activity of ITK, e.g., RN-486, and RN-486 is administered daily for a period of time at a dose of about 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, or 250 mg (e.g., 150 mg, 200 mg, or 250 mg) per day, e.g., daily in a 28-day cycle. In some embodiments, 1, 2, 3, 4, 5, 6, 7, or more cycles of RN-486 are administered.
[0124]
[0013] In certain embodiments of the methods or uses described herein, the kinase inhibitor is ridaforolimus, also known as temsirolimus; AP23573 and MK8669; (1R,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28Z,30S,32S,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.0] 4,9 ]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl dimethylphosphinate; everolimus (RAD001); rapamycin (AY22989); semapimod; (5-{2,4-bis[(3S)-3-methylmorpholin-4-yl]pyrido[2,3-d]pyrimidin-7-yl}-2-methoxyphenyl)methanol (AZD8055); 2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one (PF04691502); and N 2-[1,4-dioxo-4-[[4-(4-oxo-8-phenyl-4H-1-benzopyran-2-yl)morpholinium-4-yl]methoxy]butyl]-L-arginylglycyl-L-α-aspartylL-serine-, inner salt (SF1126); and XL765.
[0125] In some embodiments of the methods or uses described herein, the kinase inhibitor is an mTOR inhibitor, e.g., rapamycin, and the rapamycin is administered at a dose of about 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg (e.g., 6 mg) per day for a period of time, e.g., daily for a 21-day cycle or daily for a 28-day cycle. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of rapamycin are administered. In some embodiments, the kinase inhibitor is an mTOR inhibitor, e.g., everolimus, and the everolimus is administered at a dose of about 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg, 15 mg (e.g., 10 mg) per day for a period of time, e.g., daily for a 28-day cycle. In some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more cycles of everolimus are administered.
[0126] In some embodiments of the methods or uses described herein, the kinase inhibitor is an MNK inhibitor selected from CGP052088; 4-amino-3-(p-fluorophenylamino)-pyrazolo[3,4-d]pyrimidine (CGP57380); cercosporamide; ETC-1780445-2; and 4-amino-5-(4-fluoroanilino)-pyrazolo[3,4-d]pyrimidine.
[0127]
[0013] In certain embodiments of the methods or uses described herein, the kinase inhibitor is 2-amino-8-[trans-4-(2-hydroxyethoxy)cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methyl-pyrido[2,3-d]pyrimidin-7(8H)-one (PF-04691502); N-[4-[[4-(dimethylamino)-1-piperidinyl]carbonyl]phenyl]-N'-[4-(4,6-di-4-morpholinyl-1,3,5-trimethylamino ... 2-methyl-2-{4-[3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl]phenyl}propanenitrile (BEZ-235); apitolisib (GDC-0980, RG7422); 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl] -3-pyridinyl}benzenesulfonamide (GSK2126458); 8-(6-methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one maleic acid (NVP-BGT226); 3-[4-(4-morpholinylpyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]phenol (PI-103); 5 -(9-isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine (VS-5584, SB2343); and N-[2-[(3,5-dimethoxyphenyl)amino]quinoxalin-3-yl]-4-[(4-methyl-3-methoxyphenyl)carbonyl]aminophenylsulfonamide (XL765).
[0128] In some embodiments of the methods or uses described herein, the CAR-expressing immune effector cells described herein are administered to a subject in combination with a protein tyrosine phosphatase inhibitor, e.g., a protein tyrosine phosphatase inhibitor described herein. In some embodiments, the protein tyrosine phosphatase inhibitor is an SHP-1 inhibitor, e.g., an SHP-1 inhibitor described herein, such as, e.g., sodium stibogluconate. In some embodiments, the protein tyrosine phosphatase inhibitor is an SHP-2 inhibitor.
[0129] In some embodiments of the methods or uses described herein, the CAR molecule is administered in combination with another agent, and the agent is a cytokine. The cytokine can be, for example, IL-7, IL-15, IL-21, or a combination thereof. In other embodiments, the CAR molecule is administered in combination with a checkpoint inhibitor, such as a checkpoint inhibitor described herein. For example, in some embodiments, the checkpoint inhibitor inhibits an inhibitory molecule selected from PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3, and / or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and TGFR beta.
[0130] Method for producing CAR-expressing cells In another aspect, the invention pertains to a method of producing a cell (e.g., an immune effector cell or population thereof) comprising introducing (e.g., transducing) a cell, e.g., a T cell or an NK cell described herein, with a vector comprising a nucleic acid encoding a CAR, e.g., a CAR described herein; or a nucleic acid encoding a CAR molecule, e.g., a CAR described herein.
[0131] The cells in this method are immune effector cells (e.g., T cells or NK cells, or a combination thereof). In some embodiments, the cells in this method are diacylglycerol kinase (DGK) and / or Ikaros deficient.
[0132] In some embodiments, introducing the nucleic acid molecule encoding a CAR comprises transducing a vector comprising the nucleic acid molecule encoding a CAR or transfecting the nucleic acid molecule encoding a CAR, wherein the nucleic acid molecule is in vitro transcribed RNA.
[0133] In some embodiments, the method further comprises: a. providing an immune effector cell population (e.g., T cells or NK cells); and b. removing T regulatory cells from the population, thereby providing a T regulatory depleted cell population; wherein steps a) and b) are performed before introducing the nucleic acid encoding the CAR into the population.
[0134] In an embodiment of the method, the T regulatory cells comprise CD25+ T cells and are removed from the cell population using an anti-CD25 antibody or fragment thereof, which can be coupled to a substrate, e.g., a bead.
[0135] In other embodiments, the T regulatory depleted cell population provided by step (b) comprises less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1% CD25+ cells.
[0136] In yet another embodiment, the method further comprises: Prior to introducing the nucleic acid encoding the CAR into the population, cells expressing tumor antigens other than CD25 are removed from the population to provide a T regulatory-depleted and tumor antigen-depleted cell population. The tumor antigen can be selected from CD19, CD30, CD38, CD123, CD20, CD14, or CD11b, or a combination thereof.
[0137] In another embodiment, the method further comprises: Prior to introducing the nucleic acid encoding the CAR into the population, cells expressing a checkpoint inhibitor are removed from the population to provide a T regulatory-depleted and inhibitory molecule-depleted cell population. The checkpoint inhibitor can be selected from PD-1, LAG-3, TIM3, B7-H1, CD160, P1H, 2B4, CEACAM (e.g., CEACAM-1, CEACAM-3 and / or CEACAM-5), TIGIT, CTLA-4, BTLA, and LAIR1.
[0138] Further, embodiments disclosed herein include providing a population of immune effector cells. The provided immune effector cell population can be selected based on expression of one or more of CD3, CD28, CD4, CD8, CD45RA, and / or CD45RO. In some embodiments, the provided immune effector cell population is CD3+ and / or CD28+.
[0139] In some embodiments of the method, the method further comprises expanding the cell population after the nucleic acid molecule encoding the CAR is introduced. In some embodiments, the cell population is expanded for a period of 8 days or less.
[0140] In one embodiment, a cell population is expanded in culture for 5 days, and the resulting cells are more potent than the same cells expanded in culture for 9 days under the same culture conditions.
[0141] In other embodiments, the cell population is expanded in culture for 5 days and exhibits at least a 1-fold, 2-fold, 3-fold, or 4-fold increase in cell doublings upon antigen stimulation compared to the same cells expanded in culture for 9 days under the same culture conditions.
[0142] In yet another embodiment, the cell population is expanded in culture for 5 days, and the resulting cells exhibit elevated pro-inflammatory IFN-γ and / or GM-CSF levels compared to the same cells expanded in culture for 9 days under the same culture conditions.
[0143] In other embodiments, the cell population is expanded by culturing the cells in the presence of an agent that stimulates a CD3 / TCR complex-associated signal and / or a ligand that stimulates a costimulatory molecule on the cell surface, the agent being beads coupled with an anti-CD3 antibody or fragment thereof and / or an anti-CD28 antibody or fragment thereof.
[0144] In other embodiments, the cell population is expanded in an appropriate medium containing one or more interleukins that result in at least a 200-fold, 250-fold, 300-fold, or 350-fold increase in cells as measured by flow cytometry over a 14-day expansion period.
[0145] In other embodiments, the cell population is expanded in the presence of IL-15 and / or IL-7.
[0146] In certain embodiments, the method further comprises cryopreserving the cell population after a suitable expansion period.
[0147] In yet another embodiment, the method of producing the cells disclosed herein further comprises contacting the population of immune effector cells with a nucleic acid encoding a telomerase subunit, e.g., hTERT. The nucleic acid encoding the telomerase subunit can be DNA.
[0148] The present invention also provides a method for producing a population of RNA-engineered cells, e.g., cells described herein, e.g., immune effector cells (e.g., T cells, NK cells), that transiently express an exogenous RNA. The method includes introducing in vitro transcribed or synthetic RNA into the cells, wherein the RNA includes a nucleic acid encoding a CAR molecule described herein.
[0149] In another aspect, the invention relates to a method of providing anti-tumor immunity to a subject, comprising administering to the subject an effective amount of cells comprising a CAR molecule, e.g., cells expressing a CAR molecule described herein. In some embodiments, the cells are autologous T cells or NK cells. In some embodiments, the cells are allogeneic T cells or NK cells. In some embodiments, the subject is human.
[0150] In one aspect, the invention includes an autologous cell population transfected or transduced with a vector comprising a nucleic acid molecule encoding a CAR, e.g., as described herein. In some embodiments, the vector is a retroviral vector. In some embodiments, the vector is a self-inactivating lentiviral vector as described elsewhere herein. In some embodiments, the vector is delivered (e.g., by transfection or electroporation) to a cell, e.g., a T cell or an NK cell, wherein the vector comprises a nucleic acid molecule encoding a CAR of the invention as described herein, which is transcribed as an mRNA molecule, and the CAR of the invention is translated from the RNA molecule and expressed on the surface of the cell.
[0151] In another aspect, the present invention provides a population of CAR-expressing cells, e.g., CAR-expressing immune effector cells (e.g., T cells or NK cells). In some embodiments, the CAR-expressing cell population comprises a mixture of cells expressing different CARs. For example, in some embodiments, a population of CAR-expressing immune effector cells (e.g., T cells or NK cells) can comprise a first cell expressing a CAR having an antigen binding domain that binds to a first tumor antigen described herein and a second cell expressing a CAR having a different antigen binding domain that binds to a second tumor antigen described herein. As another example, a CAR-expressing cell population can comprise a first cell expressing a CAR comprising an antigen binding domain that binds to a tumor antigen described herein and a second cell expressing a CAR comprising an antigen binding domain for targeting an antigen other than a tumor antigen described herein. In some embodiments, the CAR-expressing cell population comprises, e.g., a first cell expressing a CAR comprising a primary intracellular signaling domain and a second cell expressing a CAR comprising a secondary signaling domain, e.g., a costimulatory signaling domain.
[0152] In another aspect, the present invention provides a cell population, wherein at least one cell in the population expresses a CAR having an antigen binding domain that binds to a tumor antigen described herein, and a second cell expresses another agent, e.g., an agent that enhances the activity of the CAR-expressing cell. For example, in some embodiments, the agent can be an agent that inhibits an inhibitory molecule. Examples of inhibitory molecules include PD-1, PD-L1, CTLA-4, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3, and / or CEACAM-5), LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and TGFR beta. In some embodiments, the agent that inhibits an inhibitory molecule is, e.g., a molecule described herein, e.g., an agent comprising a first polypeptide, e.g., an inhibitory molecule, associated with a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide of an inhibitory molecule such as, e.g., PD-1, LAG-3, CTLA-4, CD160, BTLA, LAIR1, TIM-3, CEACAM (e.g., CEACAM-1, CEACAM-3 and / or CEACAM-5), 2B4, and TIGIT, or a fragment of any of these, and a second polypeptide which is an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., 41BB, CD27, or CD28, e.g., as described herein) and / or a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD-1 or a fragment thereof, and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28, CD27, OX40, or 4-IBB signaling domain described herein and / or a CD3 zeta signaling domain described herein).
[0153] In some embodiments, for example, as described herein, a nucleic acid molecule encoding a CAR of the invention is expressed as an mRNA molecule. In some embodiments, cells, e.g., immune effector cells (e.g., T cells, NK cells), expressing a genetically modified CAR of the invention can be produced by transfecting or electroporating cells with an RNA molecule encoding the desired CAR (e.g., without vector sequences). In some embodiments, the CAR molecule of the invention is translated from the RNA molecule once taken up and expressed on the surface of the recombinant cell. [Brief explanation of the drawings]
[0154] [Figure 1] Figure 1: A panel of images showing flow cytometry detection of ErbB2 surface expression on tumors and cell lines. Cells were stained with anti-ErbB2 affibody-biotin and detected with streptavidin-allophycocyanin (APC) (open histograms); cells incubated with APC alone show background (gray histograms).
[0155] [Figure 2] Figures 2A, 2B, and 2C are a collection of ErbB2 detection by flow cytometry and quantitative PCR. ErbB2 copy number (ErbB2 / 1E6 actin) detected by quantitative PCR (Figure 2A). ErbB2 mean fluorescence intensity (ErbB2 MFI) as shown in the histogram in Figure 1 (Figure 2B). The collection was plotted by ErbB2 expression detected by flow cytometry (MFI, x-axis) and quantitative PCR (y-axis). The forward and reverse primers and probes used for ErbB2 quantitative PCR were as follows: ErbB2-1F, GCCTCCACTTCAACCACAGT (SEQ ID NO: 50); ErbB2-1R, TCAAACGTGTCTGTGTTGTAGGT (SEQ ID NO: 66); ErbB2-1M2, FAM-CAGTGCAGCTCACAGATG (SEQ ID NO: 51).
[0156] [Figure 3]Figure 3: A panel of images showing FACS analysis of affinity-tuned CAR expression in mRNA-electroporated T cells. T cells were electroporated with the indicated CAR mRNA, and 1 day after electroporation, CAR expression was detected using an anti-mouse IgG Fab antibody (for CD19-BBZ) or ErbB2-Fc (for ErbB2-BBZ CAR). Non-electroporated T cells were used as a negative control.
[0157] [Figure 4] Figure 4: A panel of images showing induction of CD137 (4-1BB) expression in CAR T cells after stimulation with tumor cells was measured. One day after electroporation, various CAR T cells (KD, nM) were co-cultured with the indicated tumor cell lines, and CD137 expression was measured 24 hours later.
[0158] [Figure 5] Figure 5: Cytokine secretion was measured in culture supernatants (ELISA). T cells were electroporated with 5 μg or 10 μg affinity-tuned ErbB2 CAR mRNA as indicated. One day after electroporation, CAR T cells were co-cultured with the indicated tumor cell lines for 24 hours. The bar graph shows the results of a representative experiment for IFN-gamma (values represent the mean ± SD of duplicates).
[0159] [Figure 6] Figure 6: Cytokine secretion was measured in culture supernatants (ELISA). T cells were electroporated with 5 μg or 10 μg affinity-tuned ErbB2 CAR mRNA as indicated. One day after electroporation, CAR T cells were co-cultured with the indicated tumor cell lines for 24 hours. Bar graphs show results from a representative experiment for IL-2 (values represent the mean ± SD of duplicates).
[0160] [Figure 7]Figure 7: CD107a upregulation in tumor-stimulated CAR T cells. T cells were electroporated with 5 μg or 10 μg of ErbB2 CAR mRNA encoding the indicated scFv, and one day later, CAR T cells were co-cultured with the indicated cell line for 4 hours and CD107a expression was measured by gating on CD3+CD8+ cells.
[0161] [Figure 8] Figure 8: A panel of images showing additional tumor cell lines were tested for ErbB2 expression by flow cytometry using biotin-ErbB2 affibody (streptavidin-PE) staining (open histograms). The same cells stained only with streptavidin-PE were used as a negative control (gray histograms).
[0162] [Figure 9] Figure 9: T cells electroporated with ErbB2 CAR mRNA were stimulated with the tumor lines tested in C. SK-OK3, BT-474, HCC2281, MDA-361, MDA-453, HCC-1419, HCC-1569, UACC-812, and LnCap have been reported to be ErbB2-amplified tumors, whereas MDA-175, MCF-10A, HCC38, and HG261 have been reported to be ErbB2-low or -negative cell lines. After 4 h of stimulation, CD107a on T cells was monitored by flow cytometry staining, and the % of cells expressing CD107a was plotted.
[0163] [Figure 10] Figure 10: A panel of images showing recognition of K562 cells electroporated with the indicated amount of ErbB2 mRNA and co-cultured with targets CAR T cells expressing the indicated scFv (KD, nM) for 4 hours, and % CD107a expression was quantified on CD3+CD8+ cells.
[0164] [Figure 11]Figure 11A: A panel of images showing ErbB2 expression in K562 cells after electroporation. K562 cells were electroporated with the indicated amounts of ErbB2 mRNA, and staining indicates ErbB2-expressing cells (open histogram); cells incubated with secondary antibody only show background (gray histogram).
[0165] Figure 11B: IFN-gamma secretion by a panel of ErbB2 CART cells stimulated with ErbB2 mRNA-electroporated K562 cells. K562 cells were electroporated with 2 μg or 10 μg ErbB2 CAR mRNA as indicated. CAR T cells were co-cultured with the indicated K562 targets and IFN-gamma secretion was measured by ELISA 24 hours later.
[0166] [Figure 12] Figure 12: A panel of images showing the proliferation of a panel of affinity-tuned CAR T cells after stimulation with ErbB2 mRNA-electroporated K562 cells. Resting T cells were labeled with CFSE and electroporated with 10 μg CAR mRNA. K562 cells were electroporated with the indicated doses of ErbB2 mRNA or control CD19 mRNA (19BBBZ). T cells and irradiated targets were cultured for 7 days (1:1 ratio) and CFSE dilution was measured by flow cytometry (CD3 gated); % dividing T cells are shown.
[0167] [Figure 13] Figures 13A, 13B, and 13C: Cytotoxicity of a panel of CAR T cells against ErbB2 mRNA electroporated Nalm6-CBG target cells was measured. T cells were electroporated with ErbB2 or CD19 CAR mRNA as indicated. CD19+ve Nalm6-CBG (click beetle green) target cells were electroporated with the indicated doses of ErbB2 mRNA: 10 μg ErbB2 RNA (Figure 13A); 1 μg ErbB2 RNA (Figure 13B); and 0.1 μg ErbB2 RNA (Figure 13C). One day after electroporation, CAR T cells were co-cultured with Nalm6-CBG cells at the indicated E:T ratio, and % specific lysis was calculated after 8 hours.
[0168] [Figure 14] Figure 14: A panel of images showing ErbB2 expression in the indicated primary cell lines. Primary cell lines were stained with anti-ErBb2 affibody-biotin and detected with streptavidin-allophycocyanin (APC) (open histograms); cells stained with APC only served as a control (gray histograms).
[0169] [Figure 15] Figure 15: Selective targeting of ErbB2 on primary cell lines. A panel of CAR T cells was stimulated with the indicated primary cell lines for 4 hours and the % of CAR T cells expressing CD107a was determined by gating on CD3+CD8+ cells.
[0170] [Figure 16] Figures 16A, 16B, and 16C: Panels of images showing T cells were modified with high (4D5) or low (4D5-5) affinity ErbB2 CARs using lentiviral transduction (LVV) or mRNA electroporation (RNA), as indicated. CAR expression % and brightness were measured using ErbB2-Fc (Figure 16A). ErbB2 expression on a panel of tumor lines and K562 cells electroporated with ErbB2 mRNA was detected by flow cytometry (Figures 16B and 16C); cell + cell percentage and (MFI) are shown for K562 cells.
[0171] [Figure 17] Figure 17: A panel of images showing CAR T cell recognition of the indicated tumor lines. After 4 hours of stimulation with the indicated tumor lines, CD107a upregulation was measured on lentiviral-transduced or mRNA-electroporated CAR T cells (gated on CD3+ cells).
[0172] [Figure 18]Figure 18: Panel of images showing CAR T cell recognition of K562 cells electroporated with the indicated amounts of ErbB2 mRNA. Induction of CD107a expression was measured in lentiviral-transduced or mRNA-electroporated CAR T cells after 4 hours of stimulation with ErbB2-electroporated K562 cells by gating on CD3+ cells.
[0173] [Figure 19] Figure 19: A panel of images showing ErbB2 target-dependent upregulation of CD107a on lentiviral-transduced or mRNA-electroporated T cells. As shown in the main text of Figure 4A, T cells were stimulated for 4 hours with tumor cell lines expressing ErbB2 at various levels, ranging from overexpression to low levels. CD107a upregulation was detected by flow cytometry (CD3+ gated).
[0174] [Figure 20] Figure 20: IFN-gamma secretion by lentiviral-transduced or RNA-electroporated CAR T cells was measured by ELISA after 18 hours.
[0175] [Figure 21] Figure 21: IFN-gamma production by CAR T cells measured 18 hours after stimulation with K562 cells electroporated with the indicated amounts of ErbB2 mRNA.
[0176] [Figure 22] Figure 22: A series of images showing regression of advanced vascularized tumors in mice treated with affinity-tuned ErbB2 CAR T cells. Flank tumors were established by injection of 5x106 SK-OV3-CBG (sc) into NOD-SCID-γ- / - (NSG) mice (n=5). 18 days after tumor inoculation, mice were randomized to equalize tumor burden and treated with 1x107 lentiviral-transduced T cells expressing either high-affinity (4D5.BBZ) or low-affinity (4D5-5.BBZ) CARs. Mice treated with non-transduced T cells (T cells alone) served as controls. Animals were imaged at the indicated time points after tumor inoculation.
[0177] [Figure 23] Figure 23: A series of images showing in vivo differentiation of high ErbB2 (SK-OV3) and low ErbB2 (PC3) expressing tumors by affinity-tuned CARs. T cells modified with different affinity ErbB2 CARs by lentiviral transduction were tested in dual-tumor-implanted NSG mice. Mice were implanted with PC3-CBG tumor cells (1e6 cells / mouse, sc) in the right flank on day 0. On day 5, the same mice received SK-OV3-CBG tumor cells (5e6 cells / mouse, sc) in the left flank. Mice were treated with T cells (iv) on day 23 after PC3 tumor inoculation. CAR T cells were given as a single injection of 10e6 / mouse (10M) or 3e6 / mouse (3M) as indicated. Cells treated with non-transduced T cells served as controls. Animals were imaged at the indicated times after PC3 tumor inoculation.
[0178] [Figure 24] Figure 24: SK-OV3 tumor size in dual-tumor-implanted NSG mice treated with the indicated affinity-tuned ErbB2 CARs. SK-OV3 tumor size was measured over time (days, x-axis) and tumor volume was calculated and plotted (mm, y-axis).
[0179] [Figure 25] Figure 25: PC3 tumor size in dual-tumor-implanted NSG mice treated with the indicated affinity-tuned ErbB2 CARs. PC3 tumor size was measured over time (days, x-axis) and tumor volume was calculated and plotted (mm, y-axis).
[0180] [Figure 26]Figures 26A and 26B: Set of images showing CAR expression on T cells electroporated with EGFR CAR mRNA, stained with anti-human IgG Fab and detected by flow cytometry staining (Figure 26A); affinity of scFv is shown (nM). Tumor lines (Figure 26B) were stained with anti-EGFR affibody-FITC (open histogram), and the same cells were stained with mouse IgG1-FITC as an isotype control (gray histogram).
[0181] [Figure 27] Figure 27: EGFR CAR recognition sensitivity correlates with affinity. A panel of EGFR CAR T cells with the indicated affinity of the scFv (KD, nM) was stimulated with a panel of EGFR-expressing tumors at the density shown in Figure 26B. After 4 hours of stimulation, CD107a upregulation on CAR T cells was detected by gating on CD3+ cells.
[0182] [Figure 28] Figure 28: A series of images showing ErbB2 expression in K562 cells electroporated with the indicated amounts of EGFR mRNA. EGFR expression was detected 14 hours after electroporation using anti-EGFR affibody-FITC staining.
[0183] [Figure 29] Figure 29: EGFR CAR recognition sensitivity correlates with affinity. T cells were electroporated with a panel of EGFR CARs with different affinities as indicated and stimulated with K562 electroporated with different levels of EGFR mRNA as shown in Figure 30. After 4 hours of stimulation, CD107a expression on CAR T cells was measured by gating on CD3+ cells.
[0184] [Figure 30]Figure 30: Affinity-dependent recognition of primary cell lines and tumor cells using affinity-tuned EGFR CARs. T cells were electroporated with the indicated EGFR CAR mRNA. One day after electroporation, CAR T cells were stimulated with a panel of cells for 4 hours and induction of CD107a expression on CAR T cells was quantified (CD3+ gated).
[0185] [Figure 31] Figure 31: Differential recognition of primary cell lines by T cells modified with affinity-tuned EGFR CARs. The percentage of CD8+CD107a+ double positive cells is plotted.
[0186] [Figure 32] Figure 32: Depicts the NFAT-inducible promoter-driven luciferase activity of PD1 CARs compared to control treatment with IgG1-Fc. Figure 22B depicts the NFAT-inducible promoter-driven luciferase activity of PD1 RCARs containing PD1-ECD-TM-FRB and FKBP-4 1BB-CD3 zeta compared to control treatment with IgG1-Fc.
[0187] [Figure 33]Figures 33A and 33B: Generation of folate receptor alpha (FRA)-specific fully human chimeric antigen receptor (CAR) T cells. (Figure 33A) Schematic representation of C4-based CAR constructs containing the CD3 zeta cytoplasmic domain alone (C4-z) or in combination with the CD27 costimulatory module (C4-27z). The mouse anti-human FRA MOv19-27z CAR is also shown. (Figure 33B) A series of images showing transduced T cells, CD4- and CD8-positive cells in both subsets expressing the C4 CAR. After lentiviral transduction, C4 CAR expression (open histogram) compared to untransduced (UNT) T cells (gray histogram) was detected by biotin-labeled rabbit anti-human IgG (H+L) staining followed by streptavidin-phycoerythrin. Transduction efficiency is shown with the percentage of CAR expression in parentheses. ScFv, single-chain antibody variable fragment L, linker; C4, anti-FRA scFv; VH, variable heavy chain; VL, variable light chain; TM, transmembrane region.
[0188] [Figure 34]Figures 34A, 34B, 34C, 34D, and 34E. Comparison of the antitumor activity of FR-specific C4 and MOv19 CARs and CD27 costimulatory endodomains in vitro. (Figure 34A) A series of images showing that C4 and MOv19 CAR expression on primary human T cells can be detected with biotin-labeled recombinant FRA protein followed by SA-PE. As shown, both CD8+ T and CD8- (CD4+) cells can efficiently express CARs as measured by flow cytometry. (Figure 34B) A series of graphs showing that C4- and MOv19 CAR-transduced T cells exhibited lytic function in a bioluminescent killing assay. CAR-T cells killed FR+ SKOV3 and A1847 over 20 hours at the indicated E / T ratios. Non-transduced T cells served as a negative control. The mean and SD of triplicate wells from at least three independent experiments are shown. (Figure 34C) C4 or MOv19 CAR T cells were co-cultured with FRA+ target cells (SKOV3, A1847, and T47D) and FRA- (C30) at a 1:1 E:T ratio. (Figure 34D) Set of images showing C4 or MOv19 CAR T cells stimulated with SKOV3 cells in the presence of Golgi inhibitor for 5 hours and analyzed by flow cytometry for intracellular IFN-g, TNF-a, and IL-2. (Figure 34E) IFN-g release assay of C4 and MOv19 CAR T cells after overnight co-culture with FRA+ tumor cells (1:10, 1:3, 1:1, 3:1, and 10:1 ratios).
[0189] [Figure 35]Figures 35A, 35B, 35C, and 35D: The anti-tumor activity of C4-CAR T cells is comparable to that of MOv19 CAR T cells. (Figure 35A) Tumor regression mediated by C4-27z and MOv19-27z CAR T cells. NSG mice bearing established subcutaneous tumors were treated with an iv injection of 1 x 10 C4-27z and MOv19-27z CAR+ T cells or control CD19-27z and UNT T cells or saline on days 40 and 45. Tumor growth was assessed by caliper measurement. Tumors treated with C4-27z CAR or MOv19 CAR T cells (approximately 60% CAR expression) regressed (arrows indicate the day of T cell infusion); tumors treated with saline, UNT, or CD19-27z CAR T cells did not regress 3 weeks after the first T cell administration. (Figure 35B) A series of images showing that SKOV3 fLuc+ bioluminescence signal was reduced in C4-27z and MOv19-27z CAR T cell-treated mice compared to CD19-27z and control-treated groups 3 weeks after the first T cell administration. (Figure 35C) Macroscopic evaluation of resected tumor specimens after T cell treatment. Tumors were harvested from mice at the time of euthanasia, approximately 45 days after the first T cell injection. (Figure 35D) Stable persistence of C4 CAR and MOv19 CAR T cells in vivo. Peripheral blood was collected 3 weeks after the first T cell infusion, and the absolute numbers of human CD4+ and CD8+ T cells / μL of blood were quantified. Mean cell counts ± SEM are shown, n=5 for all groups.
[0190] [Figure 36]Figures 36A, 36B, and 36C: C4 CAR T cells showed minimal cytotoxic activity in vitro. (Figure 36A) A series of images showing that human embryonic kidney 293T cells and the normal epithelial ovarian cell line IOSE6 express very low levels of FRA. SKOV3 and C30 served as positive and negative controls, respectively. (Figure 36B) C4-27z CAR T cells express minimal amounts of IFN-γ after overnight incubation with normal 293T cells and IOSE6 cell lines, which express low levels of surface FRA, compared to MOv19-27z CAR T cells. (Figure 36C) A series of images showing that C4 and MOv19 CAR T cells were stimulated with 293T or IOSE6 cells for 5 hours in the presence of a Golgi inhibitor and analyzed by flow cytometry for intracellular IFN-γ and TNF-α.
[0191] [Figure 37] Figures 37A and 37B: Fully human C4 CAR is expressed and detected on the T cell surface. (Figure 37A) A series of images showing lentiviral titers (transducing units, TU) determined using SupT1 cells based on a three-fold serial dilution of concentrated virus from 1:3 to a final dilution of 1:6,561. C4 CAR-encoding lentivirus has a higher titer when compared to that of MOv19 CAR-encoding lentivirus, following the same production and concentration protocol in parallel. (Figure 37B) A series of images showing primary human T cells infected with C4 CAR- or MOv19 CAR-encoding lentivirus at a multiplicity of infection (MOI) of 1, 2, or 5. These data represent one of at least three independent experiments.
[0192] [Figure 38]Figures 38A, 38B, 38C: Figures 38A and 38B show untransduced T cells stimulated with FRA+ SKOV3 cells in the presence of a Golgi inhibitor for 5 hours and analyzed by flow cytometry for intracellular IFN-g, TNF-a, and IL-2, and C4 or MOvl9 CAR T cells stimulated with FRA-C30 cells in the presence of a Golgi inhibitor for 5 hours and analyzed by flow cytometry for intracellular IFN-g, TNF-a, and IL-2. Figure 38C shows αFR expression on SKOV3, A1847, and T47D tumor cell lines; the C30 cell line was used as a negative control.
[0193] [Figure 39] Figures 39A, 39B, 39C: A series of images showing that CAR downregulation can impair the antitumor activity of MOv19 CAR, but not C4 CAR. C4 and MOv19 CAR T cells were stimulated with SKOV3 or C30 cells in the presence of Golgi inhibitors for 5 hours and analyzed by flow cytometry for T cell surface CAR expression and intracellular IFN-g, TNF-α, and IL-2. (Figure 39A) Flow cytometry analysis of CAR expression changes following 4 hours of coculture with αFR+ or αFR tumor cells. (Figure 39B) MOv19 and C4 CAR T cells were cocultured with αFR+ or αFR tumor cells and stained with Annexin V and 7-AAD. Apoptotic cells are shown as the percentage of gated cells. In Figure 39C, cells were stained for CD137.
[0194] [Figure 40] Figure 40: Set of images showing flow cytometry analysis of CAR expression changes after overnight co-culture with FRA+ tumor cells (at 1:10, 1:3, 1:1, 3:1 and 10:1 ratios).
[0195] [Figure 41]Figure 41, comprising Figures 41A and 41B, is a graph showing the increase in titers against influenza vaccine strains compared to placebo. In Figure 41A, the increase above baseline in influenza geometric mean titers against each of the three influenza vaccine strains (H1N1 A / California / 07 / 2009, H3N2 A / Victoria / 210 / 2009, B / Brisbane / 60 / 2008) is shown for each of the RAD001 dosing cohorts in the intention-to-treat population, compared to the increase in the placebo cohort, 4 weeks after vaccination. The thick black line indicates the 1.2-fold increase in titer against placebo that was required for two of the three influenza vaccine strains to meet the primary endpoint of the trial. An asterisk "*" indicates that the GMT titer against placebo exceeds 1 with at least an 80% posterior probability. FIG. 41B shows the same data as FIG. 41A for the subset of subjects with baseline influenza titers ≦1:40.
[0196] [Figure 42] Figure 42 shows a series of scatter plots of RAD001 concentrations versus fold increase in geometric mean titer for each influenza vaccine strain 4 weeks after vaccination. RAD001 concentrations (1 hour post-dose) were measured after subjects had been dosed for 4 weeks. All subjects with pharmacokinetic measurements were included in the analysis set. The fold increase in geometric mean titer 4 weeks after vaccination relative to baseline is shown on the y-axis.
[0197] [Figure 43] Figure 43 is a graph showing the increase in titers against heterologous influenza strains compared to placebo. The increase above baseline in influenza geometric mean titers against two heterologous influenza strains not included in the influenza vaccine (A / H1N1 strain A / New Jersey / 8 / 76 and A / H3N2 strain A / Victoria / 361 / 11) relative to the placebo cohort 4 weeks after vaccination is shown for each of the RAD001 dosing cohorts in the intention-to-treat population. * indicates an increase in titer relative to placebo of greater than 1 with at least an 80% posterior probability.
[0198] [Figure 44] Figure 44, comprising Figures 44A and 44B, is a graph of IgG and IgM levels before and after influenza vaccination. Anti-A / H1N1 / California / 07 / 2009 influenza IgG and IgM levels were measured in serum obtained from subjects before and 4 weeks after influenza vaccination. No significant changes were detected between the RAD001 and placebo cohorts (all p-values >0.05 by Kruskal-Wallis rank sum test) in anti-H1N1 influenza IgG and IgM levels from baseline to 4 weeks after vaccination.
[0199] [Figure 45]Figure 45, comprising Figures 45A, 45B, and 45C, is a graph depicting the decrease in the percent of PD-1 positive CD4 and CD8 and the increase in PD-1 negative CD4 T cells following treatment with RAD001. The percent of PD-1 positive CD4, CD8, and PD-1 negative CD4 T cells was determined by FACS analysis of PBMC samples at baseline, 6 weeks after study drug treatment (week 6), and 6 weeks after discontinuation of study drug and 4 weeks after influenza vaccination (week 12). Figure 45A shows that there was a significant decrease (-37.1% to -28.5%) in PD-1 positive CD4 T cells at week 12 in cohorts receiving RAD001 at dose levels of 0.5 mg / day (n=25), 5 mg / week (n=29), and 20 mg / week (n=30) compared to the placebo cohort (n=25), with p=0.002 (0.02), p=0.003 (q=0.03), and p=0.01 (q=0.05), respectively. Figure 45B shows that there was a significant decrease (-43.3% to -38.5%) in PD-1 positive CD8 T cells at week 12 in cohorts receiving RAD001 (n=109) at dose levels of 0.5 mg / day (n=25), 5 mg / week (n=29), and 20 mg / week (n=30) compared to the placebo cohort (n=25), with p=0.01 (0.05), p=0.007 (q=0.04), and p=0.01 (q=0.05), respectively. Figure 45C shows that there was a significant increase (3.0% to 4.9%) in PD-1 negative CD4 T cells at week 12 in cohorts receiving RAD001 (n=109) at dose levels of 0.5 mg / day (n=25), 5 mg / week (n=29), and 20 mg / week (n=30) compared to the placebo cohort (n=25), with p=0.0007 (0.02), p=0.03 (q=0.07), and p=0.03 (q=0.08), respectively.
[0200] [Figure 46]Figure 46, comprising Figures 46A and 46B, is a graph depicting the decrease in the percent of PD-1 positive CD4 and CD8 and the increase in PD-1 negative CD4 T cells following treatment with RAD001. The percent of PD-1 positive CD4, CD8, and PD-1 negative CD4 T cells was determined by FACS analysis of PBMC samples at baseline, 6 weeks after study drug treatment (week 6), and 6 weeks after discontinuation of study drug and 4 weeks after influenza vaccination (week 12). Figure 46A shows that there was a significant decrease (-37.1% to -28.5%) in PD-1 positive CD4 T cells at week 12 in cohorts receiving RAD001 at dose levels of 0.5 mg / day (n=25), 5 mg / week (n=29), and 20 mg / week (n=30) compared to the placebo cohort (n=25), with p=0.002 (0.02), p=0.003 (q=0.03), and p=0.01 (q=0.05), respectively. Figure 46B shows that there was a significant decrease (-43.3% to -38.5%) in PD-1 positive CD8 T cells at week 12 in cohorts receiving RAD001 (n=109) at dose levels of 0.5 mg / day (n=25), 5 mg / week (n=29), and 20 mg / week (n=30) compared to the placebo cohort (n=25), with p=0.01 (0.05), p=0.007 (q=0.04), and p=0.01 (q=0.05), respectively. Figure 45C shows that there was a significant increase (3.0% to 4.9%) in PD-1 negative CD4 T cells at week 12 in cohorts receiving RAD001 (n=109) at dose levels of 0.5 mg / day (n=25), 5 mg / week (n=29), and 20 mg / week (n=30) compared to the placebo cohort (n=25), with p=0.0007 (0.02), p=0.03 (q=0.07), and p=0.03 (q=0.08), respectively.
[0201] [Figure 47] FIG. 47 is a series of graphs showing increased activity and energy in response to RAD001 in elderly subjects.
[0202] [Figure 48]Figure 48, comprising Figures 48A and 48B, shows the effect of RAD001 on P70 S6K activity in cell lines. Figure 48A shows P70 S6 kinase inhibition with weekly and daily high doses of RAD001; Figure 48B shows P70 S6 kinase inhibition with weekly low doses of RAD001.
[0203] [Figure 49] Figures 49A, 49B, 49C, 49D, 49E, and 49F: Graphs showing normalized MFI values for the following genes in individual samples: CD79A (Figure 49A), CCR2 (Figure 49B), TNFRSF17 (Figure 49C), HSPB1 (Figure 49D), CD72 (Figure 49E), and CD48 (Figure 49F). The Y-axis represents normalized MFI; the X-axis represents the target gene.
[0204] [Figure 50] Figures 50A, 50B, 50C, 50D, 50E, and 50F: Graphs representing normalized MFI values for the following genes in individual samples: TNFRSF13C (Figure 50A), IL3RA (Figure 50B), SIGLEC1 (Figure 50C), LAIR1 (Figure 50D), FCAR (Figure 50E), and CD79B (Figure 50F). The Y-axis represents normalized MFI; the X-axis represents the target gene.
[0205] [Figure 51] Figures 51A, 51B, 51C, 51D, 51E, and 51F: Graphs representing normalized MFI values for the following genes in individual samples: LILRA2 (Figure 51A), CD37 (Figure 51B), CD300LF (Figure 51C), CLEC12A (Figure 51D), BST2 (Figure 51E), and CD276 (Figure 51F). The Y-axis represents normalized MFI; the X-axis represents the target gene.
[0206] [Figure 52]Figures 52A, 52B, 52C, 52D, 52E, and 52F: Graphs representing normalized MFI values for the following genes in individual samples: EMR2 (Figure 52A), HSPH1 (Figure 52B), RGS13 (Figure 52C), CLECL1 (Figure 52D), SPN (Figure 52E), and CD200 (Figure 52F). The Y-axis represents normalized MFI; the X-axis represents the target gene.
[0207] [Figure 53] Figures 53A, 53B, 53C, 53D, 53E, and 53F: Graphs showing normalized MFI values for the following genes in individual samples: LY75 (Figure 53A), SIRPB1 (Figure 53B), FLT3 (Figure 53C), CD22 (Figure 53D), PTPRC (Figure 53E), and GPRC5D (Figure 53F). The Y-axis represents normalized MFI; the X-axis represents the target gene.
[0208] [Figure 54] Figures 54A, 54B, 54C, 54D, 54E, and 54F: Graphs showing normalized MFI values for the following genes in individual samples: UMODL1 (Figure 54A), CD74 (Figure 54B), MS4A3 (Figure 54C), CD302 (Figure 54D), TNFRFSF13B (Figure 54E), and MSN (Figure 54F). The Y-axis represents normalized MFI; the X-axis represents the target gene.
[0209] [Figure 55] Figures 55A, 55B, 55C, 55D, 55E, and 55F: Graphs representing normalized MFI values for the following genes in individual samples: KIT (Figure 55A), GPC3 (Figure 55B), CD101 (Figure 55C), CD300A (Figure 55D), SEMA4D (Figure 55E), and CD86 (Figure 55F). The Y-axis represents normalized MFI; the X-axis represents the target gene.
[0210] [Figure 56]Figures 56A, 56B, 56C, 56D, 56E, and 56F: Graphs representing normalized MFI values for the following genes in individual samples: SIGLEC5 (Figure 56A), GPR114 (Figure 56B), FCRL5 (Figure 56C), ROR1 (Figure 56D), PTGFRN (Figure 56E), and IGLL1 (Figure 56F). The Y-axis represents normalized MFI; the X-axis represents the target gene.
[0211] [Figure 57] Figures 57A, 57B, 57C, 57D, and 57E: Graphs showing normalized MFI values for the following genes in individual samples: CD244 (Figure 57A), CD19 (Figure 57B), CD34 (Figure 57C), BST1 (Figure 57D), and TFRC (Figure 57E). The Y-axis represents normalized MFI; the X-axis represents the target gene.
[0212] [Figure 58] Figure 58: Cumulative representation of the mean normalized MFI values for the PP1B housekeeping gene from AML, ALL, normal bone marrow (NBM), or OV357 cell line (OV357). Y-axis represents normalized MFI; X-axis represents target gene.
[0213] [Figure 59] Figures 59A and 59B: Generation of T cells expressing a CAR targeting the folate receptor alpha. Figure 59A is a schematic diagram of the C4-27z CAR vector. Figure 59B is a series of representative FACS histogram plots of CAR expression in CD4+ and CD8+ T cells 48 hours after lentiviral transduction.
[0214] [Figure 60] Figure 60: Schematic of an in vivo experiment to test combinations of CAR-T cells and various cytokines in an ovarian tumor mouse model.
[0215] [Figure 61]Figure 61: Tumor growth curves of mice treated with various cytokine-exposed C4-27z CAR-T cells, anti-CD19-27z CAR-T cells, and non-transduced T cells. Data are shown as mean ± SEM. Arrows indicate the time of T cell injection.
[0216] [Figure 62] Figure 62: Bioluminescence images show fLuc+ SKOV3 tumors in NSG mice just before (day 38), 2 weeks (day 53), and 5 weeks (day 74) after the first intravenous injection of CAR-T cells.
[0217] [Figure 63] Figure 63: Quantification of circulating human CD4+ and CD8+ T cell numbers in mouse peripheral blood 15 days after the first dose of CAR-T cell infusion.
[0218] [Figure 64] Figure 64: Quantification of CAR expression on circulating human CD4+ and CD8+ T cells in mouse blood.
[0219] [Figure 65] Figure 65: Distribution of T cell subsets of circulating human T cells in mouse blood based on CD45RA and CD62L staining.
[0220] [Figure 66] Figure 66: A series of graphs depicting quantification of CD27 and CD28 expression on circulating human CD4+ and CD8+ T cells in mouse blood.
[0221] [Figure 67]Figures 67A, 67B, and 67C: Loss of functionality of mesoCAR T cells (TILs) over time in the tumor microenvironment compared to fresh or thawed mesoCAR T cells. A) Cytotoxicity assay (EMMESO TIL ex vivo killing assay (immediate harvest)); B) IFNγ release assay (IFNγ levels after 20 h 50:1 co-culture with 5K EMMESO / ffluc cells before / after 30 IU / ml IL-2 overnight rest); and C) Western blot analysis of ERK signaling (by phosphorylation).
[0222] [Figure 68] Figure 68: Effect of DGK deletion on mesoCAR T cell cytotoxicity. Percent target cell killing is assessed at different effector:target ratios.
[0223] [Figure 69] Figure 69: Effect of deletion of DGK on IFNγ production and release from mesoCAR T cells. IFNγ concentrations are assessed at different effector:target ratios.
[0224] [Figure 70] Figure 70: Effect of DGK deletion on ERK signaling or T cell activation in mesoCAR T cells. B: Albumin, M: Mesothelin, 3 / 28: CD3 / CD28 stimulator cells.
[0225] [Figure 71] Figure 71: Effect of DGK deletion on TGFβ sensitivity of mesoCAR T cells for cytotoxic activity.
[0226] [Figure 72] Figures 72A and 72B: Effect of DGK deletion on the therapeutic efficacy of mesoCAR T cells in tumor mouse models. A) Impact on antitumor activity as shown by tumor volume over time. B) Persistence and proliferation of tumor-infiltrating cells.
[0227] [Figure 73]Figures 73A, 73B, 73C, 73D, 73E, and 73F show cytokine production and cytotoxic mediator release in CAR-expressing T cells with reduced levels of Ikaros. Figure 73A shows Ikaros expression in wild-type and Ikzfl+ / - CAR T cells as measured by flow cytometry (left panel) and Western blot (right panel). After stimulation with mesothelin-coated beads, PMA / ionomycin (PMA / I), or BSA-coated beads (control), the percentage of cells producing IFN-γ (Figure 73B), TNF-α (Figure 73C), and IL-2 (Figure 73D), the cytotoxic mediator granzyme B (Figure 73E), and CD107a expression (Figure 73F) were determined.
[0228] [Figure 74] Figures 74A, 74B, and 74C: Cytokine production and cytotoxic mediator release in CAR-expressing T cells harboring a dominant-negative allele of Ikaros (IkDN). After stimulation with mesothelin-coated beads, PMA / ionomycin (PMA / I), or BSA-coated beads (control), the percentage of cells producing IFN-γ (Figure 74A), IL-2 (Figure 74B), and CD107a expression (Figure 74C) was determined.
[0229] [Figure 75]Figures 75A, 75B, 75C, 75D, and 75E. Ikaros depletion did not enhance CAR T cell activation and signaling after antigen stimulation. The levels of CD69 (Figure 75A), CD25 (Figure 75B), and 4-1BB (Figure 75C) in Ikzfl+ / - CAR T cells at the indicated time points were determined by flow cytometry. In Figure 75D, the RAS / ERK signaling pathway was examined in wild-type (WT) and Ikaros dominant-negative cells (IkDN) after TCR stimulation with CD3 / CD28 antibodies. The levels of phosphorylated TCR signaling proteins, such as phosphorylated PLCγ, phosphorylated Lck, phosphorylated JNK, phosphorylated Akt, phosphorylated ERK, phosphorylated IKKα, and IκBα, were assessed by Western blot. In Figure 75E, MesoCAR-transduced WT and IkDN cells were stimulated with BSA or mesothelin-coated beads, and downstream signaling pathways were examined by Western blot by assessing the levels of phosphorylated ERK and phosphorylated PLCγ.
[0230] [Figure 76] Figures 76A, 76B, 76C, 76D, and 76E: Reduction of Ikaros in CAR T cells enhances responses to target cells AE17 or mesothelin-expressing AE17 (AE17 meso) in vitro. Figure 76A shows IFNγ production in WT and Ikzfl+ / − meso CAR T cells at the indicated effector:target cell ratios. Cytolysis of meso CAR-expressing WT and Ikzfl+ / − (Figure 76B) and IkDN (Figure 76C) was measured at the indicated effector:target cell ratios. IFNγ production (Figure 76D) and cytolysis (Figure 76E) were measured for WT and Ikzfl+ / − transduced at the indicated effector:target cell ratios, where target cells were FAP-expressing 3T3 cells.
[0231] [Figure 77]Figures 77A, 77B, and 77C: Efficacy of Ikaros-depleted CAR T cells against established tumors in vivo. CAR T cells were administered to mice bearing established mesothelin-expressing AE17 tumors. Tumor volume was measured after administration of mesoCAR-expressing WT and Ikzfl+ / - (Figure 77A) or IkDN (Figure 77B). Tumor volume was measured after administration of FAP-CAR-expressing WT and Ikzfl+ / - (Figure 77C).
[0232] [Figure 78] Figures 78A, 78B, 78C, 78D, 78E, and 78F: Increased persistence and resistance of Ikzf1+ / - CAR T cells in the immunosuppressive tumor microenvironment compared to WT CAR T cells. The percentage of CAR-expressing WT or Ikzf1+ / - cells (GFP positive) was detected by flow cytometry in cells harvested from the spleen (Figure 78A) and tumor (Figure 78B). The functional capacity of CAR T cells harvested from the spleen or tumor 3 days after infusion was assessed by measuring IFNγ production after stimulation with CD3 / CD28 antibody (Figure 78C) or PMA / ionomycin (PMA / I) (Figure 78D). Regulatory T cells (CD4+FoxP3+ expression) and macrophages (CD206 expression) were assessed by measuring the expression of Treg or macrophage markers on CAR T cells harvested from the spleen or tumor 9 days after infusion.
[0233] [Figure 79] Figures 79A and 79B: T cells with low Ikaros levels are less sensitive to the soluble inhibitors TGFβ and adenosine. MesoCAR-expressing WT, Ikzfl+ / -, and IkDN cells were tested for their ability to produce IFNγ (Figure 79A) and cytotoxicity (Figure 79B) in response to TGF-β or adenosine.
[0234] [Figure 80]Figures 80A and 80B show IL-7 receptor (CD127) expression on cancer cell lines and CART cells. CD127 expression was measured by flow cytometry on three cancer cell lines: RL (mantle cell lymphoma), JEKO (also known as Jeko-1, mantle cell lymphoma), and Nalm-6 (B-ALL) (Figure 80A). CD127 expression on circulating CD3-positive (CART) cells injected into NSG mice was measured by flow cytometry (Figure 80B).
[0235] [Figure 81] Figures 81A, 81B, and 81C show the anti-tumor response after CART19 treatment followed by IL-7 treatment. NSG mice implanted with a luciferase-expressing mantle lymphoma cell line (RL-luc) on day 0 were treated with various doses of CART19 cells on day 6, and tumor burden was monitored. Mice were divided into four groups and received no CART19 cells, 0.5x10 CART19 cells (CART19 0.5E6), 1x10 CART19 cells (CART19 1E6), or 2x10 CART19 cells (CART19 2E6). Tumor burden after CART treatment was measured by detection of bioluminescence (mean BLI) (Figure 81A). Mice receiving 0.5×10 CART19 cells (CART19 0.5E6) or 1×10 CART19 cells (CART19 1E6) were randomized to receive or not receive recombinant human IL-7 (rhIL-7). Tumor burden, represented by mean bioluminescence (BLI), was monitored in three mice from Figure 81A (#3827, #3829, and #3815, which received the initial CART19 doses indicated), which received IL-7 starting on day 85 (Figure 81B). IL-7 was administered by IP injection three times per week. Tumor burden, represented here by mean bioluminescence (BLI), was compared between mice that did not receive IL-7 (CTRL) and mice that received IL-7 treatment (IL-7) before day 85 (PRE) and after day 115 (POST) (Figure 81C).
[0236] [Figure 82]Figures 82A and 82B show T cell dynamics after IL-7 treatment. The level of human T cells detected in the blood was monitored in each of the mice that received IL-7 or the control mice (Figure 82A). The level of CART19 cells (CD3+ cells) detected in the blood was measured before (PRE) and 14 days after (day 14) the start of IL-7 treatment (Figure 82B).
[0237] [Figure 83] Figure 83 is a series of images showing IL-7 receptor (IL-7R) expression as detected by flow cytometry. The top panels show IL-7R in leukemia cells: AML cell line MOLM14 (top left), B-ALL cell line NALM6 (top middle), and primary AML (top right). The bottom panels show IL-7R in AML cells after relapse in mouse models of AML treated with CART: untransduced T cells (UTD) (bottom left), CART33-treated mice (bottom middle), and CART123-treated mice (bottom right).
[0238] [Figure 84] Figure 84 shows the experimental schema in which NSG mice were implanted with luciferase + MOLM14 and treated with untransduced cells (UTD), CART33, or CART123, followed by serial BLI to assess tumor burden. Mice that experienced a relapse after an initial disease response were randomized to receive no treatment (no IL-7) or IL-7 200 ng IP three times per week. Serial BLI was performed to assess tumor burden, survival, and T cell proliferation.
[0239] [Figure 85]Figures 85A, 85B, and 85C show the antitumor response after CART treatment followed by IL-7 treatment. NSG mice implanted with luciferase-expressing MOLM14 cells were treated with untransduced T cells (UTD), CART33 cells, or CART123 cells. Tumor burden after CART treatment was measured by bioluminescence imaging (BLI) (Figure 85A). Mice receiving CART123 or CART33 initially responded to T cell treatment but relapsed by 14 days after T cell administration. These mice were assigned to treatment with or without IL-7 on day 28. Tumor burden after IL-7 (IL-7) or control treatment (no IL-7) was measured by bioluminescence imaging (BLI) (Figure 85B). Representative images of bioluminescence imaging during IL-7 treatment are shown in Figure 85C.
[0240] [Figure 86] Figures 86A and 86B show T cell proliferation and survival after IL-7 treatment in a relapsed AML model. IL-7 treatment resulted in T cell proliferation that correlated with a reduction in tumor burden (Figure 86A): T cell proliferation was assessed by measuring T cells in the blood (right Y-axis) compared with bioluminescence imaging (BLI, left Y-axis). Survival of mice receiving IL-7 treatment or control was monitored from the time of MOLM14 injection (Figure 86B).
[0241] [Figure 87] Figure 87. This schematic shows the structures of two example RCAR configurations. The antigen binding member comprises an antigen binding domain, a transmembrane domain, and a switch domain. The intracellular binding member comprises a switch domain, a costimulatory signaling domain, and a primary signaling domain. The two configurations demonstrate that the first and second switch domains described herein can be in different orientations relative to the antigen binding member and the intracellular binding member. Other RCAR configurations are further described herein.
[0242] [Figure 88]Figures 88A and 88B are a series of graphs showing the results of an aFR dissociation assay. C4-27z or MOv19-27z CAR T cells were labeled with recombinant biotinylated aFR protein and then incubated in the presence of excess non-biotinylated aFR in a time course assay at 37°C (Figure 88A) or 4°C (Figure 88B). The percent retained aFR (y-axis) was normalized and scored as mean fluorescence intensity (MFI) post-incubation ÷ pre-incubation MFI × 100.
[0243] [Figure 89] Figure 89 is a graph showing titration analysis of biotinylated aFR protein binding to aFR CAR T cells. A representative experimental result from three independent experiments is shown.
[0244] [Figure 90]Figures 90A, 90B, 90C, 90D, 90E: Antitumor activity of human T cells expressing the C4 CAR in vitro and in vivo. (A) Cytotoxicity of αFR-expressing tumor cells SKOV3 by CAR T cells in an 18-hour bioluminescence assay at the indicated E / T ratios. Untransduced (UNT) T cells and CD19 CAR T cells served as negative effector controls. C30 cells served as negative target cell controls. Percent tumor cell viability was calculated as (mean luminescence of experimental sample - background / mean luminescence of input number of target cells used in assay - background) x 100. All data are shown as the average of triplicate wells. (B) NSG mice bearing established sc tumors were treated with intravenous (iv) injection of 1 x 10 CAR+ T cells 40 days after tumor inoculation. Tumor growth was assessed by caliper measurement [V = 1 / 2 (length x width 2)]. (C) Tumor progression was tracked by in vivo bioluminescence imaging. CD27 signal incorporation enhanced antitumor activity in vivo; C4-27z T cell treatment was superior to treatment with C4-z CAR T cells lacking the CD27 costimulatory domain. (D) NSG mice received an i.p. injection of 3 x 10 SKOV3 fLuc tumor cells and were randomized into three groups. Treatment with UNT T cells or T cells expressing the C4-27z or CD19-27z CARs was initiated via i.v. infusion on days 21 and 25 after tumor inoculation. Bioluminescence images show fLuc+ SKOV3 tumors in NSG mice immediately before and 2 weeks after the second i.v. injection. (E) Photon emission from fLuc tumor cells was quantified before and 2 weeks after the second i.v. injection of 1 x 10 CAR-T cells on days 21 and 25 after tumor inoculation, and the mean ± SD bioluminescence signal was determined. Fourteen days after the second cell injection, there was a significant difference in tumor burden between the C4-27z CAR T cell group and the control T cell group (p=0.002). These results indicate that the antitumor activity mediated by C4-27z CAR T cells was antigen-specific in vivo. DETAILED DESCRIPTION OF THE INVENTION
[0245] Detailed Description definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0246] As used herein, the articles "a," "an," and "an" refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. For example, "an" or "an" refers to one or more than one component.
[0247] As used herein, the term "about," when describing a measurable value such as an amount, duration, etc., is intended to encompass a variation of ±20%, or in some embodiments ±10%, or in some embodiments ±5%, or in some instances ±1%, or in some embodiments ±0.1% from the particular value, as long as such variation is appropriate for the practice of the disclosed methods.
[0248]
[0013] The term "chimeric antigen receptor" or alternatively "CAR" refers to a set of polypeptides, generally two in the simplest embodiment, that, when in an immune effector cell, provides the cell with specificity for a target cell, generally a cancer cell, and intracellular signal production. In some embodiments, a CAR comprises at least an extracellular antigen binding domain, a transmembrane domain, and a cytoplasmic signaling domain (also referred to herein as an "intracellular signaling domain") that comprises a functional signaling domain derived from a stimulatory molecule and / or a costimulatory molecule, as defined below. In some aspects, the set of polypeptides are adjacent to one another. In some embodiments, the set of polypeptides comprises a dimerization switch that can link the polypeptides to one another, e.g., link the antigen binding domain and the intracellular signaling domain, in the presence of a dimerization molecule. In one aspect, the stimulatory molecule is a zeta chain that binds to the T cell receptor complex. In some aspects, the cytoplasmic signaling domain further comprises one or more functional signaling domains derived from at least one costimulatory molecule, as defined below. In one aspect, the costimulatory molecule is chosen from a costimulatory molecule described herein, e.g., 4-1BB (i.e., CD137), CD27, and / or CD28. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a functional signaling domain derived from a costimulatory molecule and a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising two functional signaling domains derived from one or more costimulatory molecules and a functional signaling domain derived from a stimulatory molecule. In one aspect, the CAR comprises a chimeric fusion protein comprising an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising at least two functional signaling domains derived from one or more costimulatory molecules and a functional signaling domain derived from a stimulatory molecule.In one aspect, the CAR comprises an optional leader sequence at the amino-terminus (N-terminus) of the CAR fusion protein. In one aspect, the CAR further comprises a leader sequence at the N-terminus of the extracellular antigen binding domain, wherein the leader sequence is optionally cleaved from the antigen binding domain (e.g., scFv) during cellular processing and localization of the CAR to the cellular membrane.
[0249] A CAR containing an antigen-binding domain (e.g., scFv or TCR) that targets a specific tumor marker X, such as those described herein, is also referred to as an XCAR. For example, a CAR containing an antigen-binding domain that targets CD19 is referred to as a CD19CAR.
[0250] The term "signaling domain" refers to a functional portion of a protein that acts by transmitting information within the cell to control cellular activity via defined signaling pathways, either by producing second messengers or by functioning as an effector by responding to such messengers.
[0251] As used herein, the term "antibody" refers to a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. Antibodies can be polyclonal or monoclonal, multi-chain or single-chain or intact immunoglobulins, and can be derived from natural or recombinant sources. An antibody can be a tetramer of immunoglobulin molecules.
[0252] The term "antibody fragment" refers to at least a portion of an antibody that maintains the ability to specifically interact (e.g., by binding, steric hindrance, stabilization / destabilization, spatial distribution) with an epitope on an antigen. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab'), Fv fragments, scFv antibody fragments, disulfide-linked Fv (sdFv), Fd fragments consisting of a VH domain and a CH1 domain, linear antibodies, single domain antibodies such as sdAb (either VL or VH), camelid VHH domains, multispecific antibodies formed from antibody fragments such as bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region, and isolated CDRs or other epitope-binding fragments of antibodies. Antigen-binding fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, nanobodies, intrabodies, bispecific antibodies, triabodies, tetrabodies, v-NARs, and bis-scFvs (see, e.g., Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005). Antigen-binding fragments can be grafted onto scaffolds based on polypeptides such as fibronectin type III (Fn3) (see U.S. Patent 6,703,199, describing fibronectin polypeptide minibodies).
[0253] The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising a light chain variable region and at least one antibody fragment comprising a heavy chain variable region, wherein the light and heavy chain variable regions are contiguously linked, e.g., via a synthetic linker, e.g., a short flexible polypeptide linker, and can be expressed as a single-chain polypeptide, wherein the scFv maintains the specificity of the intact antibody from which it is derived. Unless otherwise specified, an scFv as used herein may comprise the VL and VH variable regions in either order, e.g., relative to the N- and C-termini of the polypeptide, an scFv may comprise VL-linker-VH or VH-linker-VL.
[0254] The portion of the CAR of the invention comprising an antibody or antibody fragment thereof can exist in a variety of forms in which the antigen-binding domain is expressed as part of a contiguous polypeptide chain, including, for example, a single-domain antibody fragment (sdAb), a single-chain antibody (scFv), a humanized antibody, or a bispecific antibody (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one aspect, the antigen-binding domain of the CAR composition of the invention comprises an antibody fragment. In a further aspect, the CAR comprises an antibody fragment comprising an scFv. The precise amino acid sequence boundaries of a CDR can be determined using any number of well-known schemes, including those described in Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD ("Kabat" numbering scheme), Al-Lazikani et al., (1997) JMB 273,927-948 ("Chothia" numbering scheme), or a combination thereof.
[0255] As used herein, the term "binding domain" or "antibody molecule" refers to a protein, e.g., an immunoglobulin chain or fragment thereof, that comprises at least one immunoglobulin variable domain sequence. The term "binding domain" or "antibody molecule" includes antibodies and antibody fragments. In some embodiments, an antibody molecule is a multispecific antibody molecule, e.g., comprises multiple immunoglobulin variable domain sequences, where a first immunoglobulin variable domain sequence of the multiple domains has binding specificity for a first epitope and a second immunoglobulin variable domain sequence of the multiple domains has binding specificity for a second epitope. In some embodiments, a multispecific antibody molecule is a bispecific antibody molecule. Bispecific antibodies do not have specificity for more than two antigens. Bispecific antibody molecules are characterized by a first immunoglobulin variable domain sequence that has binding specificity for a first epitope and a second immunoglobulin variable domain sequence that has binding specificity for a second epitope.
[0256] The portion of the CAR of the invention comprising an antibody or antibody fragment thereof can exist in a variety of forms in which the antigen-binding domain is expressed as part of a contiguous polypeptide chain, including, for example, a single-domain antibody fragment (sdAb), a single-chain antibody (scFv), a humanized antibody, or a bispecific antibody (Harlow et al., 1999, In: Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, NY; Harlow et al., 1989, In: Antibodies: A Laboratory Manual, Cold Spring Harbor, New York; Houston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; Bird et al., 1988, Science 242:423-426). In one aspect, the antigen-binding domain of the CAR composition of the invention comprises an antibody fragment. In a further aspect, the CAR comprises an antibody fragment comprising an scFv.
[0257] The term "antibody heavy chain" refers to the larger of the two types of polypeptide chains present in antibody molecules in their naturally occurring conformations, and which usually determines the class to which the antibody belongs.
[0258] The term "antibody light chain" refers to the smaller of the two types of polypeptide chains present in the naturally occurring conformation of an antibody molecule. Kappa (κ) and lambda (λ) light chains refer to the two major antibody light chain isotypes.
[0259] The term "recombinant antibody" refers to an antibody produced using recombinant DNA technology, such as, for example, an antibody expressed in a bacteriophage or yeast expression system. The term should also be construed to mean an antibody produced by the synthesis of a DNA molecule encoding the antibody and which DNA molecule expresses an antibody protein or an amino acid sequence specifying the antibody, wherein the DNA or amino acid sequence is obtained using recombinant DNA or amino acid sequence technology that is available and well known in the art.
[0260] The term "antigen" or "Ag" refers to a molecule that elicits an immune response. This immune response may involve antibody production, activation of specific immunocompetent cells, or both. Those skilled in the art will understand that any macromolecule, including virtually any protein or peptide, can serve as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA. Those skilled in the art will understand that any DNA containing a nucleotide sequence or partial nucleotide sequence encoding a protein that elicits an immune response therefore encodes an "antigen" as the term is used herein. Furthermore, those skilled in the art will understand that an antigen need not be encoded solely by the full-length nucleotide sequence of a gene. It will be readily apparent that the present invention includes, but is not limited to, the use of partial nucleotide sequences of more than one gene and that these nucleotide sequences are arranged in various combinations to encode a polypeptide that elicits a desired immune response. Furthermore, those skilled in the art will understand that an antigen need not be encoded by a "gene" at all. It will be apparent that an antigen can be synthetically produced or derived from a biological sample or can be a macromolecule other than a polypeptide. Such biological samples can include, but are not limited to, tissue samples, tumor samples, fluids containing cells or other biological components.
[0261] The term "anti-cancer effect" refers to a biological effect that can be manifested by a variety of means, including, but not limited to, a reduction in tumor volume, a reduction in the number of cancer cells, a reduction in the number of metastases, an increase in life expectancy, a reduction in cancer cell proliferation, a reduction in cancer cell viability, or an amelioration of various physiological symptoms associated with a cancerous condition. An "anti-cancer effect" can also be manifested by the ability of peptides, polynucleotides, cells, and antibodies in preventing the occurrence of cancer in the first place. The term "anti-tumor effect" refers to a biological effect that can be manifested by a variety of means, including, but not limited to, a reduction in tumor volume, a reduction in tumor cell number, a reduction in tumor cell proliferation, or a reduction in tumor cell viability.
[0262] The term "autologous" refers to any material derived from the same individual into which it is later reintroduced.
[0263] The term "allogeneic" refers to any material derived from a different individual of the same species as the individual into which the material is being introduced. Two or more individuals may be said to be allogeneic to one another when the genes at one or more loci are not identical. In some aspects, allogeneic material from individuals of the same species may be sufficiently genetically distinct to interact antigenically.
[0264] The term "xenogeneic" refers to a graft derived from an animal of a different species.
[0265] The term "cancer" refers to a disease characterized by the uncontrolled growth of abnormal cells. Cancer cells can spread locally or through the bloodstream and lymphatic system to other parts of the body. Examples of various cancers are described herein and include, but are not limited to, breast cancer, prostate cancer, ovarian cancer, cervical cancer, skin cancer, pancreatic cancer, colorectal cancer, kidney cancer, liver cancer, brain cancer, lymphoma, leukemia, lung cancer, and the like. The terms "tumor" and "carcinoma" are used interchangeably herein, e.g., both terms include solid and liquid, e.g., generalized or circulating, tumors. As used herein, the term "cancer" or "tumor" includes pre-malignant and malignant cancers and tumors.
[0266] "Derived from," as the term is used herein, indicates a relationship between a first molecule and a second molecule. It generally refers to the structural similarity between the first molecule and the second molecule and does not imply or include any process or source limitation on the first molecule from which the second molecule is derived. For example, in the case of an intracellular signaling domain derived from a CD3 zeta molecule, the intracellular signaling domain retains sufficient CD3 zeta structure so that it has the required function, i.e., the ability to produce a signal under appropriate conditions. It does not imply or include any limitation to the particular process by which the intracellular signaling domain is produced; for example, it does not mean that one must start from the CD3 zeta sequence and remove or mutate undesired sequences to arrive at the intracellular signaling domain to provide the intracellular signaling domain.
[0267] The term "disease associated with expression of a tumor antigen described herein" includes, but is not limited to, a disease associated with expression of a tumor antigen described herein or a condition associated with cells expressing a tumor antigen described herein, including, for example, a proliferative disease such as cancer or a malignant tumor, or a precancerous condition such as myelodysplasia, myelodysplastic syndrome, or a preleukemia; or a non-cancer-related indication associated with cells expressing a tumor antigen described herein. In one aspect, a cancer associated with expression of a tumor antigen described herein is a hematological cancer. In one aspect, a cancer associated with expression of a tumor antigen described herein is a solid cancer. Further, diseases associated with expression of a tumor antigen described herein include, but are not limited to, for example, atypical and / or non-classical cancers, malignancies, precancerous conditions, or proliferative diseases associated with expression of a tumor antigen described herein. Non-cancer-related indications associated with expression of a tumor antigen described herein include, but are not limited to, for example, autoimmune diseases (e.g., lupus), inflammatory disorders (allergies and asthma), and transplantation. In some embodiments, tumor antigen-expressing cells express, or have expressed at any time, mRNA encoding a tumor antigen. In some embodiments, tumor antigen-expressing cells produce tumor antigen proteins (e.g., wild-type or mutant), and the tumor antigen proteins may be present at normal or reduced levels. In some embodiments, tumor antigen-expressing cells produce detectable levels of tumor antigen proteins at one point, and then produce substantially no detectable tumor antigen proteins thereafter.
[0268] The term "conservative sequence modifications" refers to amino acid modifications that do not significantly affect or alter the binding characteristics of an antibody or antibody fragment containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into an antibody or antibody fragment of the present invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are those in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within a CAR of the invention can be replaced with other amino acid residues within the same side chain family, and the modified CAR can be tested using the functional assays described herein.
[0269] The term "stimulation" refers to a primary response induced by the binding of a stimulatory molecule (e.g., a TCR / CD3 complex or a CAR) to its cognate ligand (or tumor antigen in the case of a CAR), thereby mediating a signal transduction event, such as, but not limited to, signaling through the TCR / CD3 complex or signaling through the signaling domain of an appropriate NK receptor or CAR. Stimulation can be mediated by altered expression of a molecule.
[0270] The term "stimulatory molecule" refers to a molecule expressed by an immune cell (e.g., T cell, NK cell, B cell) that provides cytoplasmic signaling sequences that mediate immune cell activation in a stimulatory manner for at least some aspect of an immune cell signaling pathway. In one aspect, the signal is a primary signal that is initiated, for example, by binding of the TCR / CD3 complex to a peptide-loaded MHC molecule and leads to mediation of a T cell response, including, but not limited to, proliferation, activation, differentiation, etc. Primary cytoplasmic signaling sequences (also known as "primary signaling domains") that act in a stimulatory manner can contain signaling motifs known as immunoreceptor tyrosine-based activation motifs, or ITAMs. Examples of ITAMs containing cytoplasmic signaling sequences that are particularly useful in the present invention include, but are not limited to, those derived from CD3 zeta, common FcR gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc epsilon R1b), CD3 gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10, and DAP12. In specific CARs of the invention, the intracellular signaling domain in any one or more CARs of the invention comprises an intracellular signaling sequence, e.g., the primary signaling sequence of CD3 zeta. In specific CARs of the invention, the primary signaling sequence of CD3 zeta is the sequence provided as SEQ ID NO: 18 or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc. In specific CARs of the invention, the primary signaling sequence of CD3 zeta is the sequence provided as SEQ ID NO: 20 or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc.
[0271] The term "antigen-presenting cell" or "APC" refers to a cell of the immune system, such as an accessory cell (e.g., a B cell, a dendritic cell, etc.), that displays foreign antigens complexed with major histocompatibility complexes (MHC) on its surface. T cells can recognize these complexes using the T cell receptor (TCR). APCs process antigens and present them to T cells.
[0272] "Intracellular signaling domain," as that term is used herein, refers to the intracellular portion of a molecule. The intracellular signaling domain generates a signal that promotes the immune effector function of a CAR-containing cell, e.g., a CART cell. For example, examples of immune effector function in a CART cell include cytolytic activity and helper activity, including cytokine secretion.
[0273] In some embodiments, the intracellular signaling domain can comprise a primary intracellular signaling domain. Exemplary primary intracellular signaling domains include those that respond to a primary stimulus or an antigen-dependent stimulus. In some embodiments, the intracellular signaling domain comprises a costimulatory intracellular domain. Exemplary costimulatory intracellular signaling domains include those derived from molecules responsible for costimulatory signals or antigen-independent stimulation. For example, in the case of CART, the primary intracellular signaling domain can comprise the cytoplasmic sequence of a T cell receptor, and the costimulatory intracellular signaling domain can comprise the cytoplasmic sequence from a co-receptor or costimulatory molecule.
[0274] The primary intracellular signaling domain can contain a signaling motif known as an immunoreceptor tyrosine-based activation motif, or ITAM. Examples of ITAM-containing primary cytoplasmic signaling sequences include, but are not limited to, those derived from CD3 zeta, common FcR gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc epsilon R1b), CD3 gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10, and DAP12.
[0275] The terms "zeta" or alternatively "zeta chain," "CD3 zeta," or "TCR-zeta" are defined as the protein provided as GenBank Acc. No. BAG36664.1 or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc., and a "zeta stimulatory domain" or alternatively "CD3 zeta stimulatory domain" or "TCR-zeta stimulatory domain" is defined as the amino acid residues from the cytoplasmic domain of the zeta chain, or a functional derivative thereof, sufficient to functionally transmit an initial signal necessary for T cell activation. In one aspect, the cytoplasmic domain of CD3 zeta comprises residues 52-164 of GenBank Acc. No. BAG36664.1, or the equivalent residues from a functional ortholog, non-human species, e.g., mouse, rodent, monkey, ape, etc. In one aspect, a "zeta stimulatory domain" or "CD3 zeta stimulatory domain" is the sequence provided as SEQ ID NO: 18. In one aspect, the "zeta stimulatory domain" or "CD3 zeta stimulatory domain" is the sequence provided as SEQ ID NO:20.
[0276] The term "costimulatory molecule" refers to a cognate binding partner on a T cell that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules are cell surface molecules other than antigen receptors or their ligands that contribute to an efficient immune response. Costimulatory molecules include, but are not limited to, MHC class I molecules, BTLA and Toll ligand receptors, as well as OX40, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), and 4-1BB (CD137). Further examples of such costimulatory molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8 alpha, CD8 beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, These include, but are not limited to, ligands that specifically bind to ITGB7, NKG2D, NKG2C, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, and CD83.
[0277] The costimulatory intracellular signaling domain can be the intracellular portion of a costimulatory molecule. Costimulatory molecules are represented by the following protein families: TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), and activating NK cell receptors. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, GITR, CD30, CD40, ICOS, BAFFR, HVEM, ICAM-1, lymphocyte function-associated antigen-1 (LFA-1), CD2, CDS, CD7, CD287, LIGHT, NKG2C, NKG2D, SLAMF7, NKp80, NKp30, NKp44, NKp46, CD160, B7-H3, and ligands that specifically bind to CD83.
[0278] The intracellular signaling domain can comprise the entire intracellular portion or the entire native intracellular signaling domain of the molecule from which it is derived or a functional fragment or derivative thereof.
[0279] The term "4-1BB" refers to a member of the TNFR superfamily having the amino acid sequence provided as GenBank Acc. No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc., and the "4-1BB costimulatory domain" is defined as amino acid residues 214-255 of GenBank Acc. No. AAA62478.2, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc. In one aspect, the "4-1BB costimulatory domain" is the sequence provided as SEQ ID NO: 14, or the equivalent residues from a non-human species, e.g., mouse, rodent, monkey, ape, etc.
[0280] "Immune effector cells," as that term is used herein, refer to cells that are involved in an immune response, e.g., promoting an immune effector response. Examples of immune effector cells include T cells, e.g., alpha / beta T cells and gamma / delta T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and myeloid-derived phagocytes.
[0281] "Immune effector function or immune effector response," as that term is used herein, refers to a function or response, e.g., of an immune effector cell, that enhances or promotes immune attack of a target cell. For example, an immune effector function or response refers to a property of a T cell or NK cell that promotes killing or prevents proliferation or expansion of a target cell. In the case of T cells, primary stimulation and costimulation are examples of immune effector functions or responses.
[0282] The term "encoding" refers to the inherent property of a specific nucleotide sequence in a polynucleotide, such as a gene, cDNA, or mRNA, to serve as a template for the synthesis of other polymers and macromolecules having a defined nucleotide sequence (e.g., rRNA, tRNA, and mRNA) or a defined amino acid sequence in biological processes, and the biological properties resulting therefrom. Thus, a gene, cDNA, or RNA encodes a protein if transcription and translation of the mRNA corresponding to that gene produces the protein in a cell or other biological system. The coding strand, whose nucleotide sequence is identical to the mRNA sequence and is usually provided in a sequence listing, and the non-coding strand, which is used as a transcription template for the gene or cDNA, can be said to encode the protein or other product of that gene or cDNA.
[0283] Unless otherwise specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. The term nucleotide sequence encoding a protein or RNA can also include introns, to the extent that a nucleotide sequence encoding a protein may, in some versions, contain introns.
[0284] The terms "effective amount" or "therapeutically effective amount" are used interchangeably herein and refer to an amount of a compound, preparation, substance or composition described herein effective to achieve a particular biological result.
[0285] The term "endogenous" refers to any substance from or produced within an organism, cell, tissue, or system.
[0286] The term "exogenous" refers to any material that comes from or is produced outside an organism, cell, tissue, or system.
[0287] The term "expression" refers to the transcription and / or translation of a particular nucleotide sequence driven by a promoter.
[0288] The term "transfer vector" refers to a composition that contains an isolated nucleic acid and can be used to deliver the isolated nucleic acid to a cell. Numerous vectors are known in the art, including, but not limited to, linear polynucleotides, polynucleotides bound to ionic or amphipathic compounds, plasmids, and viruses. Thus, the term "transfer vector" refers to an autonomously replicating plasmid or virus. The term should also be construed to include non-plasmid and non-viral compounds that facilitate the transfer of nucleic acids into cells, such as, for example, polylysine compounds, liposomes, etc. Examples of viral transfer vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, lentiviral vectors, etc.
[0289] The term "expression vector" refers to a vector containing a recombinant polynucleotide comprising expression control sequences operably linked to a nucleotide sequence to be expressed. An expression vector contains sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all such vectors known in the art, including cosmids, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that incorporate the recombinant polynucleotide.
[0290] The term "lentivirus" refers to the Retroviridae family. Lentiviruses are unique among retroviruses in that they can infect non-dividing cells and deliver significant amounts of genetic information into the DNA of host cells, making them one of the most efficient gene delivery vectors. HIV, SIV, and FIV are all examples of lentiviruses.
[0291] The term "lentiviral vector" refers to a vector derived from at least a portion of a lentiviral genome, including, in particular, self-inactivating lentiviral vectors such as those provided in Milone et al., Mol. Ther. 17(8): 1453-1464 (2009). Other examples of lentiviral vectors that can be used in clinical settings include, for example, LENTIVECTOR® Gene Delivery Technology from Oxford BioMedica and LENTIMAX® from Lentigen. TM Vector systems include, but are not limited to, non-clinical lentiviral vectors, etc. Non-clinical types of lentiviral vectors are also available and known to those skilled in the art.
[0292] The term "homologous" or "identity" refers to the subunit sequence identity between two polymeric molecules, e.g., between two nucleic acid molecules, such as two DNA molecules or two RNA molecules, or between two polypeptide molecules. When a subunit position in both of the two molecules is occupied by the same monomeric subunit, e.g., if a position in each of two DNA molecules is occupied by adenine, then they are homologous or identical at that position. The homology between two sequences is a direct function of the number of matching or homologous positions; for example, if half of the positions in two sequences (e.g., 5 positions in a polymer 10 subunits long) are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., 9 out of 10) are matched or homologous, the two sequences are 90% homologous.
[0293] "Humanized" forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies and antibody fragments thereof are human immunoglobulins (recipient antibody or antibody fragment) in which residues from a complementarity-determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies / antibody fragments contain residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications further refine and optimize antibody or antibody fragment performance. Typically, a humanized antibody or antibody fragment thereof will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or a substantial portion of the FR regions are those of a human immunoglobulin sequence. The humanized antibody or antibody fragment may also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321: 522-525, 1986; Reichmann et al., Nature, 332: 323-329, 1988; Presta, Curr. Op. Struct. Biol., 2: 593-596, 1992.
[0294] "Fully human" refers to an immunoglobulin, such as an antibody or antibody fragment, where the entire molecule is of human origin or consists of an amino acid sequence identical to a human form of the antibody or immunoglobulin.
[0295] The term "isolated" means altered or removed from the natural state. For example, a nucleic acid or peptide that is naturally present in a living animal is not "isolated," but the same nucleic acid or peptide that is partially or completely separated from the coexisting materials in its natural state is "isolated." An isolated nucleic acid or protein can exist in substantially pure form, or it can exist in a non-native environment such as, for example, a host cell.
[0296] In the context of the present invention, the following abbreviations are used for commonly occurring nucleobases: "A" refers to adenosine, "C" refers to cytosine, "G" refers to guanosine, "T" refers to thymidine, and "U" refers to uridine.
[0297] The term "operably linked" or "transcriptional control" refers to a functional linkage between a regulatory sequence and a heterologous nucleic acid sequence that results in expression of the heterologous nucleic acid sequence. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if it affects the transcription or expression of the coding sequence. Operably linked DNA sequences can be contiguous with each other, e.g., in the same reading frame where necessary to align two protein coding regions.
[0298] The term "parenteral" administration of an immunogenic composition refers, for example, to subcutaneous (sc), intravenous (iv), intramuscular (im) or intrasternal injection, intratumoral injection, or infusion techniques.
[0299] The term "nucleic acid" or "polynucleotide" refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single- or double-stranded form. Unless otherwise specified, the term refers to nucleic acids containing known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Unless otherwise specified, a particular nucleic acid sequence also encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitution can be achieved by producing sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).
[0300] The terms "peptide," "polypeptide," and "protein" are used interchangeably and refer to compounds consisting of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit to the maximum number of amino acids that may comprise a protein or peptide sequence. Polypeptide includes any peptide or protein containing two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, e.g., commonly referred to in the art as peptides, oligopeptides, and oligomers, and longer chains, which are commonly referred to in the art as proteins and of which there are many types. "Polypeptide" includes, inter alia, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, and fusion proteins. Polypeptides include natural peptides, recombinant peptides, or combinations thereof.
[0301] The term "promoter" refers to a DNA sequence recognized by the synthetic machinery of a cell or introduced synthetic machinery and required for initiating the specific transcription of a polynucleotide sequence.
[0302] The term "promoter / regulatory sequence" refers to a nucleic acid sequence that is necessary for expression of a gene product operably linked to the promoter / regulatory sequence. In some instances, this sequence may be the core promoter sequence, and in other instances, this sequence may also include an enhancer sequence and other regulatory elements that are necessary for expression of the gene product. The promoter / regulatory sequence may, for example, be one that expresses the gene product in a tissue-specific manner.
[0303] The term "constitutive" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes the production of the gene product in a cell under most or all physiological conditions of the cell.
[0304] The term "inducible" promoter refers to a nucleotide sequence that is operably linked to a polynucleotide that encodes or specifies a gene product and that causes production of the gene product substantially only when an inducer corresponding to the promoter is present in the cell.
[0305] The term "tissue-specific" promoter refers to a nucleotide sequence that, when operably linked to a polynucleotide encoding or specifying a gene product, causes the gene product to be produced substantially only when the cell is a cell of the tissue type corresponding to the promoter.
[0306] The terms "cancer-associated antigen" or "tumor antigen" refer interchangeably to a molecule (generally a protein, carbohydrate, or lipid) that is expressed on the surface of cancer cells, either in whole or as fragments (e.g., MHC / peptide), and that is useful for preferentially targeting drugs to cancer cells. In some embodiments, a tumor antigen is a marker expressed on both normal and cancer cells, e.g., a cell lineage marker, e.g., CD19 on B cells. In some embodiments, a tumor antigen is a cell surface molecule that is overexpressed on cancer cells compared to normal cells, e.g., 1-fold overexpression, 2-fold overexpression, 3-fold overexpression, or more overexpression compared to normal cells. In some embodiments, a tumor antigen is a cell surface molecule that is inappropriately synthesized on cancer cells, e.g., a molecule that contains deletions, additions, or mutations compared to molecules expressed on normal cells. In some embodiments, a tumor antigen is expressed exclusively, in whole or as fragments (e.g., MHC / peptide), on the cell surface of cancer cells and is not synthesized or expressed on the surface of normal cells. In some embodiments, the CAR of the present invention comprises a CAR comprising an antigen-binding domain (e.g., an antibody or antibody fragment) that binds to an MHC-presented peptide. Typically, peptides derived from endogenous proteins fill the pocket of major histocompatibility complex (MHC) class I molecules and are recognized by T cell receptors (TCRs) on CD8+ T lymphocytes. MHC class I complexes are constitutively expressed by all nucleated cells. In cancer, virus-specific and / or tumor-specific peptide / MHC complexes represent a unique class of cell surface targets for immunotherapy.TCR-like antibodies that target peptides derived from viral or tumor antigens in the context of human leukocyte antigen (HLA)-A1 or HLA-A2 have been described (e.g., Sastry et al., J Virol. 2011 85(5):1935-1942; Sergeeva et al., Blood, 2011 117(16):4262-4272; Verma et al., J Immunol 2010 184(4):2156-2165; Willemsen et al., Gene Ther 2001 8(21):1601-1608; Dao et al., Sci Transl Med 2013 5(176):176ra33; Tassev et al., Cancer Gene Ther 2012 19(2):84-100). For example, TCR-like antibodies can be identified by screening libraries such as human scFv phage display libraries.
[0307] The terms "tumor-supporting antigen" or "cancer-supporting antigen" refer interchangeably to a molecule (generally a protein, carbohydrate, or lipid) expressed on the surface of a cell that is not itself cancerous but supports cancer cells, e.g., by promoting proliferation or survival, e.g., resistance to immune cells. Representative cells of this type include stromal cells and myeloid-derived suppressor cells (MDSCs). The tumor-supporting antigen itself need not play a role in supporting tumor cells, as long as the antigen is presented on a cell that supports cancer cells.
[0308] The term "flexible polypeptide linker" or "linker," as used in the context of scFvs, refers to a peptide linker composed of amino acids, such as glycine and / or serine residues, used alone or in combination to join the variable heavy and variable light chain regions. In some embodiments, the flexible polypeptide linker is a Gly / Ser linker and comprises the amino acid sequence (Gly-Gly-Gly-Ser)n, where n is a positive integer greater than or equal to 1. For example, n=1, n=2, n=3, n=4, n=5, and n=6, n=7, n=8, n=9, and n=10 (SEQ ID NO: 28). In some embodiments, the flexible polypeptide linker includes, but is not limited to, (Gly4Ser)4 (SEQ ID NO: 29) or (Gly4Ser)3 (SEQ ID NO: 30). In other embodiments, the linker comprises multiple repeats of (Gly2Ser), (GlySer), or (Gly3Ser) (SEQ ID NO: 31). Also included within the scope of the present invention are linkers described in WO2012 / 138475, which is incorporated herein by reference.
[0309] As used herein, the 5' cap (RNA cap, RNA 7-methylguanosine cap or RNA m 7 A 5' cap (also called a G-cap) is a modified guanine nucleotide added to the "front," or 5' end, of eukaryotic messenger RNAs immediately after the transcription start site. The 5' cap consists of a terminal group attached to the first transcribed nucleotide. Its presence is important for ribosome recognition and protection from RNases. Capping is coupled to transcription and occurs co-transcriptionally, with each cap acting on the other. Shortly after transcription initiation, the 5' end of the mRNA being synthesized is attached by a cap-synthesizing complex that associates with RNA polymerase. This enzyme complex is the chemical reaction required for mRNA capping. Synthesis proceeds as a multi-step biochemical reaction. The capping moiety can be modified to modulate mRNA functionality, such as stability or translation efficiency.
[0310] As used herein, "in vitro transcribed RNA" refers to RNA, preferably mRNA, that has been synthesized in vitro. Generally, in vitro transcribed RNA is produced from an in vitro transcription vector. The in vitro transcription vector contains a template that is used to produce the in vitro transcribed RNA.
[0311] As used herein, "poly(A)" refers to a series of adenosines attached to mRNA by polyadenylation. In preferred embodiments of constructs for transient expression, the poly(A) is 50-5000 (SEQ ID NO: 34), preferably greater than 64, more preferably greater than 100, and most preferably greater than 300 or 400. The poly(A) sequence can be chemically or enzymatically modified to modulate mRNA functionality such as localization, stability, or translation efficiency.
[0312] As used herein, "polyadenylation" refers to the covalent attachment of a polyadenylyl moiety or modified variants thereof to a messenger RNA molecule. In eukaryotes, most messenger RNA (mRNA) molecules are polyadenylated at their 3' ends. The 3' poly(A) tail is a long sequence (often several hundred) of adenine nucleotides added to pre-mRNA through the action of the enzyme polyadenylate polymerase. In higher eukaryotes, the poly(A) tail is added onto transcripts that contain a specific sequence, the polyadenylation signal. The poly(A) tail and its associated proteins help protect the mRNA from exonucleolytic degradation. Polyadenylation is also important for transcription termination, export of mRNA from the nucleus, and translation. Polyadenylation occurs in the nucleus immediately after transcription of DNA into RNA, but can also occur later in the cytoplasm. After transcription is terminated, the mRNA strand is cleaved by the action of an endonuclease complex associated with RNA polymerase. The cleavage site is usually characterized by the presence of the base sequence AAUAAA near the cleavage site. After the mRNA is cleaved, an adenosine residue is added to the free 3' end of the cleavage site.
[0313] As used herein, "transient" refers to expression of a non-integrated transgene for a period of hours, days, or weeks, where the period of expression is shorter than the period of expression of the gene when integrated into the genome or contained within a stable plasmid replicon in a host cell.
[0314] As used herein, the terms "treatment" and "treating" refer to a reduction or amelioration of the progression, severity, and / or progression of a proliferative disorder or an improvement in one or more symptoms (preferably, one or more discernible symptoms) of a proliferative disorder resulting from the administration of one or more therapies (e.g., one or more therapeutic agents, such as a CAR of the invention). In certain embodiments, the terms "treatment" and "treating" refer to an improvement in at least one measurable physical parameter of a proliferative disorder, not necessarily discernible by the patient, such as tumor growth. In other embodiments, the terms "treatment" and "treating" refer to an arrest in the progression of a proliferative disorder, either physically, e.g., by stabilization of discernible symptoms, physiologically, e.g., by stabilization of physical parameters, or both. In other embodiments, the terms "treatment" and "treating" refer to a reduction or stabilization of tumor size or cancerous cell number.
[0315] The term "signal transduction pathway" refers to the biochemical relationships between various signaling molecules that play a role in transmitting a signal from one part of a cell to another part of the cell. The term "cell surface receptor" refers to molecules and complexes of molecules that can receive and transmit a signal across the membrane of a cell.
[0316] The term "subject" is intended to include living organisms in which an immune response can be elicited (eg, mammals, humans).
[0317] The term "substantially purified" cells refers to cells that are essentially free of other cell types. Substantially purified cells also refer to cells that have been separated from other cell types with which they are normally associated in their naturally occurring state. In some instances, a substantially purified cell population refers to a homogenous cell population. In other cases, the term simply refers to cells that have been separated from the cells with which they are naturally associated in their natural state. In some aspects, the cells are cultured in vitro. In other aspects, the cells are not cultured in vitro.
[0318] As used herein, the term "therapeutic" refers to treatment. A therapeutic effect is achieved by reducing, suppressing, ameliorating, or eradicating a disease state.
[0319] As used herein, the term "prevention" refers to the prophylactic or preventative treatment of a disease or disease state.
[0320] As used herein, a "tumor antigen" or "hyperproliferative disorder antigen" or "antigen associated with a hyperproliferative disorder" refers to an antigen common to a particular hyperproliferative disorder. In certain aspects, the hyperproliferative disorder antigens of the present invention are derived from cancers including, but not limited to, primary or metastatic melanoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, leukemia, uterine cancer, cervical cancer, bladder cancer, kidney cancer, and adenocarcinomas such as breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, and the like.
[0321] The terms "transfect" or "transformation" or "transduction" refer to the process of transferring or introducing exogenous nucleic acid into a host cell. A "transfected" or "transformed" or "transduced" cell is one that has been transfected, transformed or transduced with exogenous nucleic acid. The cell includes the primary subject cell and its progeny.
[0322] The term "specifically binds" refers to an antibody or ligand that recognizes and binds to a binding partner (e.g., a tumor antigen) protein present in a sample, but does not substantially recognize or bind to other molecules in the sample.
[0323] "Regulatable chimeric antigen receptor (RCAR)," as the term is used herein, refers to a set of polypeptides, generally two polypeptides in the simplest embodiment, that provide RCARX cells with specificity for target cells, generally cancer cells, and regulatable intracellular signal production or proliferation, allowing for optimization of the immune effector properties of the RCARX cells. RCARX cells rely, at least in part, on the antigen-binding domain to provide specificity for target cells that contain the antigen bound by the antigen-binding domain. In some embodiments, the RCAR contains a dimerization switch that can couple the intracellular signaling domain to the antigen-binding domain in the presence of a dimerization molecule.
[0324] "Membrane anchor" or "membrane tethering domain," as that term is used herein, refers to a polypeptide or group, e.g., a myristoyl group, sufficient to anchor an extracellular or intracellular domain to the plasma membrane.
[0325] A "switch domain," as the term is used herein, e.g., when referring to an RCAR, refers to a substance, generally a polypeptide-based substance, that binds to another switch domain in the presence of a dimerization molecule. Binding results in functional coupling of a first substance linked, e.g., fused, to the first switch domain and a second substance linked, e.g., fused, to the second switch domain. The first and second switch domains are collectively referred to as a dimerization switch. In some embodiments, the first and second switch domains are the same as each other, e.g., they are polypeptides having the same primary amino acid sequence, collectively referred to as a homodimerization switch. In some embodiments, the first and second switch domains are different from each other, e.g., they are polypeptides having different primary amino acid sequences, collectively referred to as a heterodimerization switch. In some embodiments, the switch is intracellular. In some embodiments, the switch is extracellular. In some embodiments, the switch domain is a polypeptide-based substance, e.g., FKBP- or FRB-based, and the dimerization molecule is a small molecule, e.g., a rapalog. In some embodiments, the switch domain is a polypeptide-based agent, e.g., an scFv that binds a myc peptide, and the dimerization molecule is a polypeptide, fragment thereof, or multimer of a polypeptide, e.g., a myc ligand or multimer of a myc ligand that binds one or more myc scFvs. In some embodiments, the switch domain is a polypeptide-based agent, e.g., a myc receptor, and the dimerization molecule is an antibody or fragment thereof, e.g., a myc antibody.
[0326] "Dimerization molecule," as that term is used herein, e.g., when referring to RCAR, refers to a molecule that promotes association of a first switch domain and a second switch domain. In some embodiments, the dimerization molecule is not naturally present in a subject or is not present at concentrations that result in significant dimerization. In some embodiments, the dimerization molecule is a small molecule, e.g., rapamycin or a rapalog, e.g., RAD001.
[0327] The term "bioequivalent" refers to the amount of an agent, other than a reference compound (e.g., RAD001), required to produce an effect equivalent to that produced by a reference dose or amount of the reference compound (e.g., RAD001). In some embodiments, the effect is the level of mTOR inhibition, e.g., as measured by P70 S6 kinase inhibition, e.g., as assessed in an in vivo or in vitro assay, e.g., as measured by an assay described herein, e.g., the Boulay assay. In some embodiments, the effect is an alteration in the ratio of PD-1-positive / PD-1-negative T cells, as measured by cell sorting. In some embodiments, a bioequivalent amount or dose of an mTOR inhibitor is an amount or dose that achieves the same level of P70 S6 kinase inhibition as the reference dose or control amount of the reference compound. In some embodiments, a bioequivalent amount or dose of an mTOR inhibitor is an amount or dose that achieves the same level of alteration in the ratio of PD-1-positive / PD-1-negative T cells as the reference dose or control amount of the reference compound.
[0328] The term "low, immune-enhancing dose" refers to a dose of an mTOR inhibitor that, when used in combination with an mTOR inhibitor, e.g., an allosteric mTOR inhibitor, e.g., RAD001 or rapamycin, or a catalytic mTOR inhibitor, partially but not completely inhibits mTOR activity, e.g., as measured by inhibition of P70 S6 kinase activity. Methods for assessing mTOR activity, e.g., by inhibition of P70 S6 kinase, are described herein. The dose is insufficient to produce complete immune suppression, but sufficient to enhance the immune response. In some embodiments, the low, immune-enhancing dose of an mTOR inhibitor results in a decrease in PD-1-positive T cells and / or an increase in the number of PD-1-negative T cells or an increase in the ratio of PD-1-negative T cells to PD-1-positive T cells. In some embodiments, the low, immune-enhancing dose of an mTOR inhibitor results in an increase in the number of naive T cells. In some embodiments, the low, immune-enhancing dose of an mTOR inhibitor results in one or more of the following: For example, the following markers on memory T cells, e.g., memory T cell precursors: CD62L 高 , CD127 高 , CD27 + and increased expression of one or more of BCL2; Decreased expression of KLRG1, e.g., in memory T cells, e.g., memory T cell precursors; and Memory T cell precursors, e.g., following CD62L 高 Increased CD127 高 Increased CD27 + an increase in the number of cells with any one or combination of the following characteristics: increased KLRG1, decreased KLRG1, and increased BCL2; wherein any of the above changes occur, for example, at least transiently, for example, as compared to an untreated subject.
[0329] As used herein, "refractory" refers to a disease, e.g., cancer, that does not respond to treatment. In some embodiments, a refractory cancer may be resistant to treatment before or at the start of the treatment. In other embodiments, a refractory cancer may become resistant during treatment. A refractory cancer may also be referred to as a resistant cancer.
[0330] As used herein, "relapsed" refers to the return of signs and symptoms of a disease (e.g., cancer) or a cancer-like disease after a period of improvement, e.g., after treatment with a previous therapeutic agent, e.g., cancer treatment.
[0331] Ranges: Throughout this specification, various aspects of the invention may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be construed as specifically disclosing all the possible subranges as well as individual numerical values within that range. For example, description of a range such as 1 to 6 should be construed as specifically disclosing subranges such as 1 to 3, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc., as well as individual numbers within that range, e.g., 1, 2, 2.7, 3, 4, 5, 5.3, and 6. As another example, a range such as 95-99% identity includes something with 95%, 96%, 97%, 98% or 99% identity, and includes subranges such as 96-99%, 96-98%, 96-97%, 97-99%, 97-98%, and 98-99% identity. This applies regardless of the breadth of the scope.
[0332] overview Provided herein are compositions and methods for use in treating diseases such as cancer using immune effector cells (e.g., T cells, NK cells) engineered with the CARs of the invention.
[0333]
[0013] In certain aspects, the present invention provides a number of chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., an antibody or antibody fragment, a TCR or TCR fragment) engineered for specific binding to a tumor antigen, e.g., a tumor antigen described herein. In certain aspects, the present invention provides immune effector cells (e.g., T cells, NK cells) engineered to express a CAR, wherein the engineered immune effector cells exhibit anti-cancer properties. In certain aspects, a cell is transformed with a CAR, and the CAR is expressed on the cell surface. In certain embodiments, a cell (e.g., T cell, NK cell) is transduced with a viral vector encoding a CAR. In certain embodiments, the viral vector is a retroviral vector. In certain embodiments, the viral vector is a lentiviral vector. In certain such embodiments, the cell may stably express the CAR. In other embodiments, the cell (e.g., T cell, NK cell) is transfected with a nucleic acid, e.g., mRNA, cDNA, DNA, encoding the CAR. In certain such embodiments, the cell may transiently express the CAR.
[0334] In one aspect, the antigen binding domain of the CAR described herein is an scFv antibody fragment. In one aspect, such antibody fragments are functional in that they retain equivalent binding affinity, e.g., they bind to the same antigen with equivalent affinity as the IgG antibody from which they are derived. In other embodiments, the antibody fragment has a lower binding affinity, e.g., binds to the same antigen with lower binding affinity than the antibody from which it is derived, but is still functional in providing the biological response described herein. In one embodiment, the CAR molecule binds to a target antigen with a binding affinity of 10 or more. -4 M~10 -8 M, e.g., 10 -5 M~10 -7M, e.g., 10 -6 M or 10 -7 Binding affinity K of M D In some embodiments, the antibody fragment has a binding affinity that is at least 5-fold, 10-fold, 20-fold, 30-fold, 50-fold, 100-fold, or 1,000-fold lower than a reference antibody, e.g., an antibody described herein.
[0335] In certain aspects, such antibody fragments are functional in that they provide a biological response that may include, but is not limited to, activation of an immune response, inhibition of signal transduction initiated from its target antigen, inhibition of kinase activity, etc., as will be understood by one of skill in the art.
[0336] In one aspect, the antigen binding domain of the CAR is an scFv antibody fragment that is humanized relative to the murine sequence of the scFv from which it is derived.
[0337] In one aspect, the antigen binding domain (e.g., scFv) of a CAR of the invention is encoded by a nucleic acid molecule whose sequence has been codon-optimized for expression in mammalian cells. In one aspect, the entire CAR construct of the invention is encoded by a nucleic acid molecule whose entire sequence has been codon-optimized for expression in mammalian cells. Codon optimization refers to the discovery that the frequency of occurrence of synonymous codons (i.e., codons that encode the same amino acid) in coding DNA varies from species to species. Such codon degeneracy allows the same polypeptide to be encoded by a variety of nucleotide sequences. Various codon optimization methods are known in the art, including, for example, the methods disclosed in at least U.S. Patent Nos. 5,786,464 and 6,114,148.
[0338] In one aspect, the CARs of the present invention combine the antigen binding domain of a specific antibody with an intracellular signaling molecule. For example, in one aspect, the intracellular signaling molecule includes, but is not limited to, the CD3 zeta chain, 4-1BB, and CD28 signaling modules, and combinations thereof. In one aspect, the antigen binding domain binds to a tumor antigen as described herein.
[0339] Additionally, the present invention provides CARs and CAR-expressing cells and their use in medicaments or methods for the treatment of, among other diseases, cancer or any malignancy or autoimmune disease involving cells or tissues that express the tumor antigens described herein.
[0340] In one aspect, the CARs of the invention can eradicate normal cells that express a tumor antigen described herein, thereby making them applicable for use as a cell conditioning therapy prior to cell transplantation. In one aspect, the normal cells that express a tumor antigen described herein are normal stem cells, and the cell transplantation is a stem cell transplantation.
[0341] In one aspect, the present invention provides immune effector cells (e.g., T cells, NK cells) engineered to express a chimeric antigen receptor (CAR), wherein the engineered immune effector cell exhibits anti-tumor properties. Preferred antigens are cancer-associated antigens (i.e., tumor antigens) described herein. In one aspect, the antigen binding domain of the CAR comprises a partially humanized antibody fragment. In one aspect, the antigen binding domain of the CAR comprises a partially humanized scFv. Thus, the present invention provides CARs comprising a humanized antigen binding domain engineered into cells, e.g., T cells or NK cells, and methods of using them for adoptive therapy.
[0342] In one aspect, a CAR of the invention comprises at least one intracellular domain selected from the group consisting of a CD137 (4-1BB) signaling domain, a CD28 signaling domain, a CD27 signal domain, a CD3 zeta signal domain, and any combination thereof. In one aspect, a CAR of the invention comprises at least one intracellular signaling domain derived from one or more costimulatory molecules other than CD137 (4-1BB) or CD28.
[0343] The sequences of some examples of the various elements of the CAR of the present invention are listed in Table 1, where aa is an amino acid and na is a nucleic acid that encodes the corresponding peptide. [Table 1] [Table 2]
[0344] [Table 3] [Table 4]
[0345] [Table 5] [Table 6]
[0346] [Table 7] [Table 8]
[0347] [Table 9] [Table 10]
[0348] Cancer-associated antigens The present invention provides immune effector cells (e.g., T cells, NK cells) engineered to contain one or more CARs that direct the immune effector cells to cancer. This is achieved by an antigen-binding domain on the CAR specific for a cancer-associated antigen. There are two classes of cancer-associated antigens (tumor antigens) that can be targeted by the CARs of the present invention: (1) cancer-associated antigens expressed on the surface of cancer cells; and (2) cancer-associated antigens that are themselves intracellular, however, fragments of such antigens (peptides) are presented on the surface of cancer cells by MHC (major histocompatibility complex).
[0349] Thus, the present invention provides CARs that target the following cancer-associated antigens (tumor antigens): CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1 (CLECL1), CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, mesothelin, IL-11Ra, PSCA, VEGFR2, Lewis Y, CD24, PDGFR-beta, PRSS21, SSEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1, EGFR, NCAM, prostase, PAP, ELF2M, ephrin B2, IGF-I receptor, CAIX, LMP2, gp100, bcr-a bl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, TSHR, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, legumain, HPV E6, E7, MAGE-A1, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin and telomerase, PCTA-1 / galectin 8, Melan-A / MART1, Ras mutant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxylesterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5 and IGLL1.
[0350] Tumor-supporting antigens The CAR of the present invention can comprise an antigen-binding domain (e.g., an antibody or antibody fragment, a TCR or a TCR fragment) that binds to a tumor-supporting antigen (e.g., a tumor-supporting antigen). In some embodiments, the tumor-supporting antigen is an antigen present on stromal cells or myeloid-derived suppressor cells (MDSCs). Stromal cells can secrete growth factors to promote cell division in the microenvironment. MDSC cells can inhibit T-cell proliferation and activation. Without wishing to be bound by theory, in some embodiments, CAR-expressing cells destroy tumor-supporting cells, thereby indirectly inhibiting tumor growth or survival.
[0351] In some embodiments, the stromal cell antigen is selected from one or more of bone marrow stromal cell antigen 2 (BST2), fibroblast activation protein (FAP), and tenascin. In some embodiments, the FAP-specific antibody competes for binding with or has the same CDR as sibrotuzumab. In some embodiments, the MDSC antigen is selected from one or more of CD33, CD11b, C14, CD15, and CD66b. Thus, in some embodiments, the tumor-supporting antigen is selected from one or more of bone marrow stromal cell antigen 2 (BST2), fibroblast activation protein (FAP), or tenascin, CD33, CD11b, C14, CD15, and CD66b.
[0352] Chimeric antigen receptor (CAR) The present invention encompasses recombinant DNA constructs comprising a sequence encoding a CAR, wherein the CAR comprises an antigen-binding domain (e.g., an antibody or antibody fragment, a TCR or a TCR fragment) that specifically binds to a cancer-associated antigen described herein, wherein the sequence of the antigen-binding domain is adjacent to and in the same reading frame as the nucleic acid sequence encoding the intracellular signaling domain. The intracellular signaling domain may comprise a costimulatory signaling domain and / or a primary signaling domain, e.g., a zeta chain. The costimulatory signaling domain refers to the portion of the CAR that comprises at least a portion of the intracellular domain of a costimulatory molecule.
[0353] In particular aspects, a CAR construct of the invention comprises an scFv domain, wherein the scFv can be preceded by an optional leader sequence such as provided in SEQ ID NO:2, followed by an optional hinge sequence such as provided in SEQ ID NO:4 or SEQ ID NO:6 or SEQ ID NO:8 or SEQ ID NO:10, a transmembrane region such as provided in SEQ ID NO:12, an intracellular signaling domain comprising SEQ ID NO:14 or SEQ ID NO:16, and a CD3 zeta sequence comprising SEQ ID NO:18 or SEQ ID NO:20, e.g., where the domains are contiguous and in the same reading frame to form a single fusion protein.
[0354] In one aspect, exemplary CAR constructs comprise an optional leader sequence (e.g., a leader sequence described herein), an extracellular antigen binding domain (e.g., an antigen binding domain described herein), a hinge (e.g., a hinge region described herein), a transmembrane domain (e.g., a transmembrane domain described herein), and an intracellular stimulatory domain (e.g., an intracellular stimulatory domain described herein). In one aspect, exemplary CAR constructs comprise an optional leader sequence (e.g., a leader sequence described herein), an extracellular antigen binding domain (e.g., an antigen binding domain described herein), a hinge (e.g., a hinge region described herein), a transmembrane domain (e.g., a transmembrane domain described herein), an intracellular costimulatory signaling domain (e.g., a costimulatory signaling domain described herein), and / or an intracellular primary signaling domain (e.g., a primary signaling domain described herein).
[0355] An exemplary leader sequence is provided as SEQ ID NO: 2. An exemplary hinge / spacer sequence is provided as SEQ ID NO: 4 or SEQ ID NO: 6 or SEQ ID NO: 8 or SEQ ID NO: 10. An exemplary transmembrane domain sequence is provided as SEQ ID NO: 12. An exemplary sequence of the intracellular signaling domain of 4-1BB protein is provided as SEQ ID NO: 14. An exemplary sequence of the intracellular signaling domain of CD27 is provided as SEQ ID NO: 16. An exemplary CD3 zeta domain sequence is provided as SEQ ID NO: 18 or SEQ ID NO: 20.
[0356] In one aspect, the invention encompasses a recombinant nucleic acid construct comprising a nucleic acid molecule encoding a CAR, wherein the nucleic acid molecule comprises a nucleic acid sequence encoding an antigen binding domain, e.g., as described herein, adjacent to and in the same reading frame as a nucleic acid sequence encoding an intracellular signaling domain.
[0357] In one aspect, the present invention encompasses a recombinant nucleic acid construct comprising a nucleic acid molecule encoding a CAR, wherein the nucleic acid molecule comprises a nucleic acid sequence encoding an antigen-binding domain, wherein the sequence is adjacent to and in the same reading frame as a nucleic acid sequence encoding an intracellular signaling domain. Exemplary intracellular signaling domains that can be used in a CAR include, but are not limited to, one or more intracellular signaling domains, such as, for example, CD3 zeta, CD28, CD27, 4-1BB, etc. In some examples, a CAR can comprise any combination of CD3 zeta, CD28, 4-1BB, etc.
[0358] Nucleic acid sequences encoding the desired molecules can be obtained using recombinant methods known in the art, such as by screening libraries from cells which express the nucleic acid molecule, by deriving the nucleic acid molecule from a vector known to contain it, or by isolating it directly from cells and tissues which contain it, using standard techniques. Alternatively, the nucleic acid of interest can be produced synthetically rather than cloned.
[0359] The present invention includes CAR-expressing retroviral and lentiviral vector constructs that can be directly transduced into cells.
[0360] The present invention also includes RNA constructs that can be directly transfected into cells. Methods for producing mRNA for use in transfection involve in vitro transcription (IVT) of a template using specifically designed primers, followed by polyA addition, to produce a construct containing 3' and 5' untranslated sequences ("UTRs") (e.g., 3' and / or 5' UTRs described herein), a 5' cap (e.g., a 5' cap described herein) and / or an internal ribosome entry site (IRES) (e.g., an IRES described herein), a nucleic acid to be expressed, and a polyA tail, typically 50-2000 bases in length (SEQ ID NO: 32). The RNA thus produced can efficiently transfect cells of different types. In some embodiments, the template contains sequences for the CAR. In some embodiments, the RNA CAR vector is transduced into cells, e.g., T cells or NK cells, by electroporation.
[0361] antigen-binding domain In one aspect, the CAR of the present invention comprises a target-specific binding element, also referred to as an antigen-binding domain. The selection of the portion depends on the type and number of ligands that define the surface of the target cell. For example, the antigen-binding domain can be selected to recognize a ligand that acts as a cell surface marker on the target cell associated with a particular disease state. Therefore, examples of cell surface markers that can act as ligands for the antigen-binding domain in the CAR of the present invention include those associated with viral, bacterial, and parasitic infections, autoimmune diseases, and cancer cells.
[0362] In one aspect, the CAR-mediated T cell response can be directed to an antigen of interest by means of engineering into the CAR an antigen binding domain that specifically binds to the desired antigen.
[0363] In one aspect, the portion of the CAR comprising the antigen binding domain comprises an antigen binding domain that targets a tumor antigen, e.g., a tumor antigen described herein.
[0364] The antigen-binding domain can be any domain that binds to an antigen, including, but not limited to, monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, human antibodies, and functional fragments thereof, including, but not limited to, single-domain antibodies such as heavy chain variable domains (VH), light chain variable domains (VL), and variable domains of camelid-derived nanobodies (VHH), as well as alternative scaffolds known in the art to function as antigen-binding domains, such as recombinant fibronectin domains, T cell receptors (TCR) or fragments thereof, e.g., single-chain TCRs, etc. In some instances, it is beneficial for the antigen-binding domain to be derived from the same species as the CAR will ultimately be used in. For example, for use in humans, it may be beneficial for the antigen-binding domain of the CAR to include human or humanized residues for the antigen-binding domain of an antibody or antibody fragment.
[0365] In one embodiment, an antigen binding domain against CD22 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Haso et al., Blood, 121(7): 1165-1174 (2013); Wayne et al., Clin Cancer Res 16(6): 1894-1903 (2010); Kato et al., Leuk Res 37(1):83-88 (2013); Creative BioMart (creativebiomart.net): MOM-18047-S(P).
[0366] In one embodiment, an antigen binding domain against CS-1 is an antigen binding portion, e.g., CDRs, of elotuzumab (BMS), see e.g., Tai et al., 2008, Blood 112(4):1329-37; Tai et al., 2007, Blood. 110(5):1656-63.
[0367] In one embodiment, an antigen binding domain against CLL-1 is an antigen binding portion, e.g., CDRs, of an antibody available from R&D, ebiosciences, Abcam, e.g., PE-CLL1-hu Cat# 353604 (BioLegend); and PE-CLL1(CLEC12A) Cat# 562566 (BD).
[0368] In some embodiments, the antigen binding domain against CD33 is selected from the group consisting of, e.g., Bross et al., Clin Cancer Res 7(6):1490-1496 (2001) (gemtuzumab ozogamicin, hP67.6), Caron et al., Cancer Res 52(24):6761-6767 (1992) (lintuzumab, HuM195), Lapusan et al., Invest New Drugs 30(3):1121-1131 (2012) (AVE9633), Aigner et al., Leukemia 27(5): 1107-1115 (2013) (AMG330, CD33 BiTE), Dutour et al., Adv hematol 2012:683065 (2012), and Pizzitola et al., Leukemia doi:10.1038 / Lue.2014.62 (2014) and the antigen-binding portion of the antibody, e.g., CDR.
[0369] In one embodiment, an antigen-binding domain against GD2 is an antigen-binding portion, e.g., CDR, of an antibody described in, e.g., Mujoo et al., Cancer Res. 47(4):1098-1104 (1987); Cheung et al., Cancer Res 45(6):2642-2649 (1985), Cheung et al., J Clin Oncol 5(9):1430-1440 (1987), Cheung et al., J Clin Oncol 16(9):3053-3060 (1998), Handgretinger et al., Cancer Immunol Immunother 35(3):199-204 (1992). In some embodiments, an antigen-binding domain against GD2 is an antigen-binding portion of an antibody selected from mAb 14.18, 14G2a, ch14.18, hu14.18, 3F8, hu3F8, 3G6, 8B6, 60C3, 10B8, ME36.1, and 8H9, see e.g., WO2012033885, WO2013040371, WO2013192294, WO2013061273, WO2013123061, WO2013074916, and WO201385552. In some embodiments, an antigen-binding domain against GD2 is an antigen-binding portion of an antibody described in U.S. Publication No. 20100150910 or PCT Publication No. WO2011160119.
[0370] In one embodiment, an antigen binding domain against BCMA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., WO2012163805, WO200112812, and WO2003062401.
[0371] In one embodiment, an antigen binding domain against a Tn antigen is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US8,440,798, Brooks et al., PNAS 107(22):10056-10061 (2010), and Stone et al., OncoImmunology 1(6):863-873(2012).
[0372] In some embodiments, the antigen-binding domain against PSMA is an antigen-binding portion, e.g., CDRs, of an antibody described in, e.g., Parker et al., Protein Expr Purif 89(2):136-145 (2013), US20110268656 (J591 ScFv); Frigerio et al, European J Cancer 49(9):2223-2232 (2013) (scFvD2B); WO2006125481 (mAbs 3 / A12, 3 / E7, and 3 / F11), and single-chain antibody fragments (scFv A5 and D7).
[0373]
[0023] In one embodiment, an antigen binding domain against ROR1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Hudecek et al., Clin Cancer Res 19(12):3153-3164 (2013); WO2011159847; and US20130101607.
[0374] In one embodiment, an antigen binding domain against FLT3 is an antigen binding portion, e.g., CDR, of an antibody described in, e.g., WO2011076922, US5777084, EP0754230, US20090297529, and several commercially available catalog antibodies (R&D, ebiosciences, Abcam).
[0375] In one embodiment, an antigen binding domain against TAG72 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Hombach et al., Gastroenterology 113(4):1163-1170 (1997); and Abcam ab691.
[0376] In one embodiment, an antigen binding domain against a FAP is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Ostermann et al., Clinical Cancer Research 14:4584-4592 (2008) (FAP5), U.S. Patent Publication No. 2009 / 0304718; sibrotuzumab (e.g., Hofheinz et al., Oncology Research and Treatment 26(1), 2003); and Tran et al., J Exp Med 210(6):1125-1135 (2013).
[0377] In one embodiment, an antigen binding domain against CD38 is an antigen binding portion, e.g., CDRs, of an antibody described in daratumumab (see, e.g., Groen et al., Blood 116(21):1261-1262 (2010)); MOR202 (see, e.g., US 8,263,746); or US 8,362,211.
[0378]
[0023] In one embodiment, an antigen binding domain against CD44v6 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Casucci et al., Blood 122(20):3461-3472 (2013).
[0379]
[00111] In one embodiment, an antigen binding domain against CEA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Chmielewski et al., Gastoenterology 143(4):1095-1107 (2012).
[0380] In one embodiment, the antigen binding domain against EPCAM is an antigen binding portion, e.g., CDRs, of an antibody selected from MT110, an EpCAM-CD3 bispecific Ab (see, e.g., clinicaltrials.gov / ct2 / show / NCT00635596); edrecolomab; 3622W94; ING-1; and adecatumumab (MT201).
[0381] In one embodiment, an antigen binding domain against PRSS21 is an antigen binding portion, e.g., CDRs, of an antibody described in U.S. Pat. No. 8,080,650.
[0382] In one embodiment, an antigen binding domain against B7H3 is an antigen binding portion, e.g., CDRs, of the antibody MGA271 (Macrogenics).
[0383] In one embodiment, an antigen binding domain against KIT is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US7915391, US20120288506, and several commercially available catalog antibodies.
[0384] In certain embodiments, an antigen binding domain against IL-13Ra2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., WO2008 / 146911, WO2004087758, several commercially available catalog antibodies, and WO2004087758.
[0385] In one embodiment, an antigen binding domain against CD30 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US7090843B1 and EP0805871.
[0386] In one embodiment, an antigen binding domain against GD3 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US7253263; US8,207,308; US20120276046; EP1013761; WO2005035577; and US6437098.
[0387]
[0023] In one embodiment, an antigen binding domain against CD171 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Hong et al., J Immunother 37(2):93-104 (2014).
[0388] In one embodiment, the antigen-binding domain against IL-11Ra is an antigen-binding portion, e.g., CDRs, of an antibody available from Abcam (cat# ab55262) or Novus Biologicals (cat# EPR5446). The antigen-binding domain against IL-11Ra is a peptide, see, e.g., Huang et al., Cancer Res 72(1):271-281 (2012).
[0389] In some embodiments, an antigen-binding domain against PSCA is an antigen-binding portion, e.g., CDRs, of an antibody described in, e.g., Morgenroth et al., Prostate 67(10):1121-1131 (2007) (scFv 7F5); Nejatollahi et al., J of Oncology 2013 (2013), article ID 839831 (scFv C5-II); and U.S. Patent Publication No. 20090311181.
[0390] In one embodiment, an antigen binding domain against VEGFR2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Chinnasamy et al., J Clin Invest 120(11):3953-3968 (2010).
[0391]
[00133] In one embodiment, an antigen binding domain against Lewis Y is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Kelly et al., Cancer Biother Radiopharm 23(4):411-423 (2008) (hu3S193 Ab (scFvs)); Dolezal et al., Protein Engineering 16(1):47-56 (2003) (NC10 scFv).
[0392] In one embodiment, an antigen binding domain against CD24 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Maliar et al., Gastroenterology 143(5):1375-1384 (2012).
[0393] In one embodiment, an antigen binding domain against PDGFR-beta is an antigen binding portion, e.g., CDRs, of the antibody Abeam ab32570.
[0394] In one embodiment, an antigen binding domain against SSEA-4 is an antigen binding portion, e.g., CDRs, of the antibody MC813 (Cell Signaling) or other commercially available antibodies.
[0395] In one embodiment, an antigen binding domain against CD20 is an antigen binding portion, e.g., CDRs, of the antibody rituximab, ofatumumab, ocrelizumab, veltuzumab, or GA101.
[0396]
[00133] In one embodiment, an antigen binding domain against folate receptor alpha is an antigen binding portion, e.g., CDRs, of the antibody IMGN853 or an antibody described in US20120009181; US4851332, LK26:US5952484.
[0397] In one embodiment, an antigen binding domain against ERBB2 (Her2 / neu) is an antigen binding portion, e.g., CDRs, of the antibody trastuzumab or pertuzumab.
[0398] In one embodiment, an antigen binding domain against MUC1 is an antigen binding portion, e.g., CDRs, of the antibody SAR566658.
[0399] In one embodiment, an antigen binding domain against EGFR is an antigen binding portion, e.g., CDRs, of the antibody cetuximab, panitumumab, zalutumumab, nimotuzumab, or matuzumab.
[0400] In one embodiment, an antigen binding domain against NCAM is an antigen binding portion, e.g., CDRs, of antibody clone 2-2B:MAB5324 (EMD Millipore).
[0401] In one embodiment, an antigen binding domain against EphrinB2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Abengozar et al., Blood 119(19):4565-4576 (2012).
[0402] In one embodiment, an antigen binding domain against IGF-I receptor is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US8344112B2; EP2322550A1; WO2006 / 138315, or PCT / US2006 / 022995.
[0403] In one embodiment, the antigen binding domain against CAIX is the antigen binding portion, e.g., CDRs, of antibody clone 303123 (R&D Systems).
[0404] In one embodiment, an antigen binding domain against LMP2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US 7,410,640 or US 20050129701.
[0405] In one embodiment, an antigen binding domain against gp100 is an antigen binding portion, e.g., CDRs, of the antibody HMB45, NKI beta B, or an antibody described in WO2013165940 or US20130295007.
[0406] In one embodiment, an antigen binding domain against tyrosinase is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US5843674; or US19950504048.
[0407] In one embodiment, an antigen binding domain against EphA2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Yu et al., Mol Ther 22(1):102-111 (2014).
[0408] In one embodiment, an antigen binding domain against GD3 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US7253263; US8,207,308; US20120276046; EP1013761A3; 20120276046; WO2005035577; or US6437098.
[0409] In one embodiment, an antigen binding domain against Fucosyl-GM1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US20100297138; or WO2007 / 067992.
[0410] In one embodiment, an antigen binding domain against sLe is an antigen binding portion, e.g., CDRs, of the antibody G193 (for Lewis Y), see Scott AM et al, Cancer Res 60: 3254-61 (2000), also described in Neeson et al, J Immunol May 2013 190 (Meeting Abstract Supplement) 177.10.
[0411] In one embodiment, an antigen binding domain against GM3 is an antigen binding portion, e.g., CDRs, of the antibody CA 2523449 (mAb 14F7).
[0412]
[0023] In one embodiment, an antigen binding domain against HMWMAA is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Kmiecik et al., Oncoimmunology 3(1):e27185 (2014) (PMID: 24575382) (mAb9.2.27); US6528481; WO2010033866; or US20140004124.
[0413] In one embodiment, an antigen binding domain against o-acetyl-GD2 is an antigen binding portion, e.g., CDRs, of the antibody 8B6.
[0414] In one embodiment, an antigen binding domain against TEM1 / CD248 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Marty et al., Cancer Lett 235(2):298-308 (2006); Zhao et al., J Immunol Methods 363(2):221-232 (2011).
[0415] In one embodiment, an antigen binding domain against CLDN6 is an antigen binding portion, e.g., CDRs, of the antibody IMAB027 (Ganymed Pharmaceuticals), see, e.g., clinicaltrial.gov / show / NCT02054351.
[0416] In certain embodiments, an antigen binding domain against TSHR is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., US 8,603,466; US 8,501,415; or US 8,309,693.
[0417] In one embodiment, an antigen binding domain against GPRC5D is an antigen binding portion, e.g., CDRs, of the antibody FAB6300A (R&D Systems); or LS-A4180 (Lifespan Biosciences).
[0418] In one embodiment, an antigen binding domain against CD97 is an antigen binding portion, e.g., CDRs, of, e.g., an antibody described in US 6,846,911; de Groot et al., J Immunol 183(6):4127-4134 (2009); or antibody from R&D: MAB3734.
[0419] In one embodiment, an antigen binding domain against ALK is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Mino-Kenudson et al., Clin Cancer Res 16(5):1561-1571 (2010).
[0420] In one embodiment, an antigen-binding domain against polysialic acid is an antigen-binding portion, e.g., CDR, of an antibody described in, e.g., Nagae et al., J Biol Chem 288(47):33784-33796(2013).
[0421]
[00139] In one embodiment, an antigen binding domain against PLAC1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Ghods et al., Biotechnol Appl Biochem 2013 doi:10.1002 / bab.1177.
[0422] In one embodiment, an antigen binding domain against GloboH is antibody VK9; or an antigen binding portion described in, for example, Kudryashov V et al, Glycoconj J. 15(3):243-9 (1998), Lou et al., Proc Natl Acad Sci USA 111(7):2482-2487 (2014); MBr1: Bremer EG et al. J Biol Chem 259:14773-14777 (1984).
[0423]
[00133] In one embodiment, an antigen binding domain against NY-BR-1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Jager et al., Appl Immunohistochem Mol Morphol 15(1):77-83 (2007).
[0424] In some embodiments, an antigen-binding domain against WT-1 is an antigen-binding portion, e.g., CDRs, of an antibody described in, e.g., Dao et al., Sci Transl Med 5(176):176ra33 (2013); or WO2012 / 135854.
[0425] In one embodiment, an antigen binding domain against MAGE-A1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Willemsen et al., J Immunol 174(12):7853-7858 (2005) (TCR-like scFv).
[0426] In one embodiment, an antigen binding domain against sperm protein 17 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Song et al., Target Oncol 2013 Aug 14 (PMID: 23943313); Song et al., Med Oncol 29(4):2923-2931 (2012).
[0427] In one embodiment, an antigen binding domain against Tie 2 is an antigen binding portion, e.g., CDRs, of the antibody AB33 (Cell Signaling Technology).
[0428] In one embodiment, an antigen-binding domain against MAD-CT-2 is an antigen-binding portion, e.g., CDRs, of an antibody described in, e.g., PMID: 2450952; US7635753.
[0429] In one embodiment, an antigen binding domain against Fos-related antigen 1 is an antigen binding portion, e.g., CDRs, of antibody 12F9 (Novus Biologicals).
[0430] In one embodiment, an antigen binding domain against MelanA / MART1 is an antigen binding portion, e.g., CDRs, of an antibody described in EP2514766A2; or US 7,749,719.
[0431] In one embodiment, an antigen binding domain against a sarcoma translocation breakpoint is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Luo et al, EMBO Mol. Med. 4(6):453-461(2012).
[0432] In one embodiment, an antigen binding domain against TRP-2 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Wang et al., J Exp Med. 184(6):2207-16 (1996).
[0433] In one embodiment, an antigen binding domain against CYP1B1 is an antigen binding portion, e.g., CDRs, of an antibody described in, e.g., Maecker et al, Blood 102 (9): 3287-3294 (2003).
[0434] In one embodiment, an antigen binding domain against RAGE-1 is an antigen binding portion, eg, CDRs, of the antibody MAB5328 (EMD Millipore).
[0435] In one embodiment, an antigen binding domain against human telomerase reverse transcriptase is an antigen binding portion, e.g., CDRs, of antibody catalog number LS-B95-100 (Lifespan Biosciences).
[0436] In one embodiment, an antigen binding domain against intestinal carboxylesterase is an antigen binding portion, e.g., CDRs, of the antibody 4F12: catalog number LS-B6190-50 (Lifespan Biosciences).
[0437] In one embodiment, an antigen binding domain against mut hsp70-2 is an antigen binding portion, e.g., CDRs, of the antibody Lifespan Biosciences: Monoclonal: Catalog No. LS-C133261-100 (Lifespan Biosciences).
[0438] In one embodiment, an antigen binding domain against CD79a is an antigen binding portion, e.g., CDRs, of the antibody anti-CD79a antibody [HM47 / A9] (ab3121) available from Abcam; the antibody CD79A antibody #3351 available from Cell Signaling Technology; or the antibody HPA017748 - anti-CD79A antibody produced in rabbit available from Sigma Aldrich.
[0439] In one embodiment, the antigen binding domain against CD79b is the antibody polatuzumab vedotin, an anti-CD79b described in Dornan et al., “Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma” Blood. 2009 Sep 24;114(13):2721-9. doi: 10.1182 / blood-2009-02-205500. Epub 2009 Jul 24, or “4507 Pre-Clinical Characterization of T Cell-Dependent Bispecific Antibody Anti-CD79b / CD3 As a Potential Therapy for B Cell Malignancies” Abstracts of 56 th
[0023] Antigen-binding portions, e.g., CDRs, of bispecific anti-CD79b / CD3 described at ASH Annual Meeting and Exposition, San Francisco, CA December 6-9 2014.
[0440]
[0039] In one embodiment, an antigen binding domain against CD72 is an antigen binding portion, e.g., CDRs, of antibody J3-109 described in Myers and Uckun, "An anti-CD72 immunotoxin against therapy-refractory B-lineage acute lymphoblastic leukemia." Leuk Lymphoma. 1995 Jun;18(1-2):119-22, or anti-CD72 (10D6.8.1, mIgG1) described in Polson et al., "Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection" Cancer Res March 15, 2009 69;2358.
[0441] In one embodiment, an antigen binding domain against LAIR1 is an antigen binding portion, e.g., CDRs, of the antibody ANT-301 LAIR1 antibody, available from ProSpec; or the anti-human CD305 (LAIR1) antibody available from BioLegend.
[0442] In one embodiment, an antigen binding domain against FCAR is an antigen binding portion, e.g., CDRs, of the antibody CD89 / FCAR antibody available from Sino Biological Inc. (Catalog# 10414-H08H).
[0443] In one embodiment, an antigen binding domain against LILRA2 is an antigen binding portion, e.g., CDRs, of the antibody LILRA2 monoclonal antibody (M17), clone 3C7, available from Abnova, or the murine anti-LILRA2 antibody, monoclonal (2D7), available from Lifespan Biosciences.
[0444] In one embodiment, an antigen-binding domain against CD300LF is an antigen-binding portion, e.g., CDRs, of the antibody mouse anti-CMRF35-like molecule 1 antibody, monoclonal [UP-D2] available from BioLegend or rat anti-CMRF35-like molecule 1 antibody, monoclonal [234903] available from R&D Systems.
[0445] In one embodiment, the antigen binding domain against CLEC12A is the same as that described in Noordhuis et al., “Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1xCD3 BiTE Antibody” 53 rd Antigen-binding portions, e.g., CDRs, of the antibody Bispecific T-cell Engager (BiTE) scFv-antibody and ADC and MCLA-117 (Merus) described at ASH Annual Meeting and Exposition, December 10-13, 2011.
[0446] In one embodiment, an antigen-binding domain against BST2 (also called CD317) is an antigen-binding portion, e.g., CDRs, of the antibody Mouse anti-CD317 antibody, monoclonal [3H4] available from Antibodies-Online or Mouse anti-CD317 antibody, monoclonal [696739] available from R&D Systems.
[0447] In one embodiment, an antigen binding domain against EMR2 (also referred to as CD312) is an antigen binding portion, e.g., CDRs, of the antibody Mouse anti-CD312 antibody, monoclonal [LS-B8033] available from Lifespan Biosciences or Mouse anti-CD312 antibody, monoclonal [494025] available from R&D Systems.
[0448] In one embodiment, an antigen binding domain against LY75 is an antigen binding portion, e.g., CDRs, of the antibody Mouse anti-lymphocyte antigen 75 antibody, monoclonal [HD30] available from EMD Millipore or Mouse anti-lymphocyte antigen 75 antibody, monoclonal [A15797] available from Life Technologies.
[0449] In some embodiments, the antigen-binding domain against GPC3 is an antigen-binding portion, e.g., CDR, of antibody hGC33, described in Nakano K, Ishiguro T, Konishi H, et al. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs. 2010 Nov;21(10):907-916, or MDX-1414, HN3, or YP7, all three of which are described in Feng et al., "Glypican-3 antibodies: a new therapeutic target for liver cancer." FEBS Lett. 2014 Jan 21;588(2):377-82.
[0450] In one embodiment, the antigen-binding domain against FcRL5 is an antigen-binding portion, e.g., CDRs, of an anti-FcRL5 antibody described in Elkins et al., "FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma" Mol Cancer Ther. 2012 Oct;11(10):2222-32.
[0451] In one embodiment, an antigen binding domain against IGLL1 is an antigen binding portion, e.g., CDRs, of the antibody Mouse anti-Immunoglobulin lambda-like polypeptide 1 antibody, monoclonal [AT1G4] available from Lifespan Biosciences, or Mouse anti-Immunoglobulin lambda-like polypeptide 1 antibody, monoclonal [HSL11] available from BioLegend.
[0452] In some embodiments, the antigen binding domain comprises one, two, three (e.g., all three) heavy chain CDRs, HC CDR1, HC CDR2, and HC CDR3, from an antibody listed above and / or one, two, three (e.g., all three) light chain CDRs, LC CDR1, LC CDR2, and LC CDR3, from an antibody listed above. In some embodiments, the antigen binding domain comprises a heavy chain variable region and / or a variable light chain region of an antibody listed above.
[0453] In other aspects, the antigen binding domain comprises a humanized antibody or antibody fragment. In one aspect, a non-human antibody is humanized, wherein specific sequences or regions of the antibody have been modified to increase similarity to antibodies, or fragments thereof, naturally produced in humans. In one aspect, the antigen binding domain is humanized.
[0454] Humanized antibodies can be produced by a variety of techniques, including CDR-grafting (see, e.g., European Patent No. EP 239,400; International Publication No. WO 91 / 09967; and U.S. Patent Nos. 5,225,539, 5,530,101, and 5,585,089, each of which is incorporated herein by reference in its entirety), veneering, or resurfacing (see, e.g., European Patent Nos. EP 592,106 and EP 519,596, each of which is incorporated herein by reference in its entirety; Padlan, 1991, Molecular Immunology, 28(4 / 5):489-498; Studnicka et al., 1994, Protein Engineering, 7(6):805-814; and Roguska et al., 1994, PNAS, 91:969-973), chain shuffling (see, for example, U.S. Patent No. 5,565,332, the entire contents of which are incorporated herein by reference), and, for example, U.S. Patent Application Publication No. US2005 / 0042664, U.S. Patent Application Publication No. US2005 / 0048617, U.S. Patent No. 6,407,213, U.S. Patent No. 5,766,886, International Publication No. WO9317105, Tan et al., J. Immunol., 169:1119-25 (2002), Caldas et al., Protein Eng., 13(5):353-60 (2000), Morea et al., Methods, 20(3):267-79 (2000), Baca et al., J. Biol. Chem., 272(16):10678-84 (1997), Roguska et al., Protein Eng., 9(10):895-904 (1996), Couto et al., Cancer Res., 55 (23 Supp):5973s-5977s (1995), Couto et al., Cancer Res., 55(8):1717-22 (1995), Sandhu JS, Gene, 150(2):409-10 (1994) and Pedersen et al., J. Mol. Biol., 235(3):959-73 (1994). Often, framework residues in the framework regions are replaced with corresponding residues from the CDR donor antibody to alter, e.g., improve, antigen binding. These framework substitutions are identified by methods well known in the art, such as modeling the interactions of CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at specific positions (see, e.g., Queen et al., U.S. Pat. No. 5,585,089; and Riechmann et al., 1988, Nature, 332:323, which are incorporated herein by reference in their entireties).
[0455] A humanized antibody or antibody fragment retains one or more amino acid residues from a source that is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. As provided herein, a humanized antibody or antibody fragment comprises one or more CDRs from a non-human immunoglobulin molecule and framework regions, in which the amino acid residues comprising the framework are derived entirely or predominantly from human germline. Numerous techniques for humanizing antibodies or antibody fragments are well known in the art and are essentially as described in Winter et al. (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536). (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody, i.e., by CDR-grafting (EP 239,400; PCT Publication No. WO 91 / 09967; and U.S. Patent Nos. 4,816,567; 6,331,415; 5,225,539; 5,530,101; 5,585,089; and 6,548,640, which are incorporated herein by reference in their entireties). In such humanized antibodies and antibody fragments, substantially less than the entire human variable domain has been substituted by the corresponding sequence from a non-human species. Humanized antibodies are often human antibodies in which some CDR residues and possibly some framework (FR) residues are substituted by residues from analogous sites in rodent antibodies.Humanization of antibodies and antibody fragments can also be achieved by veneering or resurfacing (EP 592,106; EP 519,596; Padlan, 1991, Molecular Immunology, 28(4 / 5):489-498; Studnicka et al., Protein Engineering, 7(6):805-814 (1994); and Roguska et al., PNAS, 91:969-973 (1994)) or chain shuffling (U.S. Patent No. 5,565,332), each of which is incorporated herein by reference in its entirety.
[0456] The human variable domains, both light and heavy, used to produce humanized antibodies are intended to reduce antigenicity. According to the so-called "best fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable domain sequences. The human sequence that is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (Sims et al., J. Immunol., 151:2296 (1993); Chothia et al., J. Mol. Biol., 196:901 (1987)). Another method uses a specific framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains. The same framework can be used for several different humanized antibodies (see, e.g., Nicholson et al. Mol. Immun. 34 (16-17): 1157-1165 (1997); Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); Presta et al., J. Immunol., 151:2623 (1993), the contents of which are incorporated herein by reference in their entireties). In some embodiments, the framework regions of the heavy chain variable region, e.g., all four framework regions, are derived from the VH4_4-59 germline sequence. In some embodiments, the framework regions can contain one, two, three, four, or five modifications, e.g., substitutions, from, e.g., amino acids of the corresponding murine sequence. In some embodiments, the framework regions of the light chain variable region, e.g., all four framework regions, are derived from the VK3_1.25 germline sequence. In some embodiments, the framework regions can include, for example, 1, 2, 3, 4, or 5 modifications, eg, substitutions, from the amino acids of the corresponding murine sequence.
[0457] In some aspects, portions of the CAR compositions of the invention, including antibody fragments, are humanized while retaining high affinity for the target antigen and other favorable biological properties. According to one aspect of the invention, humanized antibodies and antibody fragments are produced by a process of conceptual humanization using analysis of the parental sequences and three-dimensional models of the parental and humanized sequences. Three-dimensional immunoglobulin models are commercially available and familiar to those skilled in the art. Computer programs are available that model and display the predicted three-dimensional conformation of selected candidate immunoglobulin sequences. Inspection of these displays allows for analysis of the likely role of residues in the function of the candidate immunoglobulin sequence, for example, analysis of residues that affect the ability of the candidate immunoglobulin to bind to the target antigen. In this manner, FR residues can be selected and combined from the recipient and import sequences to achieve desired antibody or antibody fragment characteristics, such as increased affinity for the target antigen. Generally, CDR residues are directly and most substantially involved in influencing antigen binding.
[0458] A humanized antibody or antibody fragment may retain antigenic specificity similar to that of the original antibody, e.g., the ability to bind to a human cancer-associated antigen described herein. In some embodiments, a humanized antibody or antibody fragment may have improved binding affinity and / or specificity for a human cancer-associated antigen described herein.
[0459] In some aspects, the antigen binding domains of the invention are characterized by particular functional traits or properties of antibodies or antibody fragments, e.g., in one aspect, the portion of a CAR composition of the invention comprising an antigen binding domain specifically binds to a tumor antigen described herein.
[0460] In some aspects, an anti-cancer associated antigen binding domain as described herein is a fragment, e.g., a single chain variable fragment (scFv). In some aspects, an anti-cancer associated antigen binding domain as described herein is an Fv, Fab, (Fab')2, or a bifunctional (e.g., bispecific) hybrid antibody (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)). In some aspects, the antibodies and fragments thereof of the present invention bind to a cancer associated antigen protein as described herein with wild-type or enhanced affinity.
[0461] In some instances, scFvs can be produced according to methods known in the art (e.g., Bird et al., (1988) Science 242:423-426 and Huston et al., (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). ScFv molecules can be produced by linking the VH and VL domains using a flexible polypeptide linker. The scFv molecule contains a linker of optimized length and / or amino acid composition (e.g., a Ser-Gly linker). Linker length affects how the variable regions of the scFv fold and interact. In fact, when short polypeptide linkers are used (e.g., 5-10 amino acids), intrachain folding is prevented. Interchain folding is also required for the two variable regions to join together to form a functional epitope-binding site. For examples of linker orientations and sizes, see, e.g., Hollinger et al. 1993 Proc Natl Acad. Sci. USA 90:6444-6448, U.S. Patent Application Publication Nos. 2005 / 0100543, 2005 / 0175606, 2007 / 0014794, and PCT Publication Nos. WO2006 / 020258 and WO2007 / 024715, which are incorporated herein by reference.
[0462] An scFv can include a linker of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, or more amino acid residues between the VL and VH regions. The linker sequence can include any naturally occurring amino acid. In some embodiments, the linker sequence includes the amino acids glycine and serine. In other embodiments, the linker sequence includes several sets of glycine and serine repeats, such as (Gly4Ser)n, where n is a positive integer equal to or greater than 1 (SEQ ID NO: 22). In some embodiments, the linker can be (Gly4Ser)4 (SEQ ID NO: 29) or (Gly4Ser)3 (SEQ ID NO: 30). Varying the linker length can maintain or enhance activity, resulting in superior efficacy in activity tests.
[0463] In another aspect, the antigen binding domain is a T cell receptor ("TCR") or a fragment thereof, e.g., a single-chain TCR (scTCR). Methods for producing such TCRs are known in the art. See, e.g., Willemsen RA et al, Gene Therapy 7: 1369-1377 (2000); Zhang T et al, Cancer Gene Ther 11: 487-496 (2004); Aggen et al, Gene Ther. 19(4):365-74 (2012) (cited references are incorporated herein by reference in their entireties). For example, scTCRs can be engineered that contain Vα and Vβ genes from a T cell clone linked by a linker (e.g., a flexible peptide). This approach is highly useful for cancer-associated targets that are themselves intracellular; however, fragments of such antigens (peptides) are presented on the cancer cell surface by MHC.
[0464] Bispecific CAR In some embodiments, a multispecific antibody molecule is a bispecific antibody molecule. A bispecific antibody does not have specificity for more than two antigens. A bispecific antibody molecule is characterized by a first immunoglobulin variable domain sequence having binding specificity for a first epitope and a second immunoglobulin variable domain sequence having binding specificity for a second epitope. In some embodiments, the first epitope and the second epitope are on the same antigen, e.g., the same protein (or subunit of a multimeric protein). In some embodiments, the first epitope and the second epitope overlap. In some embodiments, the first epitope and the second epitope do not overlap. In some embodiments, the first epitope and the second epitope are on different antigens, e.g., different proteins (or different subunits of a multimeric protein). In some embodiments, a bispecific antibody molecule comprises heavy chain variable domain sequences and light chain variable domain sequences having binding specificity for a first epitope and heavy chain variable domain sequences and light chain variable domain sequences having binding specificity for a second epitope. In some embodiments, a bispecific antibody molecule comprises a half antibody having binding specificity for a first epitope and a half antibody having binding specificity for a second epitope. In some embodiments, a bispecific antibody molecule comprises a half antibody, or fragment thereof, having binding specificity for a first epitope and a half antibody, or fragment thereof, having binding specificity for a second epitope. In some embodiments, a bispecific antibody molecule comprises an scFv, or fragment thereof, having binding specificity for a first epitope and an scFv, or fragment thereof, having binding specificity for a second epitope.
[0465] In some embodiments, the antibody molecule is a multispecific (e.g., bispecific or trispecific) antibody molecule. Methods for producing bispecific or heterodimeric antibody molecules are known in the art and include, for example, the "knob-in-hole" approach described in, for example, US5731168; electrostatic steering Fc pairing, for example, as described in, for example, WO09 / 089004, WO06 / 106905, and WO2010 / 129304; strand exchange engineering domain (SEED) heterodimerization, for example, as described in, for example, WO07 / 110205; Fa heterodimerization, for example, as described in, for example, WO08 / 119353, WO2011 / 131746, and WO2013 / 060867. b-arm exchange; bispecific antibody conjugates, e.g., by antibody cross-linking, using heterobifunctional reagents having an amine-reactive group and a sulfhydryl-reactive group to produce bispecific structures, e.g., as described in U.S. Pat. No. 4,433,059; bispecific antibody determinants produced by recombining half-antibodies (heavy-light chain pairs or Fab) from different antibodies through cycles of reduction and oxidation of the disulfide bond between the two heavy chains, e.g., as described in U.S. Pat. No. 4,444,878; trifunctional antibodies, e.g., as described in U.S. Pat. No. 5,273,743; Biosynthetic binding proteins, e.g., pairs of scFvs cross-linked via C-terminal tails, preferably via disulfide or amine reactive chemical cross-links, as described, e.g., in US5534254; bifunctional antibodies, e.g., Fab fragments with different binding specificities dimerized by leucine zippers (e.g., c-fos and c-jun) in which the constant domains have been replaced, as described, e.g., in US55918; Bispecific and oligospecific monovalent and oligovalent receptors, such as those described in US Pat. No. 28, e.g., the VH-CH1 regions of two antibodies (two Fab fragments) linked via a polypeptide spacer between the CH1 region of one antibody and the VH region, generally with the associated light chain, of the other antibody; bispecific DNA-antibody conjugates, e.g., cross-linking of antibodies or Fab fragments via a double-stranded fragment of DNA, e.g., as described in US Pat. No. 5,635,602; bispecific fusion proteins, such as those described in US Pat. No. 5,637,481.Expression constructs comprising two scFvs with a hydrophilic helical peptide linker between them and a complete constant region; multivalent and multispecific binding proteins, e.g., dimers of polypeptides having a first domain with an Ig heavy chain variable region binding region and a second domain with an Ig light chain variable region binding region, generally bispecific antibodies (including higher order structures to create bispecific, trispecific or tetraspecific molecules), as described, for example, in US5837242; minibody constructs with linked VL and VH chains further connected by a peptide spacer to the antibody hinge and CH3 regions, which can be dimerized to form bispecific / multivalent molecules, as described, for example, in US5837821; These include, but are not limited to, VH and VL domains linked in any orientation without a linker; trimers and tetramers, as described, for example, in US Pat. No. 5,844,094; a series of VH domains (or VL domains in family members) joined by peptide bonds via crosslinkable groups at the C-terminus, which are further combined with a VL domain to form a series of FVs (or scFvs), as described, for example, in US Pat. No. 5,864,019; and single-chain binding polypeptides in which both VH and VL domains linked by peptide linkers are joined into multivalent structures via non-covalent or chemical crosslinking, to form, for example, homobivalent, heterobivalent, trivalent, and tetravalent structures, using both scFVs or bispecific antibody-type formats, as described, for example, in US Pat. No. 5,869,620. Further representative multispecific and bispecific molecules and methods of producing the same are described in, e.g., US5910573, US5932448, US5959083, US5989830, US6005079, US6239259, US6294353, US6333396, US6476198, US6511663, US6670453, US6743896, US6809185, US6833441, US7129330, US7183076, US7521056, US7527787, US7534866, US7612181,US2002004587A1, US2002076406A1, US2002103345A1, US2003207346A1, US2003211078A1, US2004219643A1, US2004220388A1, US20042428 47A1, US2005003403A1, US2005004352A1, US2005069552A1, US2005079170A1, US2005100543A1, US2005136049A1, US2005136051A1, US200 No. 5163782A1, No. US2005266425A1, No. US2006083747A1, No. US2006120960A1, US No. 2006204493A1, No. US2006263367A1, No. US2007004909A1, No. US2007087381A1, US2007128150A1, US2007141049A1, US2007154901A1, US2007274985A1, US2008050370A1, US2008069820A1, US2008152645A1, US200817185 No. 5A1, No. US2008241884A1, No. US2008254512A1, No. US2008260738A1, No. US2009130106A1, No. US2009148905A1, No. US2009155275A1, No. US2009162359A1, No. US200 No. 9162360A1, No. US2009175851A1, No. US2009175867A1, No. US2009232811A1, No. US2009234105A1, No. US2009263392A1, No. US2009274649A1, No. EP346087A2, WO00 06605A2, WO02072635A2, WO04081051A1, WO06020258A2, WO2007044887A2, WO2007095338A2, WO2007137760A2, WO2008119353A1, WO2009021754A2, WO2009068630A1, WO9103493A1, WO9323537A1, WO9409131A1, WO9412625A2, WO9509917A1, WO9637621A2, WO9964460A1. The contents of the above-cited applicationThe entire contents of which are incorporated herein by reference.
[0466] Within each antibody or antibody fragment (e.g., scFv) of a bispecific antibody molecule, the VH can be upstream or downstream of the VL. In some embodiments, the upstream antibody or antibody fragment (e.g., scFv) has its VH (VH1) positioned upstream of its VL (VL1), and the downstream antibody or antibody fragment (e.g., scFv) has its VL (VL2) positioned upstream of its VH (VH2), such that the overall bispecific antibody molecule has the configuration VH1-VL1-VL2-VH2. In other embodiments, the upstream antibody or antibody fragment (e.g., scFv) has its VL (VL1) positioned upstream of its VH (VH1), and the downstream antibody or antibody fragment (e.g., scFv) has its VH (VH2) positioned upstream of its VL (VL2), such that the overall bispecific antibody molecule has the configuration VL1-VH1-VH2-VL2. Optionally, a linker is placed between two antibodies or antibody fragments (e.g., scFvs), for example, between VL1 and VL2 if the construct is configured as VH1-VL1-VL2-VH2, or between VH1 and VH2 if the construct is configured as VL1-VH1-VH2-VL2. The linker can be a linker described herein, for example, a (Gly4-Ser)n linker (where n is 1, 2, 3, 4, 5, or 6, preferably 4) (SEQ ID NO: 65). Generally, the linker between two scFvs should be long enough to avoid mispairing between the two scFv domains. Optionally, a linker is placed between the VL and VH of the first scFv. Optionally, a linker is placed between the VL and VH of the second scFv. In constructs with multiple linkers, any two or more linkers can be the same or different. Thus, in some embodiments, the bispecific CAR comprises a VL, a VH and optionally one or more linkers in an arrangement as described herein.
[0467] Stability and Mutation The stability of an antigen-binding domain, e.g., an scFv molecule (e.g., a soluble scFv), against a cancer-associated antigen described herein can be assessed with reference to the biophysical properties (e.g., thermal stability) of a conventional control scFv molecule or a full-length antibody. In certain embodiments, the humanized scFv has thermal stability that is about 0.1°C, about 0.25°C, about 0.5°C, about 0.75°C, about 1°C, about 1.25°C, about 1.5°C, about 1.75°C, about 2°C, about 2.5°C, about 3°C, about 3.5°C, about 4°C, about 4.5°C, about 5°C, about 5.5°C, about 6°C, about 6.5°C, about 7°C, about 7.5°C, about 8°C, about 8.5°C, about 9°C, about 9.5°C, about 10°C, about 11°C, about 12°C, about 13°C, about 14°C or about 15°C greater than a control binding molecule (e.g., a conventional scFv molecule) in the assays described.
[0468] The improved thermal stability of the antigen-binding domain, e.g., scFv, for a cancer-associated antigen described herein can then be transferred to the entire CAR construct, leading to improved therapeutic properties of the CAR construct. The thermal stability of the antigen-binding domain, e.g., scFv, for a cancer-associated antigen described herein can be improved by at least about 2°C or 3°C compared to a conventional antibody. In some embodiments, the antigen-binding domain, e.g., scFv, for a cancer-associated antigen described herein has a thermal stability that is improved by 1°C compared to a conventional antibody. In other embodiments, the antigen-binding domain, e.g., scFv, for a cancer-associated antigen described herein has a thermal stability that is improved by 2°C compared to a conventional antibody. In other embodiments, the scFv has a thermal stability that is improved by 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, or 15°C compared to a conventional antibody. For example, a comparison can be made between the scFv molecules disclosed herein and the scFv molecules or Fab fragments of the antibodies from which the scFv VH and VL are derived. Thermal stability can be measured using methods known in the art. For example, in some embodiments, Tm can be measured. Methods for measuring Tm and other methods for determining protein stability are described in more detail below.
[0469] Mutations in the scFv (either due to humanization of soluble scFv or direct mutagenesis) can alter the stability of the scFv, improving the overall stability of the scFv and CAR construct. The stability of the humanized scFv is compared to that of the mouse scFv using measurements such as Tm, denaturation temperature, and aggregation temperature.
[0470] The binding ability of the variant cFv can be determined using assays known in the art and described herein.
[0471] In some embodiments, the antigen-binding domain of a cancer-associated antigen described herein, e.g., an scFv, comprises at least one mutation resulting from the humanization process, such that the mutated scFv contributes to improved stability in a CAR construct. In other embodiments, the antigen-binding domain of a cancer-associated antigen described herein, e.g., an scFv, comprises at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mutations resulting from the humanization process, such that the mutated scFv contributes to improved stability in a CAR construct.
[0472] Methods for assessing protein stability The stability of an antigen-binding domain can be evaluated, for example, using the methods described below. Such methods allow for the determination of multiple thermal unfolding transitions, where the least stable domain in a cooperatively unfolding multidomain unit (e.g., a multidomain protein exhibiting a single unfolding transition) unfolds first or limits the overall stability threshold. The least stable domain can be determined by a number of additional methods. Mutagenesis can be performed to explore which domain limits overall stability. Furthermore, protease resistance of a multidomain protein can be performed under conditions where the least stable domain is known to intrinsically unfold using DSC or other spectroscopic methods (Fontana, et al., (1997) Fold. Des., 2: R17-26; Dimasi et al. (2009) J. Mol. Biol. 393: 672-692). Once the least stable domain is identified, the sequence encoding that domain (or a portion thereof) can be used as a test sequence in the present method.
[0473] a) Thermal stability The thermal stability of the composition can be analyzed using a number of non-limiting biophysical or biochemical techniques known in the art. In some embodiments, thermal stability is assessed by analytical spectroscopy.
[0474] A representative analytical spectroscopy method is differential scanning calorimetry (DSC). DSC uses a calorimeter that is sensitive to the heat absorption associated with the denaturation of most proteins or protein domains (see, e.g., Sanchez-Ruiz, et al., Biochemistry, 27: 1648-52, 1988). To determine the thermal stability of a protein, a protein sample is placed in the calorimeter and the temperature is raised until the Fab or scFv unfolds. The temperature at which the protein unfolds is an indicator of overall protein stability.
[0475] Another representative analytical spectroscopic method is circular dichroism (CD) spectroscopy. CD spectroscopy measures the optical activity of a composition as a function of increasing temperature. Circular dichroism (CD) spectroscopy measures the difference in absorption of left-handed polarized light versus right-handed polarized light caused by structural asymmetry. A disordered or denatured structure will produce a CD spectrum that is significantly different from that of an ordered or folded structure. The CD spectrum reflects the sensitivity of a protein to the denaturing effects of increasing temperature and is therefore an indicator of the thermal stability of the protein (see van Mierlo and Steemsma, J. Biotechnol., 79(3):281-98, 2000).
[0476] Another exemplary analytical spectroscopic method for measuring thermal stability is fluorescence emission spectroscopy (see van Mierlo and Steemsma, supra). Yet another exemplary analytical spectroscopic method for measuring thermal stability is nuclear magnetic resonance (NMR) spectroscopy (see, e.g., van Mierlo and Steemsma, supra).
[0477] The thermal stability of a composition can be measured biochemically. A representative biochemical method for measuring thermal stability is a heat challenge assay. In a "heat challenge assay," a composition is subjected to a range of elevated temperatures for a set period of time. For example, in one embodiment, a test scFv molecule or molecule containing an scFv molecule is subjected to a wide range of elevated temperatures, e.g., for 1 to 1.5 hours. The activity of the protein is then assayed by a relevant biochemical assay. For example, if the protein is a binding protein (e.g., an scFv or scFv-containing polypeptide), the binding activity of the binding protein can be determined by functional or quantitative ELISA.
[0478] Such assays can be performed in a high-throughput format, as disclosed in the Examples, using E. coli and high-throughput screening. Libraries of antigen-binding domains, e.g., those containing antigen-binding domains, e.g., scFv variants, to the cancer-associated antigens described herein, can be created using methods known in the art. For example, expression of antigen-binding domains, e.g., scFv variants, to the cancer-associated antigens described herein can be induced, e.g., antigen-binding domains, e.g., scFv variants, to the cancer-associated antigens described herein can be subjected to heat challenge. The challenged test samples can be assayed for binding, and stable antigen-binding domains, e.g., scFv variants, to the cancer-associated antigens described herein can be scaled up and further characterized.
[0479] Thermal stability is assessed by measuring the melting temperature (Tm) of the composition using any of the above techniques (e.g., analytical spectroscopy techniques). The melting temperature is the temperature at the midpoint of the thermal transition curve at which 50% of the molecules of the composition are in a folded state (see, e.g., Dimasi et al. (2009) J. Mol. Biol. 393: 672-692). In some embodiments, the Tm values of the antigen-binding domains, e.g., scFvs, against the cancer-associated antigens described herein are approximately 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, or 64°C. , 65℃, 66℃, 67℃, 68℃, 69℃, 70℃, 71℃, 72℃, 73℃, 74℃, 75℃, 76℃, 77℃, 78℃, 79℃, 80℃, 81℃, 82℃, 83℃, 84℃, 85℃, 86℃, 87℃, 88℃, 89℃, 90℃, 91℃, 92℃, 93℃, 94℃, 95℃, 96℃, 97℃, 98℃, 99℃, 100℃. In some embodiments, the Tm values of IgG are about 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C , 69℃, 70℃, 71℃, 72℃, 73℃, 74℃, 75℃, 76℃, 77℃, 78℃, 79℃, 80℃, 81℃, 82℃, 83℃, 84℃, 85℃, 86℃, 87℃, 88℃, 89℃, 90℃, 91℃, 92℃, 93℃, 94℃, 95℃, 96℃, 97℃, 98℃, 99℃, 100℃. In certain embodiments, the Tm value of the multivalent antibody is about 40°C, 41°C, 42°C, 43°C, 44°C, 45°C, 46°C, 47°C, 48°C, 49°C, 50°C, 51°C, 52°C, 53°C, 54°C, 55°C, 56°C, 57°C, 58°C, 59°C, 60°C, 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 67°C, 68°C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C, 96°C, 97°C, 98°C, 99°C, 100°C, 101°C, 102°C, 103°C, 104°C, 105°C, 106°C, 107°C, 108°C, 109°C, 110°C, 111°C, 112°C, 113°C, 114°C, 115°C, 116°C, 117°C, 118°C, 11 °C, 69°C, 70°C, 71°C, 72°C, 73°C, 74°C, 75°C, 76°C, 77°C, 78°C, 79°C, 80°C, 81°C, 82°C, 83°C, 84°C, 85°C, 86°C, 87°C, 88°C, 89°C, 90°C, 91°C, 92°C, 93°C, 94°C, 95°C, 96°C, 97°C, 98°C, 99°C, 100°C.
[0480] Thermal stability can also be assessed by measuring the specific heat or heat capacity (Cp) of a composition using analytical calorimetry techniques (e.g., DSC). The specific heat of a composition is the energy (e.g., kcal / mol) required to raise the temperature of 1 mole of water by 1°C. A large Cp is characteristic of a denatured or inactive protein composition. The change in heat capacity (ΔCp) of a composition is measured by determining the specific heat of the composition before and after a thermal transition. Thermal stability can also be assessed by measuring or determining other parameters of thermodynamic stability, including the Gibbs free energy of denaturation (ΔG), the enthalpy of denaturation (ΔH), or the entropy of denaturation (ΔS). One or more of the above biochemical assays (e.g., a heat challenge assay) can be used to determine the temperature (i.e., T) at which 50% of the composition retains its activity (e.g., binding activity). C value).
[0481] Furthermore, mutations in the antigen-binding domain of a cancer-associated antigen described herein, e.g., an scFv, can be made to alter the thermal stability of the antigen-binding domain of a cancer-associated antigen described herein, e.g., an scFv, compared to the unmutated antigen-binding domain of a cancer-associated antigen described herein, e.g., an scFv. When a humanized antigen-binding domain of a cancer-associated antigen described herein, e.g., an scFv, is incorporated into a CAR construct, the antigen-binding domain of a cancer-associated antigen described herein, e.g., a humanized scFv, confers overall thermal stability to the CAR of the invention. In one embodiment, the antigen-binding domain of a cancer-associated antigen described herein, e.g., an scFv, contains a single mutation that confers thermal stability to the antigen-binding domain of a cancer-associated antigen described herein, e.g., an scFv. In another embodiment, the antigen-binding domain of a cancer-associated antigen described herein, e.g., an scFv, contains multiple mutations that confers thermal stability to the antigen-binding domain of a cancer-associated antigen described herein, e.g., an scFv. In some embodiments, multiple mutations in an antigen binding domain, e.g., an scFv, to a cancer associated antigen described herein have an additive effect on the thermal stability of the antigen binding domain, e.g., an scFv, to a cancer associated antigen described herein.
[0482] b) % flocculation The stability of a composition can be determined by measuring its ability to aggregate. Aggregation can be measured by a number of non-limiting biochemical or biophysical techniques. For example, aggregation of a composition can be assessed using chromatography, such as size exclusion chromatography (SEC). SEC separates molecules based on size. A column is filled with semi-solid beads of a polymerized gel that allows ions and small molecules to enter the interior but not larger ones. When a protein composition is loaded onto the column, small folded proteins (i.e., non-aggregated proteins) disperse in a larger volume of solvent than large protein aggregates. As a result, large aggregates move more rapidly down the column, and in this manner, a mixture can be separated or fractionated into its components. Each fraction can be separately quantified (e.g., by light scattering) as it elutes from the gel. Thus, the percent aggregation of a composition can be determined by comparing the concentration of the fraction to the total concentration of protein applied to the gel. A stable composition will elute from the column as essentially a single fraction and will have essentially a single peak in the elution profile or chromatogram.
[0483] c) binding affinity The stability of a composition can be evaluated by determining its target binding affinity. A wide variety of methods for determining binding affinity are known in the art. A representative method for measuring binding affinity uses surface plasmon resonance. Surface plasmon resonance is an optical phenomenon that allows for the analysis of real-time biomolecular specific interactions by detecting changes in protein concentration within a biosensor matrix, for example, using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ). For further description, see Jonsson, U., et al. (1993) Ann. Biol. Clin. 51:19-26; Jonsson, U., i (1991) Biotechniques 11:620-627; Johnsson, B., et al. (1995) J. Mol. Recognit. 8:125-131; and Johnnson, B., et al. (1991) Anal. Biochem. 198:268-277.
[0484] In one aspect, the antigen binding domain of the CAR has an amino acid sequence that is homologous to an antigen binding domain amino acid sequence described herein, wherein the antigen binding domain maintains the desired functional property of the antigen binding domain described herein.
[0485] In certain aspects, the CAR compositions of the invention comprise an antibody fragment. In a further aspect, the antibody fragment comprises an scFv.
[0486] In various aspects, the antigen binding domain of the CAR is engineered by modifying one or more amino acids within one or both variable regions (e.g., VH and / or VL), such as within one or more CDR regions and / or one or more framework regions. In certain aspects, the CAR compositions of the invention comprise an antibody fragment. In a further aspect, the antibody fragment comprises an scFv.
[0487] Those skilled in the art will understand that the antibodies or antibody fragments of the present invention can be further modified such that the amino acid sequence is altered (e.g., from wild-type) but the desired activity is not altered. For example, additional nucleotide substitutions can be made in the protein, resulting in amino acid substitutions at "non-essential" amino acid residues. For example, a non-essential amino acid residue in the molecule can be replaced with another amino acid residue from the same side chain family. In other embodiments, a stretch of amino acids can be replaced with a structurally similar stretch that differs in the order and / or composition of the side chain family members, e.g., conservative substitutions can be made in which an amino acid residue is replaced with an amino acid residue having a similar side chain.
[0488] Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0489] Percent identity, in the context of two or more nucleic acid or polypeptide sequences, refers to two or more sequences that are the same. Two sequences are "substantially identical" if they have a specified percentage of amino acid residues or nucleotides that are the same (e.g., 60% identity, optionally 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identity over a specified region, or, when not specified, over the entire sequence), when compared over a comparison window, or designated region, and aligned for maximum correspondence, as determined using one of the following sequence comparison algorithms or by manual alignment and visual inspection. Optionally, identity exists over a region that is at least about 50 nucleotides (or 10 amino acids) in length, or more preferably over a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length.
[0490] For sequence comparison, generally, one sequence serves as a reference sequence to which a test sequence is compared. When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identity of the test sequence relative to the reference sequence based on the program parameters. Methods for aligning sequences for comparison are well known in the art. Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith and Waterman, (1970) Adv. Appl. Math. 2:482c, the homology alignment algorithm of Needleman and Wunsch, (1970) J. Mol. Biol. 48:443, the similarity search of Pearson and Lipman, (1988) Proc. Nat'l. Acad. Sci. USA 85:2444, computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and inspection (see, e.g., Brent et al., (2003) Current Protocols in Molecular Biology).
[0491] Two examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1977) Nuc. Acids Res. 25:3389-3402; and Altschul et al., (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information.
[0492] The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller, (1988) Comput. Appl. Biosci. 4:11-17), which is incorporated into the ALIGN program (version 2.0) and uses a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. Additionally, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (1970) J. Mol. Biol. 48:444-453 algorithm, which is incorporated into the GAP program in the GCG software package (available at www.gcg.com), and uses a Blossom 62 matrix or a PAM250 matrix and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
[0493] In one aspect, the present invention contemplates modifications of the starting antibody or fragment (e.g., scFv) amino acid sequence that produce functionally equivalent molecules. For example, the VH or VL of an antigen binding domain, e.g., scFv, to a cancer associated antigen described herein that is comprised in a CAR can be modified to maintain at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the starting VH or VL framework region of the antigen binding domain, e.g., scFv, to a cancer associated antigen described herein. The present invention contemplates modifications of the entire CAR construct, for example, modifications in the amino acid sequence of one or more of the various domains of the CAR construct, to produce functionally equivalent molecules. The CAR construct can be modified to maintain at least about 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the starting CAR construct.
[0494] Transmembrane domain With regard to the transmembrane domain, in various embodiments, a CAR can be designed to include a transmembrane domain that is linked to the extracellular domain of the CAR. The transmembrane domain can include one or more additional amino acids adjacent to the transmembrane region, e.g., one or more amino acids that are linked to the extracellular region of the protein from which the transmembrane domain is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the extracellular region) and / or one or more additional amino acids that are linked to the intracellular region of the protein from which the transmembrane protein is derived (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 up to 15 amino acids of the intracellular region). In one aspect, the transmembrane domain is linked to other domains of the CAR; for example, in one embodiment, the transmembrane domain can be derived from the same protein from which the signaling domain, costimulatory domain, or hinge domain is derived. In other aspects, the transmembrane domain is not derived from the same protein from which any other domain of the CAR is derived. In some instances, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to transmembrane domains of the same or different surface membrane proteins, e.g., to minimize interactions with other members of the receptor complex. In one aspect, the transmembrane domain can homodimerize with other CARs on the cell surface of a CAR-expressing cell. In a different aspect, the amino acid sequence of the transmembrane domain can be modified or substituted to minimize interactions with the binding domains of natural binding partners present on the same CAR-expressing cell.
[0495] The transmembrane domain can be naturally derived or derived from a recombinant source. When the source is natural, the domain can be derived from any membrane-bound or transmembrane protein. In one aspect, the transmembrane domain can transmit signals to the intracellular domain when the CAR binds to the target. Transmembrane domains particularly useful in the present invention can include at least the transmembrane region of, for example, the alpha, beta, or zeta chain of the T cell receptor, CD28, CD27, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, or CD154. In some embodiments, the transmembrane domain is selected from the group consisting of, for example, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, IL2R beta, IL2R gamma, IL7R alpha, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITG It may contain at least the transmembrane domains of AM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKG2D, and NKG2C.
[0496] In some examples, the transmembrane domain can be attached to the extracellular region of the CAR, e.g., the antigen-binding domain of the CAR, via a hinge, e.g., a hinge from a human protein. For example, in some embodiments, the hinge can be a human Ig (immunoglobulin) hinge (e.g., an IgG4 hinge, an IgD hinge), a GS linker (e.g., a GS linker described herein), a KIR2DS2 hinge, or a CD8a hinge. In some embodiments, the hinge or spacer comprises (e.g., consists of) the amino acid sequence of SEQ ID NO: 4. In one aspect, the transmembrane domain comprises (e.g., consists of) the transmembrane domain of SEQ ID NO: 12.
[0497] In one aspect, the hinge or spacer comprises an IgG4 hinge. For example, in one embodiment, the hinge or spacer comprises the amino acid sequence [ka] In some embodiments, the hinge or spacer comprises a hinge of [ka] and a hinge encoded by the nucleotide sequence of
[0498] In one aspect, the hinge or spacer comprises an IgD hinge. For example, in one embodiment, the hinge or spacer comprises the amino acid sequence [ka] In some embodiments, the hinge or spacer comprises a hinge of [ka] and a hinge encoded by the nucleotide sequence of
[0499] In one aspect, the transmembrane domain may be engineered and, in this case, comprises primarily hydrophobic residues such as leucine and valine. In one aspect, a triplet of phenylalanine, tryptophan, and valine may be found at each end of the engineered transmembrane domain.
[0500] Optionally, a short oligo- or polypeptide linker, 2-10 amino acids in length, can form the linkage between the transmembrane domain and the cytoplasmic region of the CAR. A glycine-serine doublet provides a particularly suitable linker. For example, in one aspect, the linker can be [ka] In some embodiments, the linker comprises the amino acid sequence [ka] It is encoded by the nucleotide sequence In one aspect, the hinge or spacer comprises a KIR2DS2 hinge.
[0501] Cytoplasmic domain The cytoplasmic domain or region of a CAR comprises an intracellular signaling domain. The intracellular signaling domain is generally responsible for activating at least one of the normal effector functions of the immune cell into which the CAR is introduced. The term "effector function" refers to a specialized function of a cell. The effector function of a T cell can be, for example, cytolytic activity or helper activity, including cytokine secretion. Thus, the term "intracellular signaling domain" refers to a portion of a protein that transmits an effector function signal and instructs the cell to perform a specialized function. While the entire intracellular signaling domain can usually be used, it is often not necessary to use the entire chain. To the extent that a truncated portion of the intracellular signaling domain is used, such a truncated portion can be used in place of the complete chain, so long as it transmits the effector function signal. The term intracellular signaling domain is therefore intended to include any truncated portion of the intracellular signaling domain sufficient to transmit the effector function signal.
[0502] Examples of intracellular signaling domains for use in the CARs of the invention include the cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen receptor binding, as well as any derivative or variant of these sequences and any recombinant sequence that has the same functional capability.
[0503] It is known that signals generated via the TCR alone are insufficient for full activation of T cells, and that secondary and / or costimulatory signals are also required. Therefore, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation via the TCR (primary intracellular signaling domains) and those that act in an antigen-independent manner to provide secondary or costimulatory signals (secondary cytoplasmic domains, e.g., costimulatory domains).
[0504] The primary signaling domain controls the primary activation of the TCR complex in either a stimulatory or inhibitory manner. Primary intracellular signaling domains that act in a stimulatory manner may contain signaling motifs known as immunoreceptor tyrosine-based activation motifs, or ITAMs.
[0505] Examples of ITAM-containing primary intracellular signaling domains particularly useful in the present invention include those of CD3 zeta, common FcR gamma (FCER1G), Fc gamma RIIa, FcR beta (Fc epsilon R1b), CD3 gamma, CD3 delta, CD3 epsilon, CD79a, CD79b, DAP10, and DAP12. In some embodiments, a CAR of the present invention comprises an intracellular signaling domain, e.g., a primary signaling domain, of CD3 zeta.
[0506] In some embodiments, the primary signaling domain comprises a modified ITAM domain, e.g., a mutated ITAM domain, that has altered (e.g., increased or decreased) activity compared to the native ITAM domain. In some embodiments, the primary signaling domain comprises a modified ITAM-containing primary intracellular signaling domain, e.g., an optimized and / or truncated ITAM-containing primary intracellular signaling domain. In some embodiments, the primary signaling domain comprises one, two, three, four, or more ITAM motifs.
[0507] The intracellular signaling domain of the CAR may comprise a CD3 zeta signaling domain alone, or may be combined with any other desired intracellular signaling domain useful for the CAR in the context of the present invention. For example, the intracellular signaling domain of the CAR may comprise a CD3 zeta chain portion and a costimulatory signaling domain. The costimulatory signaling domain refers to the portion of the CAR that comprises the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen receptor or its ligand that is necessary for the efficient response of lymphocytes to antigens. Examples of such molecules include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, and a ligand that specifically binds to CD83. For example, CD27 costimulation has been shown to enhance the proliferation, effector function, and survival of human CART cells in vitro and to enhance human T cell persistence and antitumor activity in vivo (Song et al. Blood. 2012; 119(3):696-706).Further examples of such costimulatory molecules include CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD160, CD19, CD4, CD8 alpha, CD8 beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, and CD29. , ITGB2, CD18, LFA-1, ITGB7, TNFR2, TRANCE / RANKL, DNAM1(CD226), SLAMF4(CD244, 2B4), CD84, CD96(Tactile), NKG2D, CEACAM1, CRTAM, Ly9(CD229), CD160(BY55), P Contains SGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp and CD19a.
[0508] The intracellular signaling sequences within the cytoplasmic portion of the CAR of the present invention can be linked to each other randomly or in a specific order. Optionally, a short oligo- or polypeptide linker, e.g., 2 to 10 amino acids (e.g., 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids) in length, can form the linkage between the intracellular signaling sequences. In some embodiments, a glycine-serine doublet can be used as a suitable linker. In some embodiments, a single amino acid, e.g., alanine, glycine, can be used as a suitable linker.
[0509] In some aspects, the intracellular signaling domain is designed to comprise two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains. In some embodiments, the two or more, e.g., 2, 3, 4, 5, or more, costimulatory signaling domains are separated by a linker molecule, e.g., a linker molecule described herein. In some embodiments, the intracellular signaling domain comprises two costimulatory signaling domains. In some embodiments, the linker molecule is a glycine residue. In some embodiments, the linker is an alanine residue.
[0510] In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3 zeta and the signaling domain of CD28. In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3 zeta and the signaling domain of 4-1BB. In one aspect, the signaling domain of 4-1BB is the signaling domain of SEQ ID NO: 14. In one aspect, the signaling domain of CD3 zeta is the signaling domain of SEQ ID NO: 18.
[0511] In one aspect, the intracellular signaling domain is designed to comprise the signaling domain of CD3 zeta and the signaling domain of CD27. In one aspect, the signaling domain of CD27 comprises [ka] In one aspect, the signaling domain of CD27 comprises the amino acid sequence of: [ka] It is encoded by the nucleic acid sequence of
[0512] In one aspect, the CAR-expressing cells described herein further comprise a second CAR, e.g., a second CAR comprising a different antigen binding domain, e.g., directed against the same target or a different target (e.g., a target other than a cancer-associated antigen described herein or a different cancer-associated antigen described herein). In one embodiment, the second CAR comprises an antigen binding domain directed against a target expressed on the same cancer cell type as the cancer-associated antigen. In one embodiment, the CAR-expressing cells comprise a first CAR that targets a first antigen and comprises an intracellular signaling domain with a costimulatory signaling domain but without a primary signaling domain, and a second CAR that targets a second, different antigen and comprises an intracellular signaling domain with a primary signaling domain but without a costimulatory signaling domain. Without wishing to be bound by theory, placement of a costimulatory signaling domain, e.g., 4-1BB, CD28, CD27, or OX-40, on the first CAR and a primary signaling domain, e.g., CD3 zeta, on the second CAR can restrict CAR activity to cells in which both targets are expressed. In one embodiment, the CAR-expressing cells comprise a first cancer-associated antigen CAR that includes an antigen binding domain that binds to a target antigen described herein, a transmembrane domain, and a costimulatory domain, and a second CAR that targets a different target antigen (e.g., an antigen expressed on the same cancer cell type as the first target antigen) and includes an antigen binding domain, a transmembrane domain, and a primary signaling domain. In other embodiments, the CAR-expressing cells comprise a first CAR that includes an antigen binding domain that binds to a target antigen described herein, a transmembrane domain, and a primary signaling domain, and a second CAR that targets an antigen other than the first target antigen (e.g., an antigen expressed on the same cancer cell type as the first target antigen) and includes an antigen binding domain for that antigen, a transmembrane domain, and a costimulatory signaling domain.
[0513] In some embodiments, the CAR-expressing cells comprise an XCAR and an inhibitory CAR described herein. In some embodiments, the inhibitory CAR comprises an antigen-binding domain that binds to an antigen that is also found in normal cells, e.g., normal cells expressing CLL, but not in cancer cells. In some embodiments, the inhibitory CAR comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain of an inhibitory molecule. For example, the intracellular domain of the inhibitory CAR can be the intracellular domain of PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3, and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, or TGFR beta.
[0514] In some embodiments, when a CAR-expressing cell comprises two or more different CARs, the antigen-binding domains of the different CARs can be such that the antigen-binding domains do not interact with each other. For example, a cell expressing a first and a second CAR can have the antigen-binding domain of the first CAR, e.g., as a fragment, e.g., an scFv, which does not bind to the antigen-binding domain of the second CAR, e.g., the antigen-binding domain of the second CAR, which is a VHH.
[0515] In some embodiments, the antigen-binding domain comprises a single-domain antigen-binding (SDAB) molecule, which includes molecules whose complementarity-determining regions are part of a single-domain polypeptide. Examples include, but are not limited to, heavy chain variable domains, binding molecules that naturally lack light chains, single domains derived from traditional four-chain antibodies, engineered domains, and single-domain scaffolds other than those derived from antibodies. SDAB molecules can be any current or future single-domain molecule. SDAB molecules can be derived from any species, including, but not limited to, mouse, human, camel, llama, lamprey, fish, shark, goat, rabbit, and cow. The term also includes naturally occurring single-domain antibody molecules derived from species other than camelids and sharks.
[0516] In one aspect, SDAB molecules can be derived from the variable regions of immunoglobulins found in fish, such as those derived from the immunoglobulin isotype known as the novel antigen receptor (NAR) found in shark serum. For methods of producing single domain molecules derived from the variable regions of NARs ("IgNARs"), see WO 03 / 014161 and Streltsov (2005) Protein Sci. 14:2901-2909.
[0517] In another aspect, SDAB molecules are naturally occurring single-domain antigen-binding molecules known as heavy chains lacking light chains. Such single-domain molecules are disclosed, for example, in WO9404678 and Hamers-Casterman, C. et al. (1993) Nature 363:446-448. For clarity, the variable domains derived from these naturally lacking heavy chain heavy chain molecules are referred to herein as VHHs or nanobodies to distinguish them from the conventional VHs of four-chain immunoglobulins. Such VHH molecules can be derived from Camelidae, such as camels, llamas, dromedaries, alpacas, and guanacos. Other species besides Camelidae can also naturally produce heavy chain molecules lacking light chains, and such VHHs are within the scope of the present invention.
[0518] SDAB molecules can be recombinant, CDR-grafted, humanized, camelized, deimmunized and / or in vitro produced (eg, selected by phage display).
[0519] It has also been discovered that cells having multiple chimeric membrane-embedded receptors containing antigen-binding domains that interact with each other may be undesirable, for example, because one or more of the antigen-binding domains inhibits the ability of the antigen-binding domains to bind to their cognate antigen. Thus, disclosed herein are cells having first and second non-naturally occurring chimeric membrane-embedded receptors containing antigen-binding domains that minimize such interactions. Also disclosed herein are nucleic acids encoding first and second non-naturally occurring chimeric membrane-embedded receptors containing antigen-binding domains that minimize such interactions, as well as methods for producing and using such cells and nucleic acids. In some embodiments, one antigen-binding domain of the first and second non-naturally occurring chimeric membrane-embedded receptors comprises an scFv, and the other comprises a single VH domain, for example, a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence.
[0520] In some embodiments, the present invention includes a first and a second CAR, wherein the antigen-binding domain of one of the first CAR and the second CAR does not comprise a variable light domain and a variable heavy domain. In some embodiments, the antigen-binding domain of one of the first CAR and the second CAR is an scFv, and the other is not an scFv. In some embodiments, the antigen-binding domain of one of the first CAR and the second CAR comprises a single VH domain, such as a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence. In some embodiments, the antigen-binding domain of one of the first CAR and the second CAR comprises a nanobody. In some embodiments, the antigen-binding domain of one of the first CAR and the second CAR comprises a camelid VHH domain.
[0521] In some embodiments, the antigen-binding domain of one of the first CAR and the second CAR comprises an scFv, and the other comprises a single VH domain, e.g., a camelid, shark, or lamprey single VH domain, or a single VH domain derived from a human or mouse sequence. In some embodiments, the antigen-binding domain of one of the first CAR and the second CAR comprises an scFv, and the other comprises a nanobody. In some embodiments, the antigen-binding domain of one of the first CAR and the second CAR comprises an scFv, and the other comprises a camelid VHH domain.
[0522] In some embodiments, when present on the surface of a cell, binding of the antigen binding domain of the first CAR to its cognate antigen is not substantially reduced by the presence of the second CAR, hi some embodiments, binding of the antigen binding domain of the first CAR to its cognate antigen in the presence of the second CAR is 85%, 90%, 95%, 96%, 97%, 98% or 99% of the binding of the antigen binding domain of the first CAR to its cognate antigen in the absence of the second CAR.
[0523] In some embodiments, when present on the surface of a cell, the antigen binding domains of the first CAR and the second CAR bind to each other less than when both are scFv antigen binding domains, hi some embodiments, the antigen binding domains of the first CAR and the second CAR bind to each other 85%, 90%, 95%, 96%, 97%, 98% or 99% less than when both are scFv antigen binding domains.
[0524] In other aspects, a CAR-expressing cell described herein can further express another agent, e.g., an agent that enhances the activity of the CAR-expressing cell. For example, in some embodiments, the agent can be an agent that inhibits an inhibitory molecule. An inhibitory molecule, e.g., PD1, can, in some embodiments, reduce the ability of a CAR-expressing cell to mount an immune effector response. Examples of inhibitory molecules include PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3, and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, and TGFR beta. In some embodiments, the agent that inhibits an inhibitory molecule is, e.g., a molecule described herein, e.g., an agent comprising a first polypeptide, e.g., an inhibitory molecule, linked to a second polypeptide that provides a positive signal to the cell, e.g., an intracellular signaling domain described herein. In one embodiment, the agent comprises a first polypeptide of an inhibitory molecule such as, e.g., PD1, PD-L1, CTLA4, TIM3, CEACAM (e.g., CEACAM-1, CEACAM-3 and / or CEACAM-5), LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR beta, or a fragment of any of these (e.g., at least a portion of the extracellular domain of any of these), and an intracellular signaling domain described herein (e.g., comprising a costimulatory domain (e.g., as described herein, e.g., 41BB, CD27 or CD28) and and / or a second polypeptide that is a primary signaling domain (e.g., a CD3 zeta signaling domain described herein). In one embodiment, the agent comprises a first polypeptide of PD1 or a fragment thereof (e.g., at least a portion of the extracellular domain of PD1) and a second polypeptide of an intracellular signaling domain described herein (e.g., a CD28 signaling domain described herein and / or a CD3 zeta signaling domain described herein). PD1 is an inhibitory member of the CD28 family of receptors, which also includes CD28, CTLA-4, ICOS, and BTLA.PD-1 is expressed on activated B cells, T cells, and myeloid cells (Agata et al. 1996 Int. Immunol 8:765-75). Two ligands for PD1, PD-L1 and PD-L2, have been shown to downregulate T cell activation by binding to PD1 (Freeman et al. 2000 J Exp Med 192:1027-34; Latchman et al. 2001 Nat Immunol 2:261-8; Carter et al. 2002 Eur J Immunol 32:634-43). PD-L1 is abundant in human cancers (Dong et al. 2003 J Mol Med 81:281-7; Blank et al. 2005 Cancer Immunol. Immunother 54:307-314; Konishi et al. 2004 Clin Cancer Res 10:5094). Immune suppression can be reversed by inhibiting the local interaction of PD1 and PD-L1.
[0525] In some embodiments, the agent comprises the extracellular domain (ECD) of an inhibitory molecule, e.g., programmed cell death 1 (PD1), fused to a transmembrane domain and an intracellular signaling domain, such as 41BB and CD3 zeta (also referred to herein as a PD1 CAR). In some embodiments, the PD1 CAR improves T cell persistence when used in combination with an XCAR described herein. In some embodiments, the CAR is a PD1 CAR comprising the extracellular domain of PD1 underlined in SEQ ID NO:26. In some embodiments, the PD1 CAR comprises the amino acid sequence of SEQ ID NO:26. [ka]
[0526] In one embodiment, the PD1 CAR comprises the amino acid sequence shown below ...
Claims
1. 1. A composition comprising an immune effector cell (e.g., a population of immune effector cells) comprising a chimeric antigen receptor (CAR) molecule for use in combination with an agent that enhances the effectiveness of the immune effector cell in treating a subject having a disease associated with expression of a tumor antigen, comprising: (i) the CAR molecule comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain comprising a costimulatory domain and / or a primary signaling domain, wherein the antigen-binding domain binds to a tumor antigen associated with a disease, and the tumor antigen is thyroid stimulating hormone receptor (TSHR); CD171; CS-1 (CD2 subset 1, CRACC, SLAMF7, CD319 and 19A24); C-type lectin-like molecule-1 (CLL-1); ganglioside GD3 (aNeu5Ac(2-8)aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer); Tn antigen (Tn Ag); Fms-like tyrosine kinase 3 (FLT3); CD38; CD44v6; B7H3 (CD276); KIT (CD117); interleukin-13 receptor subunit alpha-2 (IL-13Ra2); interleukin-11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); protease serine 21 (PRSS21); vascular endothelial growth factor receptor 2 (VEGFR2); Y antigen; CD24; platelet-derived growth factor receptor beta (PDGFR-beta); stage-specific embryonic antigen-4 (SSEA-4); mucin 1, cell surface associated (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); carbonic anhydrase IX (CAIX); proteasome (prosome, macropain) subunit, beta, 9 (LMP2); ephrin type A receptor 2 (Eph A2); Fucosyl GM1; Sialyl Lewis adhesion molecule (sLe); Ganglioside GM3 (aNeu5Ac(2-3)bDGalp(1-4)bDGlcp(1-1)Cer; TGS5; High molecular weight melanoma associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); Folate receptor beta; Tumor endothelial marker 1 (TEM1 / CD248); Tumor endothelial marker 7 related (TEM7R); Claude CLDN6; G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); polysialic acid; placenta-specific 1 (PLAC1); hexasaccharide moiety of globoH glycoceramide (GloboH); mammary differentiation antigen (NY-BR-1); uroplakin 2 (UPK2);Hepatitis A virus cellular receptor 1 (HAVCR1); adrenergic receptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K9 (LY6K); olfactory receptor 51E2 (OR51E2); TCR gamma alternative reading frame protein (TARP); Wilms tumor protein (WT1); ETS translocation variant gene 6 located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X antigen family, member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; p53 mutant; human telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-acetylglucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); androgen receptor; cyclin B1; v-myc avian myelocytoma viral oncogene neuroblastoma-derived homolog (MYCN); Ras homolog family member C (RhoC); cytochrome P450 1B1 (CYP1B1); CCCTC-binding factor (zinc finger protein)-like (BORIS); squamous cell carcinoma antigen recognized by T cells 3 (SART3); paired box protein Pax-5 (PAX5); proacrosin-binding protein p32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A-kinase anchor protein 4 (AKAP-4); synovial sarcoma, X-breakpoint 2 (SSX2); CD79a; CD79b; CD72; leukocyte-associated Immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); Bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); Lymphocyte antigen 75 (LY75); Glypican-3 (GPC3);Fc receptor-like 5 (FCRL5); and Immunoglobulin lambda-like polypeptide 1 (IGLL1); and (ii) Drugs that enhance the efficacy of immune cells (i) a protein phosphatase inhibitor; (ii) a kinase inhibitor; (iii) cytokines; (iv) an inhibitor of immune inhibitory molecules; or (v) T REG Agents that decrease the levels or activity of cells The composition is selected from one or more of the following:
2. 1. A method of treating a subject having a disease associated with expression of a tumor antigen, comprising administering to the subject an effective amount of an immune effector cell (e.g., a population of immune effector cells) that comprises a chimeric antigen receptor (CAR) molecule in combination with an agent that enhances the effectiveness of the immune cell, wherein: (i) the CAR molecule comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain comprising a costimulatory domain and / or a primary signaling domain, wherein the antigen-binding domain binds to a tumor antigen associated with the disease, the tumor antigen being TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, mesothelin, IL-11Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-beta, SSEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1, EGFR, NCAM, prostase, PAP, ELF2M, ephrin B2, IGF-I receptor, CAIX, LMP2, gp100, bcr-ab l, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, legumain, HPV E6,E7, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin and telomerase, PCTA-1 / galectin 8, MelanA / MART1, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxylesterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5 and IGLL1; and (ii) Drugs that enhance the efficacy of immune cells (i) a protein phosphatase inhibitor; (ii) a kinase inhibitor; (iii) cytokines; (iv) an inhibitor of immune inhibitory molecules; or (v) T REG Agents that decrease the levels or activity of cells and thereby treating a subject.
3. 1. A method of treating a subject having a disease associated with expression of a tumor antigen, comprising administering to the subject an effective amount of an immune effector cell (e.g., a population of immune effector cells) that comprises a chimeric antigen receptor (CAR) molecule, wherein: (i) the CAR molecule comprises an antigen-binding domain, a transmembrane domain, and an intracellular domain comprising a costimulatory domain and / or a primary signaling domain, wherein the antigen-binding domain binds to a tumor antigen associated with the disease, the tumor antigen being TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, prostate-specific membrane antigen (PSMA), ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, mesothelin, interleukin-11 receptor a (IL-11Ra), PSCA, PRSS21, VEGFR2, Lewis Y, CD24, platelet-derived growth factor receptor-beta (PDGFR-beta), SSEA-4, CD20, folate receptor alpha, ERBB2 (Her2 / neu), MUC1, epidermal growth factor receptor (EGFR), NCAM, prostase, PAP, ELF2M, ephrin B2, IG F-I receptor, CAIX, LMP2, gp100, bcr-abl, tyrosinase, EphA2, fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-1a, MAGE-A1, legumain, HPV E6,E7, MAGE A1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostein, survivin and telomerase, PCTA-1 / galectin 8, MelanA / MART1, Ras mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxylesterase, mut hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5 and IGLL1; and (ii) the antigen-binding domain of the CAR molecule has a binding affinity that is at least 5-fold lower than the antibody from which the antigen-binding domain is derived; method.
4. A method of treating a subject having a disease associated with expression of a tumor antigen, comprising administering to the subject an effective amount of an immune effector cell (e.g., a population of immune effector cells) comprising a chimeric antigen receptor (CAR) molecule, wherein the CAR molecule comprises an antigen binding domain, a transmembrane domain, and an intracellular domain, wherein the intracellular domain comprises a costimulatory domain and / or a primary signaling domain, wherein the antigen binding domain binds to a tumor antigen associated with the disease, wherein the tumor antigen is selected from the group consisting of TSHR, TSHR, CD171, CS-1, CLL-1, GD3, Tn Ag, FLT3, CD38, CD44v6, B7H3, KIT, IL-13Ra2, IL-11Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-beta, SSEA-4, MUC1, EGFR, NCAM, CAIX, LMP2, EphA2, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor Body beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53 mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1; A method of treating a subject thereby.
5. The use or method according to any of claims 1 to 4, wherein the disease associated with expression of a tumor antigen is selected from the group consisting of proliferative diseases, precancerous conditions, cancer and non-cancer related indications associated with expression of a tumor antigen.
6. If the cancer is chronic lymphocytic leukemia (CLL), acute leukemia, acute lymphocytic leukemia (ALL), B-cell acute lymphocytic leukemia (B-ALL), T-cell acute lymphocytic leukemia (T-ALL), chronic myelogenous leukemia (CML), B-cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell or large cell follicular lymphoma 6. The use or method of claim 5, wherein the cancer is a blood cancer selected from one or more of the group consisting of: lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, marginal zone lymphoma, multiple myeloma, myelodysplasia and myelodysplastic syndromes, non-Hodgkin's lymphoma, Hodgkin's lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom's hypergammaglobulinemia or pre-leukemic conditions.
7. Cancers include colon cancer, rectal cancer, renal cell carcinoma, liver cancer, non-small cell lung cancer, small intestine cancer, esophageal cancer, melanoma, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, anal region cancer, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, non-Hodgkin's lymphoma, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue cancer, 6. The use or method of claim 5, wherein the cancer is selected from the group consisting of tumors, cancer of the urethra, cancer of the penis, childhood solid tumors, cancer of the bladder, cancer of the kidney or ureter, cancer of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphomas, tumor angiogenesis, tumors of the spinal axis, brain stem gliomas, pituitary adenomas, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers, combinations of said cancers and metastatic lesions of said cancers.
8. (i) the protein phosphatase inhibitor is an SHP-1 inhibitor and / or an SHP-2 inhibitor; (ii) the kinase inhibitor is selected from one or more of a CDK4 inhibitor, a CDK4 / 6 inhibitor (e.g., palbociclib), an mTOR inhibitor (e.g., rapamycin or everolimus), an MNK inhibitor, or a dual P13K / mTOR inhibitor; (iii) the agent that inhibits the immune inhibitory molecule comprises an antibody or antibody fragment that inhibits expression of the inhibitory molecule, an inhibitory nucleic acid, a clustered regularly interspaced short palindromic repeat (CRISPR), a transcription activator-like effector nuclease (TALEN) or a zinc finger endonuclease (ZFN); and / or (iv) T REG The agent that reduces the level or activity of the cells is selected from cyclophosphamide, anti-GITR antibody, CD25 depletion, or a combination thereof; 8. The use or method according to any of claims 1-2 or 5-7.
9. 9. The use or method of any of claims 1-2 or 5-8, wherein the immune inhibitory molecule is selected from the group consisting of PD1, PD-L1, CTLA-4, TIM-3, LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, TGFR beta, CEACAM-1, CEACAM-3 and CEACAM-5.
10. 9. The use or method of any of claims 1-2 or 5-8, wherein the agent that inhibits an inhibitory molecule comprises a first polypeptide comprising the inhibitory molecule or a fragment thereof and a second polypeptide that provides a positive signal to a cell, wherein said first and second polypeptides are expressed on a CAR-containing immune cell, and wherein (i) the first polypeptide comprises PD1, PD-L1, CTLA-4, TIM-3, LAG-3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, TGFR beta, CEACAM-1, CEACAM-3 and CEACAM-5 or fragments thereof; and / or (ii) the second polypeptide comprises an intracellular signaling domain comprising a primary signaling domain and / or a costimulatory signaling domain.
11. The use or method of claim 10, wherein the primary signaling domain comprises a functional domain of CD3 zeta; and / or the costimulatory signaling domain comprises a functional domain of a protein selected from 41BB, CD27 and CD28.
12. The use or method according to any of claims 1 to 2 or 5 to 11, wherein the cytokine is selected from IL-15 or IL-21 or both.
13. 13. The use or method of any of claims 1-2 or 5-12, wherein the immune effector cell comprising a CAR molecule and the agent that increases the efficacy of the immune effector cell are administered substantially simultaneously or sequentially.
14. The use or method of any of claims 1 to 13, wherein immune cells comprising a CAR molecule are administered in combination with a molecule that targets GITR and / or modulates GITR function.
15. 15. The use or method of claim 14, wherein the molecule that targets GITR and / or modulates GITR function is administered prior to the CAR-expressing cell or population of cells or prior to apheresis.
16. The use or method according to any one of claims 1 to 15, wherein the subject is a human.
17. 1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen binding domain, a transmembrane domain, and an intracellular signaling domain comprising a costimulatory domain and / or a primary signaling domain, wherein the antigen binding domain is selected from the group consisting of TSHR, CD171, CS-1, CLL-1, GD3, Tn Ag, FLT3, CD38, CD44v6, B7H3, KIT, IL-13Ra2, IL-11Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-beta, SSEA-4, MUC1, EGFR, NCAM, CAIX, LMP2, EphA2, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor agonist (GAA) and / or GABA receptor agonist (GABA). Body beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, ETV6-AML, sperm protein 17, XAGE1, Tie 2. An isolated nucleic acid molecule which binds to a tumor antigen selected from the group consisting of MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53 mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5 and IGLL1.
18. (i) The antigen-binding domain is an antibody, an antibody fragment, an scFv, an Fv, an Fab, an (Fab') 2 , a single domain antibody (SDAB), a VH or VL domain or a camelid VHH domain; and / or (ii) a transmembrane domain of the alpha, beta or zeta chain of the T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278 ), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R alpha, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, IT GAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1(C D226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, C 18. The isolated nucleic acid molecule of claim 17, comprising a transmembrane domain of a protein selected from the group consisting of D100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKp44, NKp30, NKp46, NKG2D and NKG2C.
19. The encoded transmembrane domain (i) an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO: 12, or a sequence having 95-99% identity to the amino acid sequence of SEQ ID NO: 12; or (ii) comprising the amino acid sequence of SEQ ID NO: 12; 19. An isolated nucleic acid molecule according to claim 17 or 18.
20. 20. The isolated nucleic acid molecule according to any one of claims 17 to 19, wherein the nucleic acid sequence encoding the transmembrane domain comprises the nucleotide sequence of SEQ ID NO: 13 or a sequence having 95-99% identity thereto.
21. 21. The isolated nucleic acid molecule according to any of claims 17 to 20, wherein the antigen binding domain is connected to the transmembrane domain by a hinge region, wherein the hinge region nucleic acid encodes an amino acid sequence comprising SEQ ID NO:2 or SEQ ID NO:6, or a sequence having 95-99% identity thereto; or the hinge region comprises the nucleotide sequence of SEQ ID NO:3 or SEQ ID NO:7, or a nucleotide sequence having 95-99% identity thereto.
22. 22. The isolated nucleic acid molecule of claims 17 to 21, wherein the intracellular signaling domain comprises a sequence encoding a primary signaling domain and / or a sequence encoding a costimulatory signaling domain.
23. 23. The isolated nucleic acid molecule of any of claims 17 to 22, wherein the intracellular signaling domain comprises a sequence encoding a primary signaling domain.
24. 24. The isolated nucleic acid molecule of claim 22 or 23, wherein the encoded primary signaling domain comprises a functional signaling domain of a protein selected from the group consisting of CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCER1G), FcR beta (Fc epsilon R1b), CD79a, CD79b, Fc gamma RIIa, DAP10 and DAP12.
25. Encoding primary signaling domain (i) an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO:18 or SEQ ID NO:20, or a sequence having 95-99% identity to the amino acid sequence of SEQ ID NO:18 or SEQ ID NO:20; or (ii) comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 20; An isolated nucleic acid molecule according to any one of claims 22 to 24.
26. 26. The isolated nucleic acid molecule of any of claims 17 to 25, wherein the intracellular signaling domain comprises a sequence encoding a costimulatory signaling domain or a sequence encoding a primary signaling domain and a sequence encoding a costimulatory signaling domain.
27. Ligands that specifically bind encoded costimulatory signaling domains include CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, CD83, CDS, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, and NKp 80 (KLRF1), CD160, CD19, CD4, CD8 alpha, CD8 beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX , CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2 B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLA 27. The isolated nucleic acid molecule of claim 26, comprising a functional signaling domain of a protein selected from the group consisting of MF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, NKp44, NKp30, NKp46 and NKG2D.
28. Encoding costimulatory signaling domains (i) an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO:14 or SEQ ID NO:16, or a sequence having 95-99% identity to the amino acid sequence of SEQ ID NO:14 or SEQ ID NO:16; or (ii) comprising the sequence of SEQ ID NO: 14 or SEQ ID NO: 16, An isolated nucleic acid molecule according to any one of claims 17 to 27.
29. 28. The isolated nucleic acid molecule of any of claims 17 to 27, wherein the nucleic acid sequence encoding the costimulatory signaling domain comprises the sequence of SEQ ID NO: 15 or SEQ ID NO: 17 or a sequence having 95-99% identity thereto.
30. 30. The isolated nucleic acid molecule of any of claims 17 to 29, wherein the encoded intracellular domain comprises the sequence of SEQ ID NO:14 or SEQ ID NO:16 and the sequence of SEQ ID NO:18 or SEQ ID NO:20, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.
31. 30. The isolated nucleic acid molecule according to any of claims 17 to 29, wherein the nucleic acid sequence encoding the intracellular signalling domain comprises the sequence of SEQ ID NO:15 or SEQ ID NO:17 or a sequence with 95-99% identity thereto and the sequence of SEQ ID NO:19 or SEQ ID NO:21 or a sequence with 95-99% identity thereto.
32. 32. The isolated nucleic acid molecule of any one of claims 17 to 31, further comprising a leader sequence comprising SEQ ID NO:
2.
33. 33. The isolated nucleic acid molecule of any of claims 17 to 32, wherein the antigen-binding domain has a binding affinity at least 5-fold lower than the antibody from which the antigen-binding domain is derived.
34. A vector comprising a nucleic acid molecule encoding the CAR molecule of any of claims 17 to 33, wherein the vector is selected from a DNA vector, an RNA vector, a plasmid, a lentivirus vector, an adenovirus vector, or a retrovirus vector.
35. 35. The vector of claim 34, further comprising a promoter selected from the group consisting of an EF-1 promoter, a CMV IE gene promoter, an EF-1α promoter, a ubiquitin C promoter, or a phosphoglycerate kinase (PGK) promoter.
36. The vector of claim 35, wherein the EF-1 promoter comprises the sequence of SEQ ID NO:
1.
37. The vector according to any one of claims 34 to 36, wherein the vector is an in vitro transcription vector or the vector further comprises a poly(A) tail or a 3'UTR.
38. A polypeptide molecule encoded by the nucleic acid molecule according to any one of claims 17 to 33.
39. 1. An isolated chimeric antigen receptor (CAR) polypeptide molecule comprising an antigen binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the antigen binding domain is selected from the group consisting of TSHR, CD171, CS-1, CLL-1, GD3, Tn Ag, FLT3, CD38, CD44v6, B7H3, KIT, IL-13Ra2, IL-11Ra, PSCA, PRSS21, VEGFR2, Lewis Y, CD24, PDGFR-beta, SSEA-4, MUC1, EGFR, NCAM, CAIX, LMP2, EphA2, Fucosyl GM1, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, folate receptor Body beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, ETV6-AML, sperm protein 17, XAGE1, Tie 2. An isolated CAR polypeptide molecule that binds to a tumor antigen selected from the group consisting of MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53 mutant, hTERT, sarcoma translocation breakpoints, ML-IAP, ERG (TMPRSS2 ETS fusion gene), NA17, PAX3, androgen receptor, cyclin B1, MYCN, RhoC, CYP1B1, BORIS, SART3, PAX5, OY-TES1, LCK, AKAP-4, SSX2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, and IGLL1.
40. (i) The antigen-binding domain is an antibody, an antibody fragment, an scFv, an Fv, an Fab, an (Fab') 2 , a single domain antibody (SDAB), a VH or VL domain or a camelid VHH domain; and / or (ii) a transmembrane domain of the alpha, beta or zeta chain of the T cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (C D278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2R beta, IL2R gamma, IL7R alpha, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNF R2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (B Y55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, PAG / Cbp, NKp44, NKp30, NKp46, NKG2D and NKG2C, 40. The isolated CAR polypeptide molecule of claim 39.
41. The transmembrane domain (i) an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO: 12, or a sequence having 95-99% identity to the amino acid sequence of SEQ ID NO: 12; or (ii) comprising the sequence of SEQ ID NO: 12; 41. An isolated CAR polypeptide molecule according to claim 39 or 40.
42. 42. The isolated CAR polypeptide molecule of any of claims 39-41, wherein the antigen binding domain is connected to the transmembrane domain by a hinge region, wherein the hinge region comprises SEQ ID NO:2 or SEQ ID NO:6, or a sequence having 95-99% identity thereof.
43. 43. The isolated CAR polypeptide molecule of any of claims 39-42, wherein the intracellular signaling domain comprises a primary signaling domain and / or a costimulatory signaling domain, wherein the primary signaling domain comprises a functional signaling domain of a protein selected from CD3 zeta, CD3 gamma, CD3 delta, CD3 epsilon, common FcR gamma (FCER1G), FcR beta (Fc epsilon R1b), CD79a, CD79b, Fc gamma RIIa, DAP10, or DAP12.
44. Primary signaling domain (i) an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of the amino acid sequence of SEQ ID NO:18 or SEQ ID NO:20, or a sequence having 95-99% identity to the amino acid sequence of SEQ ID NO:18 or SEQ ID NO:20; or (ii) comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 20; 44. The isolated CAR polypeptide molecule of claim 43.
45. The intracellular signaling domain comprises a costimulatory signaling domain or a primary signaling domain and a costimulatory signaling domain, wherein the costimulatory signaling domain is a domain that specifically binds to CD27, CD28, 4-1BB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, a ligand that specifically binds to CD83, CD S, ICAM-1, GITR, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, CD4, CD8 alpha, CD8 beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a , LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD6 9. The isolated CAR polypeptide molecule of any one of claims 39 to 44, comprising a functional signaling domain of a protein selected from the group consisting of SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, NKp44, NKp30, NKp46 and NKG2D.
46. 46. The isolated CAR polypeptide molecule of any of claims 43-45, wherein the costimulatory signaling domain comprises an amino acid sequence having at least one, two or three modifications but not more than 20, 10 or 5 modifications of an amino acid sequence of SEQ ID NO:14 or SEQ ID NO:16, or a sequence with 95-99% identity to an amino acid sequence of SEQ ID NO:14 or SEQ ID NO:
16.
47. 47. The isolated CAR polypeptide molecule of any of claims 43-46, wherein the costimulatory signaling domain comprises the sequence of SEQ ID NO: 14 or SEQ ID NO:
16.
48. 48. The isolated CAR polypeptide molecule of any of claims 43-47, wherein the intracellular domain comprises the sequence of SEQ ID NO:14 or SEQ ID NO:16 and the sequence of SEQ ID NO:18 or SEQ ID NO:20, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.
49. 49. The isolated CAR polypeptide molecule of any of claims 30-48, further comprising a leader sequence comprising the sequence of SEQ ID NO:
2.
50. 50. The isolated CAR polypeptide molecule of any of claims 39-49, wherein the antigen binding domain has a binding affinity at least 5-fold lower than the antibody from which the antigen binding domain is derived.
51. (i) a nucleic acid molecule according to any one of claims 17 to 33; (ii) a CAR polypeptide molecule according to any one of claims 38 to 50; or (iii) A vector according to any one of claims 34 to 37. An immune effector cell (e.g., a population of immune effector cells).
52. The cell of claim 51, comprising a first nucleic acid molecule encoding a first CAR molecule according to any of claims 17 to 33, a first CAR polypeptide molecule according to any of claims 38 to 50, or a vector according to any of claims 34 to 37, and further comprising a second nucleic acid molecule encoding a second CAR molecule, or a second vector comprising a nucleic acid molecule encoding the second CAR molecule.
53. 53. The cell of claim 51 or 52, wherein the second CAR molecule targets the same antigen as the first CAR molecule, and wherein the antigen binding domain of the second CAR molecule is different from the antigen binding domain of the first CAR molecule.
54. The cell of any of claims 51 to 53, wherein the antigen-binding domain of the second CAR molecule targets a different antigen than the antigen-binding domain of the first CAR molecule.
55. 55. The cell of any of claims 51-54, wherein the first CAR molecule comprises an intracellular signaling domain comprising a costimulatory signaling domain but does not comprise a primary signaling domain, and the second CAR molecule comprises an intracellular signaling domain comprising a primary signaling domain but does not comprise a costimulatory signaling domain.
56. The cell of claim 55, wherein the first CAR molecule comprises a costimulatory signaling domain comprising a functional signaling domain of a protein selected from the group consisting of 4-1BB, CD28, CD27 or OX-40, and the second CAR molecule comprises a primary signaling domain comprising a functional signaling domain of CD3 zeta.
57. 57. The cell of claim 56, wherein the second CAR is an inhibitory CAR, wherein the inhibitory CAR comprises an antigen-binding domain, a transmembrane domain and an intracellular domain of an inhibitory molecule, wherein the inhibitory molecule is selected from the group consisting of PD1, PD-L1, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4, TGFR beta, CEACAM-1, CEACAM-3 and CEACAM-5.
58. The cell of claim 57, wherein the second CAR molecule further comprises an intracellular signaling domain comprising a primary signaling domain and / or an intracellular signaling domain, wherein the intracellular signaling domain comprises a primary signaling domain comprising a functional domain of CD3 zeta and a costimulatory signaling domain comprising a functional domain of 4-1BB.
59. The cell of claim 58, wherein the second CAR molecule comprises the amino acid sequence of SEQ ID NO:
26.
60. The immune effector cells are human T cells (e.g., CD8 + 60. The cell of any one of claims 51 to 59, which is a human NK cell, optionally wherein the T cell is diacylglycerol kinase (DGK) and / or Ikaros deficient.
61. CAR molecule (i) encoded by a nucleic acid molecule according to any one of claims 17 to 33; (ii) a CAR polypeptide molecule according to any one of claims 38 to 50; or (iii) Encoded by a vector according to any one of claims 34 to 37.
17. The use or method according to any one of claims 1 to 16.
62. The use or method according to any of claims 1 to 16, wherein the immune effector cells used or administered are according to any of claims 51 to 60.
63. 38. A method of producing a CAR-expressing immune effector cell (e.g. a population of CAR-expressing immune effector cells), the method comprising introducing a nucleic acid molecule encoding a vector of any of claims 34 to 37, or a CAR of any of claims 17 to 33, into an immune effector cell under conditions whereby the CAR molecule is expressed.
64. a) providing a population of immune effector cells (e.g., T cells or NK cells); and b) removing T regulatory cells from the population, thereby providing a population of T regulatory depleted cells; wherein steps a) and b) are performed prior to introducing a nucleic acid encoding a CAR into the population.
64. The method of claim 63.
65. 65. The method of claim 64, wherein T regulatory cells are removed from the cell population using an anti-CD25 antibody or an anti-GITR antibody.
66. 34. A method of producing a population of RNA engineered cells (e.g. RNA engineered immune effector cells), comprising introducing in vitro transcribed RNA or synthetic RNA into a cell or population of cells, wherein the RNA comprises a nucleic acid molecule encoding a CAR according to any of claims 17 to 33.
67. 81. A method of providing anti-tumor immunity to a subject, comprising administering to the subject an effective amount of an immune effector cell according to any one of claims 61 to 80, wherein the cell is an autologous T cell or an allogeneic T cell or an autologous T cell or an allogeneic NK cell.
68. 68. The method of claim 67, wherein the allogeneic T cells or allogeneic NK cells lack or have low expression of a functional TCR or functional HLA.
69. 13. An isolated nucleic acid molecule according to any of claims 17 to 33, an isolated CAR polypeptide molecule according to any of claims 38 to 50, an immune effector cell according to any of claims 51 to 60 or a vector according to any of claims 34 to 37 for use as a medicament.
70. 13. The isolated nucleic acid molecule of any of claims 17 to 33, the isolated CAR polypeptide molecule of any of claims 38 to 50, the immune effector cell of any of claims 51 to 60 or the vector of any of claims 34 to 37 for use in the treatment of a disease expressing a tumor antigen.
Citation Information
Patent Citations
Calreticulin-soluble programmed death receptor 1 fusion protein, and preparation method and purpose thereof
CN102898528A
Extracellular region multimer of cell surface functional molecule
JP2012157357A
Switch costimulatory receptors
WO2013019615A2
Cited By
Semiconductor device
CN121712040A
